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ABSTRACT 
 
Cardiac hypertrophy often develops to compensate for hemodynamic overload and is 
associated with heart failure. Recent studies have revealed that overexpression and PKA-
mediated phosphorylation of heat shock protein 20 (HSP20) at Ser16 can attenuate 
hypertrophic growth of cardiomyocytes and trigger cardioprotective functions following 
sustained β-adrenergic stimulation (Fan et al., 2004, 2005, 2006). However, the molecular 
mechanism of HSP20 induced cardioprotection remains to be fully elucidated. In order to 
gain insight into the protective mode of action of HSP20, I attempted to (1) investigate the 
spatiotemporal control of PKA-mediated phosphorylation of HSP20, as well as (2) 
identifying novel protein binding partners for HSP20 utilising cutting edge ProtoArray 
technology.  
Initially, I set up an in vitro hypertrophy model using sustained isoprenaline (ISO)-
stimulated neonatal rat cardiomyocytes. Cell size, protein synthesis and fetal gene 
expression were assessed as parameters of hypertrophic growth. In the first section of my 
studies, members of the cAMP-specific PDE4 family were shown to form signalling 
complexes with HSP20, and that the PKA-mediated phosphorylation of HSP20 could be 
modulated by PDE4. Based on peptide array data, a cell-permeable peptide ‘bs906’ was 
developed to inhibit the interaction of PDE4 with HSP20. Interestingly, the disruption of 
the PDE4-HSP20 complex was shown to induce PKA-mediated phosphorylation of HSP20 
and trigger cardioprotection against the hypertrophic response measured in neonatal 
cardiomyocytes upon chronic β-adrenergic stimulation. 
In the second part of my studies, protein kinase D1 (PKD1) was identified as one 
interacting partner that robustly associated with HSP20. This interaction was confirmed by 
biochemical and immunocytochemical means. Using similar approaches to those used for 
the PDE4-HSP20 interaction, a cell-permeable peptide ‘HJL09’ was generated to promote 
disruption of the PKD1-HSP20 complex. Experimentation using the peptide concluded that 
the disruption of the PKD1-HSP20 complex reduced HSP20 phosphorylation and 
attenuated the hypertrophic response in cultured cardiomyocytes as shown by reduced 
increases in cell size, protein content and actin reorganisation. In undertaking this work, I 
also defined a novel PKD phosphorylation site (Ser16) on HSP20 that conforms to the 
ii 
 
PKD phosphorylation motif of RxxS (also a PKA site). My biochemical data suggested 
that PKD1 may regulate the cardioprotective function of HSP20 via phosphorylation at 
Ser16.  In situ proximity ligation assay (PLA) further revealed a role of HSP20 as 
‘molecular escort’ in targeting the nuclear translocation of PKD1. This function, in part, 
may be responsible for the  induction of fetal gene reexpression as  selective disruption of 
PKD1-HSP20 complex using ‘HJL09’ hindered the nuclear influx of the complex, thereby 
attenuating hypertrophic signalling.  
In summary, these studies describe some exciting findings which provide further insight 
into novel signalling mechanism of cardiac hypertrophy in neonatal rat cardiomyocytes. I 
have shown that PKA and PKD1 exhibiting opposite functions despite sharing the 
phosphorylation site on HSP20. In this regard, HSP20 functions as a molecular nexus for 
the opposing actions of the PKA and PKD1 signalling pathways in hypertrophy, 
suggesting that crosstalk may occur between anti-hypertrophic and pro-hypertrophic 
pathways. The identification and characterisation of these complexes should help to build a 
better understanding of the hypertrophic signalling pathway, and may provide novel 
therapeutic strategies for the treatment of cardiac hypertrophy. 
 
 
Keywords: HSP20, hypertrophy, phosphodiesterase, cAMP-dependent PKA, PKD1, 
phosphorylation 
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1.1        Heat shock protein  
Heat shock proteins (HSPs) are ubiquitously found in both prokaryotic and eukaryotic cells 
under normal or stressful conditions. These proteins are currently under investigation by 
researchers from many different scientific fields due to their remarkable properties. 
Besides being a chaperone for proteins, HSPs have also been described as key mediators of 
cytoprotection in response to various stimuli. Several recent advances in our understanding 
of HSPs have provided important insights into their roles in pathophysiologic conditions. 
This chapter will briefly review the current understanding of the structure and functions of 
HSPs in eukaryotic cells. In particular, the protective roles of HSP20 in heart will be 
highlighted here. 
 
1.1.1    Background 
The heat response in cells was first discovered by an Italian investigator, Ferruccio Ritossa 
(1962) during a study of elevated temperature effects on the salivary glands of fruit fly 
Drosophila embryos. He reported that an unusual gene expression had occurred which 
rapidly induced the synthesis of a new set of proteins in response to the heat stress 
(elevation of approximately 5
o
 above normal growth temperature). Subsequently, a 
dramatic change in the flies’ polytene chromosomal puffing patterns was observed under 
light microscopic examination. It was later discovered by Tissieres and his co-workers 
(1974) that the puffs were sites of messenger RNA (mRNA) transcription leading to 
enhanced synthesis of a group of proteins which he named them HSPs. Initially, it was 
believed that these proteins were only found in fruit flies. However, Schlesinger (1986) 
later demonstrated that there were also identical heat responses in avian and mammalian 
tissue culture cells. With similar discoveries from other scientists in prokaryotes like E. 
coli (Yamamori et al., 1978) and Tetrahymena (Fink and Zeuther, 1978), the heat shock 
response appeared to be a universal
 
response in all living organisms. Accordingly, 
Schlesinger (1986) believed that virtually all organisms from prokaryotes to eukaryotes 
might have a set of special proteins to enhance their survival ability and help the cells to 
recover from stress when favourable conditions pertain. 
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1.1.2   Functions  
Heat shock proteins (HSPs) form a multigenic family of proteins that are ubiquitously 
expressed in all major subcellular compartments. It is believed that this protein family 
perform protective functions across the whole biological spectrum. HSPs are able to 
maintain cell stability and protect cells from severe damage. They are synthesised in 
organisms in response to unfavourable conditions such as heat, pH changes and oxidative 
injury, which can alter protein functions and lead to deleterious effects in cells (Visick and 
Clarke, 1995; reviewed in Benjamin and McMillan, 1998). Despite also being named as 
stress proteins, HSPs have critical roles during unstressed conditions (Hartl, 1996). As 
these proteins play such an indispensable role in regulation of intracellular homeostasis, 
they have been highly conserved in structure through evolution among widely divergent 
organisms from bacteria to mammals (Lindquist, 1986; Benjamin and McMillan, 1998). 
Previous research has provided evidence about the different functional properties of HSPs. 
For some time, their function as molecular chaperones for other proteins has been known. 
For example, they have been involved in various intra-cellular processes and protein-
protein interactions such as protein biosynthesis, transport to mitochondria or endoplasmic 
reticulum, cell signalling, assembly of multi-subunit complexes, and degradation of toxic 
metabolites through ubiquitination and proteasome lysis (Chiang et al., 1989; Hightower, 
1991; Hendrick and Hartl, 1993; Becker and Craig, 1994). Most of the HSPs facilitate 
proper de novo folding, assembly and disassembly of proteins by recognising hydrophobic 
features of misfolded or partially unfolded substrate polypeptides (Gething and Sambrook, 
1992; Hartl, 1996). Via the action of HSPs, the distorted proteins can be restored to their 
native conformation and stabilised to prevent unwanted aggregation of denatured proteins. 
Enzymatic repair mechanism for methionine oxidation, proline isomerisation and 
formation of isoaspartyl residues may also stem from the reversal of a particular form of 
protein damage (Visick and Clarke, 1995). Additionally, HSPs also assist in the 
maintenance of proper protein structure during intracellular trafficking, denatured protein 
repair and direction of unsaveable proteins to intracellular “garbage disposal machines” 
(proteasome) for protein degradation (Hightower, 1991).  
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1.1.3    Synthesis of heat shock proteins 
Increases in HSPs synthesis is a key part of heat shock response against cell insults such as 
elevated temperatures, physiological or chemical stresses. Although there is a beneficial 
impact of HSPs upon stressful stimulation (increased HSPs level for cell survival), too 
much HSPs or prolonged exposure to HSPs can also be destructive. This can be explained 
by the cell adaptation mechanism. For example, when the temperature has been elevated 
for some time, the cellular conditions have probably adjusted to the temperature increase 
so that no further proteins are denatured, meaning that high concentrations of free HSPs 
could be lethal. This happens when the synthesis of more HSPs deplete the cell’s energy 
and nutrient stores, thus interfering with ongoing process in the cell. As HSPs can have 
both a positive and a negative impact on fitness, natural selection may have acted to 
balance these impacts in regulating the level of HSP expression (Feder and Hofmann, 
1999). Indeed, the heat shock gene expression is transcriptionally regulated by heat shock 
factors (HSF1-4), in particular HSF-1 in vertebrates, which is normally present in latent 
state under normal cellular conditions (McMillan et al., 1998). In resting cells, HSFs are 
bound to various HSPs in the cytosol. After stress, damaged proteins become abundant and 
there is a reduction of free HSPs, hence resulting in dissociation of HSFs from the HSPs. 
The stress signal then induces HSFs formation of monomers to homotrimers and initiates 
the translocation of HSFs from the cytosolic to the nuclear compartment. In the nucleus, 
HSFs transcriptional activity is activated upon phosphorylation and high-affinity DNA 
binding to an upstream promoter, sequence-specific heat shock element (HSE) which is 
located in the TATA-box-proximal 5’-flanking regions of heat shock genes (Amin et al., 
1988). As a result, the expression of new HSPs is increased. Upon cell recovery, HSF is 
dephosphorylated and most of the HSP exits the nucleus and return to the cytoplasm. In 
short, heat stress response actually depends on de novo synthesis of the HSPs (Fishelson et 
al. 2001). 
 
1.1.4    Families of heat shock proteins 
Traditionally, HSPs are classified into six major families: HSP40, HSP60, HSP70, HSP90, 
HSP100, and small HSPs (sHSPs) where the monomer size typically ranges between 12- to 
30-kDa proteins (Kappe et al., 2003). In addition, the subfamily of sHSPs in mammalian 
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system consists of 10 members (HSPB1-HSPB10) that can be further classified into two 
major categories (Class I and II) according to their subcellular or tissue distribution, gene 
expression patterns and transcriptional regulation (Taylor and Benjamin, 2005). In fact, 
HSPs are named mainly according to their structure and molecular weights which is 
expressed in kilodalton (kDa) (Rakonczay et al., 2003). For instance, the most widely-
studied HSP70 and HSP90 refer to HSPs of 70 and 90 kDa in size, respectively, although 
sizes may vary slightly among different organisms. Interestingly, the small 8-kDa protein 
ubiquitin which is responsible for heat- or stress-damaged protein degradation, also shares 
similar properties as HSPs (Raboy et al., 1991).  
 
1.1.5    Structure of heat shock proteins 
Although HSP families are genetically and biochemically different, there are significant 
homologies present in members from the same HSP family. For instance, all of the related 
HSP70 proteins have two distinct functional domains: a highly conserved N-terminal 
nucleotide binding domain which is responsible for ATPase activity, and a C-terminal 
domain substrate binding domain (Rudiger et al., 1997). Recently, it is shown that these 
two domains are connected by an adjacent exposed linker, which is important for 
mediating interdomain communication and chaperone function (Jiang, et al., 2005).  
As for sHSPs, their structures mainly consist of a poorly conserved N-terminal domain 
which is involved in chaperone activity and oligomerisation, followed by a highly flexible, 
variable C-terminal extension that shares similar polarity and hydrophobicity which is 
responsible for stabilising quaternary structure (de Jong et al., 1993; Kappe et al., 2003). 
Although the sizes of sHSPs vary considerably, all members of sHSPs share a highly 
conserved, homologous α-crystallin domain at the C-terminal with signature amino acid 
motif that is about 80-100 residues long (Casper et al., 1995). Excitingly, the crystal 
structure of rat HSP20 α-crystallin domain was solved recently, revealing two pockets and 
a shared groove interface at the C-terminal extension that are associated with 
homodimerisation (Bagneris et al., 2009). Notably, the interface is more extended 
compared to other sHSPs, thereby resulting in a less compact dimer which contributes to 
the versatility of HSP20 binding nature. 
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In addition, unlike other HSPs of higher molecular weight which contain ATP/ADP 
binding site, sHSPs promote proper refolding of denatured proteins by preventing 
aggregation in an ATP-independent fashion. Nevertheless, there is evidence showing that 
ATP hydrolysis is required for the interactions between sHSPs and other ATP-dependent 
chaperones, suggesting a cooperative relationship exists among these proteins (Wang and 
Spector, 2001).  
 
1.2      Heat shock protein 20  
Heat shock protein 20 (HSP20), also referred to as P20 or HSPB6 represents a prominent 
example of the sHSPs family. With apparent molecular mass of 20 kDa, HSP20 was first 
discovered in extracts of rat and human skeletal muscle when co-purified with HSP27 and 
αB-crystallin, suggesting similar functional properties for all three proteins (Kato et al., 
1994). HSP20 may exist as monomers or larger oligomeric structures, but has stronger 
tendency to form disulfide-linked dimers in a concentration-dependent manner (van de 
Klundert et al., 1998). Further experiments have demonstrated that HSP20 is active in the 
dimer form at low concentrations, whereas its activity is weakened when forming large 
oligomers at high concentration (Lee et al., 2005). In addition, size exclusion 
chromatography (SEC) has shown that subunits of HSP20 can be readily exchanged and 
interconverted for different sHSPs in complexes, to form heterooligomeric complexes that 
confer distinct biochemical properties (Bukach et al., 2004). Notably, the phosphorylation 
status of HSP20 is associated with its structural organisation which presents different 
aggregation patterns with respect to its functional role (van de Klundert et al., 1998). It was 
demonstrated that HSP20 phosphorylation at Ser16 altered its ability to aggregate thereby, 
triggering its protective effect, which is in agreement with earlier notion that the N-
terminal domain is essential for oligomerisation. Conversely, non-phosphorylatable HSP20 
favoured the formation of larger aggregates which ultimately resulted in loss of 
cardioprotection (Qian et al., 2009). On the other hand, there were studies reported that the 
phosphorylation of HSP20 is regulated by its formation of heterooligomeric complexes 
with other sHSPs. For example, HSP27 forms heterooligomeric complexes with HSP20 
and inhibits the rate of HSP20 phosphorylation by cAMP-dependent protein kinase 
(Bukach et al., 2009). Taken together, it is accepted that the different oligomerisation 
patterns of sHSPs is likely to affect their cytoprotective ability during cellular stress.  
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Moreover, intracellular concentration and cellular distribution of HSP20 tend to change in 
response to different cellular conditions. At basal level, HSP20 is primarily found in the 
cytosol but a subpopulation may translocate into the nuclear compartment in response to 
stress signals (Fan et al., 2005). Because HSP20 is ubiquitously expressed in almost all 
tissues, it is no surprise that numerous studies have focused on the functions of HSP20 in a 
variety of cellular processes, notably apoptosis and actin cytoskeletal rearrangements. In 
addition, as HSP20 presents at high levels especially in heart, skeletal and smooth muscle 
(reviewed in Fan et al., 2011), extensive work has also been carried out to examine the 
potential roles of HSP20 in cardiovascular disease (discussed later in Section 1.3.). 
 
1.2.1     HSP20 phosphorylation 
HSP20 is inactive or partially active under physiological conditions and converts to an 
active phosphorylated state upon modulation by stress-kinases. The phosphorylation of 
HSP20 normally occurs in response to increased levels of cyclic nucleotide second 
messengers that activate such upstream kinases. There are several phosphorylation sites 
identified to date, which play important roles in the functioning of HSP20. Serine 16, 
which is phosphorylated by cAMP-dependent protein kinase A (PKA) and cGMP-
dependent protein kinase G (PKG), has roles in mediating cyclic nucleotide-dependent 
smooth muscle relaxation and rate of relaxation in cardiomyocytes (Beall et al., 1997; 
Woodrum et al., 1999; Rembold et al., 2000; Pipkin et al., 2003; Chu et al., 2004). There 
is evidence showing that phosphorylation of HSP20 could be induced by sodium 
nitroprusside, a nitric oxide donor (Pipkin et al., 2003). Moreover, it was found that 
agonist-induced muscle contraction was inhibited by the introduction of phosphopeptide 
analogues of HSP20. It was thought that the phosphorylated HSP20 increased shortening 
and lengthening rates in rat cardiomyocytes through rapid uptake of calcium. In addition, 
HSP20 has been shown to localise in sarcomeric transverse bands, suggesting a role in 
regulating cytoskeletal or contractile dynamics of cardiomyocytes (Pipkin et al., 2003). 
Indeed, previous mechanistic studies have highlighted dynamic interactions between 
HSP20 and the cytoskeletal element, actin, as well as actin-binding protein α-actinin 
(Brophy et al., 1999; Tessier et al., 2003). Treatment of cells with ISO results in HSP20 
redistribution to the cytoskeleton and colocalisation with actin and this dynamic transition 
is most likely a phosphorylation-dependent reaction (Fan et al., 2004). Notably, non-
phosphorylated HSP20 associates with filamentous actin (F-actin), whereas 
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phosphorylated HSP20 binds to globular actin (G-actin). The actin-binding region 
spanning residues 110-121 of HSP20 shares sequence homology with the myofilament 
protein cardiac troponin I, a key regulator of cardiac contraction and relaxation (Rembold 
et al., 2000; Layland et al., 2005; Solaro et al., 2008). Clearly, this binding region is 
important to inhibit crossbridge formation via direct interaction with contractile elements, 
resulting in relaxation of smooth muscle. Indeed, Dreiza et al. (2005) showed that the 
phosphopeptide motif of HSP20 could modulate actin cytoskeletal dynamics by preventing 
the association of cofilin, an actin-depolymerising protein to the scaffold protein 14-3-3 
through a competitive binding mechanism.  
Other phosphorylation sites include serine 59 which is phosphorylated by protein kinase C 
(PKC) and serine 157 which is phosphorylated by insulin stimulation (Wang et al., 1999; 
Chu et al., 2004). Serine 157 phosphorylation site is not conserved in human HSP20 and 
the physiological significance of serine 59 phosphorylation is unclear. To date, most 
assumptions about the significance of HSP20 phosphorylation have been made around 
serine 16, which is located within the sequence motif (RRXS), a characteristic consensus 
motif for PKA/PKG (Fan and Kranias, 2005). More interestingly, HSP20 is the only 
sHSPs that possesses this target motif despite sharing considerable sequence homology 
with HSP27 and αB-crystallin (Kato et al., 1994). 
The phosphorylation of HSP20 is thought to be a critical aspect of neurohormonal 
regulation. Indeed, increasing evidence has suggested that HSP20 phosphorylation is an 
important event in the β-adrenergic signalling cascade in the myocardium, pointing to its 
potential role as a mediator in cardiac responses. This is supported by previous findings 
which showed that HSP20 expression was increased and its phosphorylation was 
specifically induced by the β-adrenergic agonist, ISO in cardiomyocytes (Chu et al., 2004). 
Similar observations were also obtained in post-infarcted animal hearts, pinpointing a 
compensatory role of HSP20 phosphorylation in the pathophysiology of heart (Fan et al., 
2005; Qian et al., 2009). 
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1.3      HSP20 in the cardiovascular system 
There has been a rapid increase in the prevalence of cardiovascular disease in recent years. 
Despite therapeutic advances, heart diseases which are often caused by the malfunction of 
cardiac cell homeostasis remain as leading causes of death in industrialised nations. 
Because HSPs are normally up-regulated in response to stress stimuli in order to modulate 
cellular homeostasis, the many emerging roles of sHSPs in a cardiac setting may suggest 
potential therapeutic avenues for intervention in heart diseases (Ghayour-Mobarhan et al., 
2009). Numerous studies have been carried out to define the roles of HSP20 in cellular 
protection systems, in particular, its protective capabilities against myocardial dysfunction. 
In short, the roles of HSP20 in heart can be broadly divided into three areas, i.e. 
ischaemia/reperfusion injury, apoptosis and hypertrophy.  
 
1.3.1     Ischaemia/reperfusion injury 
In the heart, ischaemia is often accompanied by reperfusion and induces apoptosis, which 
may ultimately lead to myocardial defects (Eefting et al., 2004). Because HSPs synthesis 
tends to increase as a response to protect cell after stress stimuli, much research has also 
been carried out to investigate the contribution of HSP20 to protect cells during ischaemia 
and reperfusion injury. Using transgenic mice with cardiac-specific overexpression of 
HSP20, it is reported that the expression of total HSP20 was upregulated by 
ischaemic/reperfusion insult. This in turn promoted protection against 
ischaemia/reperfusion-induced injury by reducing myocardial infarction size in HSP20 
transgenic hearts in vivo and improving their cardiac function during reperfusion, as 
compared with wild-type mice (Fan et al., 2005). Correspondingly, blockade of HSP20 
phosphorylation by expression of a phospho-null HSP20 (S16A) mutant in hearts increased 
susceptibility to ex vivo ischaemia/reperfusion-induced cellular disruptions such as 
necrosis and apoptosis (Qian et al., 2009). Interestingly, autophagy, a process which 
degrades damaged or non-functional cytoplasmic organelles, was activated in wild-type 
but not in S16A hearts. Notably, further investigation revealed that S16A hearts pre-treated 
with rapamycin, an activator of autophagy, led to improvement of functional recovery 
compared to untreated control. Hence, it was proposed that HSP20 protects against 
ischaemia/reperfusion injury via its phosphorylation which increases autophagy activity 
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and decreases cell death. In contrast, HSP20 suppresses autophagy activity when HSP20 
phosphorylation of Ser16 is blocked, thereby increasing cell death and lead to cardiac 
injury (Qian et al., 2009). Clearly, the phosphorylation status of HSP20 and corresponding 
level of autophagy are likely to determine the fate of the heart in response to 
ischaemia/reperfusion insult. More recently, HSP20 phosphorylation at Ser16 was shown 
to be associated with an autophagy marker, Beclin 1, to promote cardiac autophagy, 
thereby inducing cardioprotection (Zhu et al., 2011). 
In addition, similar salutary effects were also reported in chronic doxorubicin (DOX)-
triggered cardiac toxicity in HSP20 transgenic mice (Fan et al., 2008). The overexpression 
of HSP20 in the heart attenuated doxorubicin (DOX)-induced ischemia/reperfusion injury 
and inhibited cardiac apoptosis via Akt phosphorylation.  Evidence also exists delineating 
the relationship between HSP20 and microRNA, a small non-coding RNA which regulate 
gene expression via RNA destruction or RNA-induced silencing complexes (Latronico et 
al., 2007). It was reported that overexpression of microRNA-320 promotes apoptosis and 
cell death in cultured adult rat cardiomyocytes and transgenic mice during 
ischaemia/reperfusion injury, whereas cytoprotection was initiated in knockdown model 
via negative regulation of HSP20 (Ren et al., 2009). In addition, gene transfer of HSP20 in 
rat hearts in vivo displayed better functional recovery and reduced myocardial necrosis and 
apoptosis upon ischaemia/reperfusion injury (Zhu et al., 2005). Collectively, these 
observations underscore the adaptive protective response of HSP20 in the heart upon 
physiological and pathophysiological stress. These HSP20-mediated processes are 
exceptionally important in reducing injury from ischemia/reperfusion, which is often 
manifested during heart diseases, organ transplantation and post-operatively.  
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1.3.2     Apoptosis 
Apoptosis is defined as programmed cell death that does not involve an inflammatory 
reaction. It can also be induced when cells are exposed to non-physiological conditions 
such as stress insult. Previous work has shown that prolonged stimulation with ISO 
induces cardiac apoptosis, resulting in the decompensation of hypertrophic myocardium 
and the progression of end-stage heart failure (Tevaearai and Koch, 2004). Because 
apoptosis can directly lead to cardiomyopathy without undergoing cell replacement 
(Bishopric et al., 2001), it has been regarded to be an important prognostic indicator in 
patient with ischaemic heart disease and heart failure. Hence, special attention has been 
given to investigations of the induction of cytoprotective mechanisms in apoptotic 
signalling pathways.  
Recent studies utilising adenovirally expressed HSP20 have shown that the overexpression 
of HSP20 confers cellular protection against ISO-mediated apoptosis in cardiomyocytes, as 
indicated by reduced pyknotic nuclei (Fan et al., 2004, 2006). It is clear from this report, 
that the alteration of HSP20 expression levels triggers an adaptive response to adrenergic 
stress. Further studies using loss-of-function and gain-of-function cardiomyocyte models 
verified that the HSP20 phosphorylation state correlates with its anti-apoptotic function. In 
fact, using non-phosphorylatable HSP20 (S16A) and constitutively phosphorylated HSP20 
(S16D) forms, it was further proven that S16D overexpression conferred greater anti-
apoptotic effect than wild-type through the inhibition of caspase-3 activation (Fan et al., 
2004). However, the protective effect was abrogated in S16A mutant. In view of these 
findings, it is likely that, HSP20 phosphorylation at Ser16 promotes its anti-apoptotic 
function. 
To date, possible downstream targets of HSP20 in cardiac survival/apoptosis pathways 
activated by the cAMP-PKA pathway include actin and Bax. HSP20 association with these 
targets results in stabilisation of cytoskeletal architecture and inhibition of apoptosis, 
respectively (Fan et al., 2004; 2005) (Fig. 1.1). The cascade begins with phosphorylation 
of HSP20 by a stress-kinase, followed by oligomer dissociation and conformational change 
of HSP20 to promote binding to the targets. Here, HSP20 is shown to translocate to the 
actin filaments and stabilise the microfilament assembly. Anti-apoptotic effects were 
achieved via the binding of HSP20 to Bax, thereby preventing the translocation of Bax 
from the cytosol into the mitochondria. As a result, the integrity of mitochondria was 
maintained, inhibiting the release of cytochrome C and repressing caspase-3 activity. 
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Furthermore, Wang et al. (2009) found that overexpression of HSP20 could improve 
contractility and cell viability in response to endotoxin-induced myocardial dysfunction 
and apoptosis. These protective effects appear to be mediated through suppression of 
nuclear factor–κB (NF-κB) activation which reduced proinflammatory cytokine production 
such as tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) production, and 
inhibition of caspase-3 activity.  
It is also noteworthy that there are opposing effects of β-adrenoceptor subtypes on 
apoptosis in cardiomyocytes. Pharmacological studies have reported that stimulation of β1-
adrenoceptors leads to cardiac apoptosis, whereas stimulation of β2-adrenoceptors confers 
protection against apoptosis (Zaugg et al., 2000). Nevertheless, it is conceivable that 
HSP20 is a negative regulator of apoptosis as it could prevent the effector steps of 
apoptotic cell death. This special ability of HSP20 is essential to confer cardioprotection 
during heart failure as this complication is often accompanied by apoptosis. 
Other studies have utilised mutational analyses to reveal a single nucleotide base mutation 
of C59T, changing a highly conserved proline residue to leucine at position 20 (P20L) in 
human HSP20. This mutation was shown to affect HSP20 phosphorylation at Ser16 and 
abrogate its cytoprotective effects (Nicolaou et al., 2008). This mutation conferred no 
protection against apoptosis as shown by Hoechst staining and DNA fragmentation. It was 
further confirmed that the impaired ability was due to diminished phosphorylation at Ser16, 
reaffirming its critical role in cardioprotection. 
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Figure 1.1 HSP20 and its cardioprotective roles. Schematic diagram showing the roles 
of HSP20 and its phosphorylation in regulation of actin reorganisation and apoptosis 
activity upon β-adrenergic stimulation. (Adapted from Fan et al., 2005) 
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1.3.3     Hypertrophy 
Besides having well-establised roles in cardiac injury and apoptosis, there is also emerging 
evidence to suggest a role for HSP20 in the physiological adaptation during cardiac 
hypertrophy. The development of the heart is differentially regulated depending on 
different stages of morphogenesis. Cardiomyocytes actively proliferate at embryonic and 
fetal stages, but gradually lose their capacity for cell division during the early post-natal 
period. After birth, any growth of the myocardium is primarily due to hypertrophic growth 
(Ahuja et al., 2007). 
Cardiac hypertrophy involves ventricular enlargement, remodeling and generally presents 
as an increase in cell size without cell division or any increase in cell number. It often 
develops in response to long-term excessive hemodynamic stress such as pressure and 
volume overload in response to various intrinsic and extrinsic stimuli, including 
neurohormones, growth factor and mechanical stress (Sugden, 1999). The process of 
hypertrophy can be mainly divided into two stages of development: the compensatory 
hypertrophy stage and decompensatory stage which potentially leads to heart failure. 
Cardiac hypertrophy may initially be an adaptive physiological process that normalises 
wall stress and compensates for the lost contractile performance in the short term. Such a 
phenotype of heart enlargement is reversible and is regarded as a physiological 
phenomenon, normally seen during chronic exercise or pregnancy. However, due to 
ancillary changes such as fibrosis, reduced contractility and chamber dilatation, prolonged 
hypertrophy can be maladaptive and detrimental, often accompanied by irreversible 
damage. Consequently, it may eventually impair cardiac function, resulting in reduced 
pump function and invariably leading to the progression of catastrophic heart failure (Frey 
and Olson, 2003).  
The development of cardiac hypertrophy is also accompanied by phenotypic modifications. 
The typical cellular features of pathological hypertrophy promote cardiac remodelling 
which is associated with an increase in cardiomyocyte size, enhanced protein synthesis and 
reorganisation of actin filament (reviewed in Frey and Olson, 2003). In addition, there are 
also alterations in gene expression which can be divided into three phases. Initially, 
immediate-early gene expression including c-fos, c-jun and Egf, which are involved in 
regulation of myofibrillar proteins are rapidly increased (Izumo et al., 1988). This is 
followed by the re-expression of fetal genes such as natriuretic peptide hormones [atrial 
natriuretic factor (ANF) and brain natriuretic factor (BNF)] and embryonic contractile 
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proteins [β-myosin heavy chain (β-MHC) and skeletal muscle α-actin]. This fetal gene 
expression normally occurs during 12 to 24 h. After 24 h, other constitutive contractile 
protein genes like cardiac muscle α-actin and ventricular myosin light chain 2 (vMLC2) 
are re-expressed (Chien et al., 1991; Rosenzweig and Seidman, 1991). As such, these 
genes are regarded as molecular markers of cardiac hypertrophy. 
Interestingly, there are different pathways activated in response to different durations of 
hypertrophic stimuli during the hypertrophy signaling process. Short-term exposure to β-
adrenergic stimulation is particularly important in mediating heart contractility upon fight-
or-flight response. However, chronic stimulation of β-adrenergic agonists has been shown 
to have deleterious effects in animal models and human subjects, resulting in pathological 
cardiac remodeling and the progression of heart failure. Recent studies have revealed that 
sustained ISO stimulation results in the over-expression and phosphorylation of the small 
heat shock protein 20 (HSP20). Together, these actions combine to attenuate the 
hypertrophic growth of cardiomyocytes by triggering cardioprotective functions (Fan et al., 
2005). In addition, it has become apparent that apoptosis signal-regulating kinase 1 (ASK1) 
is involved in the regulation of stress-activated protein kinases, such as c-Jun N-terminal 
kinase (JNK) and p38 mitogen-activated protein kinase (MAPK), which are implicated in 
the onset of cardiac hypertrophy (Hirotani et al., 2002). Further work has revealed an 
association between increased HSP20 expression and the downregulation of ASK1 in mice 
infused with prolonged ISO (Fan et al., 2006). After treatment, transgenic mice 
overexpressing HSP20 exhibited minimal heart enlargement and smaller increases in cross-
sectional area of cardiomyocytes, as well as downregulation of fetal gene expression. It 
was deduced that both the overexpression and phosphorylation of HSP20 were involved in 
the downregulation of ASK1-JNK/p38 signalling. Consequently, this led to the attenuation 
of cardiac remodeling and inhibition of ISO-triggered apoptosis in vivo and in vitro, 
thereby hindering ISO-mediated hypertrophy and the downstream progression of heart 
failure. Nevertheless, the molecular mechanism of HSP20 induced cardioprotection is not 
yet clearly defined. Not much is known about the regulation of HSP20 and if other 
signalling pathways are also involved.  
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1.4      HSP20 in other diseases 
With ever-increasing interest on the function of HSP20 in cardiovascular system, it is also 
apparent that HSP20 is implicated in many other pathological processes. Besides the 
aforementioned examples, HSP20 can also be found in blood and was found at lower level 
in injured arteries. Subsequently, the release of HSP20 is induced from the arterial walls 
into the circulation as an immediate response to endothelial injury and thus affects platelet 
functions (Kozawa et al., 2002). It has been shown that HSP20 suppresses platelet 
aggregation by binding to platelets at its N-terminal platelet aggregation inhibitory domain 
via protease activated receptor-1 (PAR-1) and platelet glycoprotein complex (GPIb/V/IX-
von Willebrand factor axis), which may be beneficial in myocardial infarction (Matsuno et 
al., 2003; Fan et al., 2005). There have also been studies examining the role of HSP20 in 
the mediation of PKA-dependent airway smooth muscle (ASM) relaxation (Komalavilas et 
al., 2008). Using human airway smooth muscle (HASM) cell lines, the PKA-mediated 
phosphorylation of HSP20 has been shown to lead to relaxation of ASM, which is 
associated with the disruption of actin stress fibers. In contrast, inhibition of this pathway 
prevents alterations in stress fiber morphology and focal adhesion complex formation 
which favour bronchospasm in asthma. Because phosphorylation of HSP20 is associated 
with dephosphorylation of cofilin to disrupt actin in ASM, it is suggested that HSP20 
mediates ASM relaxation through its direct regulation of actin filament assembly. 
In addition, HSP20 is also implicated in the prevention of β-amyloid (Aβ) fibril formation 
in senile plaques in the brain, a pathological hallmark of neurodegenerative diseases such 
as Alzheimer’s disease (Lee et al., 2005, 2006). It is known that Aβ deposits readily in 
vitro and in vivo, and forms toxic fibrils and protofibrils upon aggregation. Interestingly, 
HSP20 was shown to reduce Aβ-mediated cytotoxicity by interacting with Aβ and 
preventing its aggregation, thereby resulting in the solubilisation and clearance of toxic Aβ 
oligomers in neuronal cells (Lee et al., 2005, 2006). This suggests a potential role of 
HSP20 as an antagonist of the biological action of Aβ, in particular the formation of Aβ 
aggregates. 
Recent studies have also highlighted possible roles of HSP20 in carcinogenesis. It was 
reported that HSP20 expression decreases with tumour growth in patients with 
hepatocellular carcinoma (HCC), pinpointing a suppressive effect of HSP20 on the 
progression of human HCC (Noda et al., 2007). Accordingly, HSP20 expression was 
inversely correlated with tumour stage by TNM (Tumour, Node, Metastasis) classification, 
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degree of metastasis and tumour size. Further investigations on the role of HSP20 in HCC 
proliferation revealed that overexpression of HSP20 inhibited the growth of HCC via the 
suppression of MAPKs and AKT signalling pathways (Matsushima-Nishiwaki et al., 2011). 
Seemingly, HSP20 negatively regulate MAPK/ERK kinase (MEK) [mitogen-activated 
protein kinase (MAPK)/ extracellular signal-regulated kinase (ERK)], c-jun N-terminal 
kinase (JNK) and PDK1 (3-phosphoinositide-dependent protein kinase-1), leading to the 
downregulation of cyclin D1 expression, thereby hindering neoplastic transformation and 
growth. In contrast, the decrease in HSP20 expression promotes proliferation of HCC, 
hence contribute to tumour progression. 
Taken all together, it is clear that HSP20 shows versatile functions, being implicated in a 
wide range of biological roles. It is purported that the versatility of HSP20 is partly due to 
its interaction with 14-3-3, resulting in the displacement of many other 14-3-3 binding 
partners from their complexes with 14-3-3 (Seit-Nebi and Gusev, 2010). Moreover, HSP20 
is regulated by various protein kinases which are key regulators of many cellular functions 
(Fan et al., 2006, 2008). Undoubtedly, the multifunctional nature of HSP20 makes it a 
particular attractive molecular target for future therapeutic interventions.  
 
1.5      Cardiac cell-based model 
The use of relevant models for cardiovascular research is essential to provide valuable 
information to reflect the physiological condition of heart tissue, as well as to unravelling 
mechanisms of the pathogenesis of cardiovascular diseases. To date, the most commonly 
used experimental models include intact whole heart and primary culture of 
cardiomyocytes. Amongst those models, neonatal and adult rat cardiomyocytes have been 
used extensively for decades as tools to study and understand the morphological, 
biochemical and electrophysiological characteristics of the heart under controlled 
conditions. These models have also been used to evaluate cardiac toxicity and identify 
candidate molecules for testing in animals. Because rats share a high degree of genetic 
homology to humans, it is anticipated that the experimental findings will be of relevance to 
human biology. 
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In view of previous studies which have documented that cardiac hypertrophy can be 
induced by sustained adrenergic stimulation (Morisco et al. 2001; Zhang et al., 2002), 
animal models of chronic agonist administration have been considered as a suitable 
experimental setting to study the effect of sympathetic overactivation on myocardial 
function. Hence, in the present study, neonatal rat cardiomyocytes were mainly utilised as 
an in vitro cardiac cell system to study the cellular and molecular aspects of cardiac 
function, particularly hypertrophic signalling in response to prolonged β-adrenergic 
stimulation. Importantly, it is economical, readily available, versatile, manageable and 
labour-saving, as compared to the calcium-sensitive adult rat cardiomyocytes model, which 
is more prone to cellular disintegration, hence requiring more stringent protocols. 
Moreover, previous studies have shown that the phenotype of cultured neonatal 
cardiomyocytes is very stable. Their contractile profiles correspond to the hearts in situ and 
hypertrophic growth is quite similar to the adult myocardium, thereby allowing better 
functional evaluation of hearts (Yamashita et al., 1994).  
 
1.6       Aims of research 
On the basis of the aforementioned findings, it is evident that HSP20 is a multifaceted 
protein which plays many pivotal roles in cardioprotection. My PhD project aims to further 
elucidate the molecular mechanisms that underpin HSP20’s unique ability in this regard. 
My thesis focuses on induced cardioprotection against cardiac dysfunction, in particular 
hypertrophy, as there is a great paucity of information on this subject regarding HSP20. 
This study is divided into three parts:  
(1)   neonatal rat cardiomyocytes as a model system to study hypertrophy signalling  
(2)   investigations into the role(s) of the PDE4-HSP20 complex in hypertrophy;  
(3)  identification of novel signalling complexes containing HSP20 and characterisation of 
their possible mechanisms of action 
It is anticipated that my findings may enhance our current knowledge about the functions 
of HSP20 and provide direction towards a novel treatment for hypertrophy. 
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2.1   Materials 
The chemicals used in this study were of analytical grade. All chemicals were supplied by 
Sigma-Aldrich unless otherwise indicated. Isoprenaline (ISO) and disruptor peptides were 
dissolved in dimethly sulfoxide (DMSO) and added to cell media at a final concentration 
of 0.001% of DMSO. The water used in all experiments was purified by a water 
purification system with automatic sanitization module (Millipore, France).  
 
2.2   Expression and Purification of Recombinant Proteins 
2.2.1     Histidine (His) Fusion Protein 
Ultimate™ ORF clone IOH57317 (Invitrogen), containing the open reading frame (ORF) 
of human HSP20 in pENTR221 vector, was used to generate an N-terminal His-tagged 
protein by Gateway cloning technology into pDEST-17 vector (Invitrogen). Escherichia 
Coli (E. Coli) cells containing the plasmid were inoculated into 10 ml of Luria-Bertani 
(LB) medium supplemented with 100 µg/ml ampicillin and grown overnight in an orbital 
shaker at 37 
o
C. The overnight culture was then added to 500 ml of LB medium 
supplemented with 100 µg/ml ampicillin and grown for a further 2.5 h. The density of the 
cell growth was monitored at regular intervals. Once the cell density reached OD600 ≈ 0.6-
0.7 indicating that the culture was in the logarithmic phase, the exponentially growing cells 
were then subjected to 1 mM of isopropyl-β-D-thiogalactopyranoside (IPTG) to induce 
protein expression. Cells were grown for a further 3 h at 37 
o
C and subsequently pelleted 
by centrifugation at 6000 x g for 10 min at 4 
o
C. The cell pellets were resuspended in 10 ml 
of lysis buffer (50 mM Tris-HCl; pH 8.0, 300 mM NaCl, 10 mM imidazole) supplemented 
with protease cocktail inhibitor tablet (Roche) and frozen at -80 
o
C overnight. Imidazole 
was added to the lysis buffer to increase purity by minimising binding of untagged and 
contaminating proteins. Frozen cells were thawed on ice  the following day and subjected 
to sonication (40-60 kHz; Sonicator, Jencons, England) for 10 min (seven cycles of 30 sec 
each with a one-min pause for cooling after every treatment) to ensure sufficient cell lysis 
occurred. Following lysis, cell lysates were centrifuged at 13000 rpm for 15 min at 4 
o
C to 
collect the soluble fractions and remove cell debris. The cell supernatants were then 
incubated end-over-end with pre-equilibrated nickel-nitrilotriacetic acid (Ni-NTA) resins 
(Qiagen) for 1 h at 4 
o
C with gentle agitation for binding of expressed fusion protein. The 
resins with bound protein was then transferred to a disposable column and washed 
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extensively with wash buffer (50 mM Tris-HCl, 300 mM NaCl; pH 8.0) containing 10 mM 
imidazole to reduce background contaminants. The fusion protein was then eluted from the 
Ni-NTA resins with elution buffer (50 mM Tris-HCl, 300 mM NaCl, pH 8.0) containing 
linearly increasing concentrations of imidazole (25-250 mM) to increase purity of 
recombinant fusion protein.  
40 µl samples from each step were collected for analysis by SDS-PAGE and Coomassie 
staining as described in Section 2.6.1 and 2.6.2. The most pure eluted fractions (indicated 
by single band on a gel) were then pooled and subjected to ultrafiltration using a Vivaspin 
device (Sartorius Stedim Biotech) containing dialysis buffer (5% glycerol (v/v), 50 mM 
Tris-HCl; 100 mM NaCl, pH 8.0) for buffer exchange and sample concentration. After 
obtaining the desired concentration, the purified recombinant fusion protein was frozen on 
dry ice and stored as aliquots at -80 
o
C until further use.  
 
2.2.2    Glutathione-S-Transferase (GST) Fusion Proteins 
Full–length human PDE4D5 was expressed as an N-terminal GST-fusion protein using 
pGEX-6P1 vector (Invitrogen). Culture were grown, induced, harvested and lysed as 
described above. Purification of GST fusion proteins were carried out using glutathione 
sepharose resin (Amersham Biosciences) and elution buffer composed of 10 mM reduced 
glutathione, 50 mM Tris-HCl; pH 8.0. The subsequent procedures were similar to the 
purification of His protein as described above in Section 2.2.1. 
 
2.3       Plasmid DNA 
All plasmid work was carried out in a sterile environment and all buffers were autoclaved 
prior to use. 
2.3.1     Transformation of competent cells 
BL21 competent cells (Invitrogen) were stored at -80 
o
C and thawed on ice prior to use. 1-
10 ng of DNA was added to 50 µl of competent cells and incubated on ice for 15 mins. The 
cells were then heat shocked at 42 
o
C for 45 sec then placed on ice for 2 mins. The solution 
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was added to 450 µl Luria Broth (LB) media (1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-
yeast extract and 170 mM NaCl) containing 100 µg/ml ampicillin and incubated at 37 
o
C 
for 1 h with shaking. 50-250 µl of transformation mix was then spread on 100 mm petri 
dishes containing LB media, 1.5% (w/v) agar and 100  µg/ml ampicillin, and incubated 
overnight at 37 
o
C. The growth of bacterial colonies indicated successful cell 
transformation.  
 
2.3.2     Isolation of Plasmids DNAs 
Single colonies were picked and grown overnight in 5 ml LB media containing 100  µg/ml 
ampicillin in an orbital shaker at 37 
o
C. QIAprep Miniprep Kit (Qiagen) was used to isolate 
smaller amounts of plasmid DNA. Alternatively, for a larger volume of bacterial culture, 
the 5 ml overnight bacterial culture was added onto a 500 ml LB media supplemented with 
100 µg/ml ampicillin and incubated a further 12-16 h. The large amounts of plasmid DNA 
was extracted using QIAprep Maxiprep Kit (Qiagen) according to the manufacturer’s 
instructions. The purified DNA was then eluted with either sterile H20 or TE buffer (10 
mM Tris-Cl, 1 mM EDTA; pH 7.5) and stored at -20 
o
C. 
 
2.3.3    Storage of plasmid DNA 
For plasmid storage, 1 ml of overnight culture was removed and mixed with 500 µl 
sterilised glycerol in a sterile cryovial. The glycerol stock was then snap-frozen on dry ice 
and stored at -80 
o
C until required. 
Glycerol stocks could also be used to inoculate culture media by scraping the frozen stock 
with a sterile pipette tip and then transferred into 5 ml LB media containing 100 µg/ml 
ampicillin. The plasmid isolation was then performed as described in Section 2.3.2. 
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2.3.4     Analysis of plasmid DNA 
Agarose gel electrophoresis was used to separate DNA by molecular weight. Negatively 
charged DNA samples will migrate from the cathode toward the anode during 
electrophoresis. The DNA was resolved on a 1 % agarose gel dissolved in Tris-acetate 
acid-EDTA (TAE) buffer containing 40 mM Tris-Cl; pH 8.5, 0.114% (v/v) glacial acetic 
acid and 2 mM EDTA. The solution was allowed to cool slightly before adding 0.5 µg/ml 
ethidium bromide. For gel casting, the solution was poured into the Bio-Rad Mini-Sub Cell 
GT agarose gel system with comb inserted to create wells and allowed to set at room 
temperature. Once set, the comb was removed and the gel was placed in a gel tank 
containing TAE buffer.  DNA samples were diluted 1:6 in loading buffer (0.25% (w/v) 
bromophenol blue, 0.25% (w/v) xylene cyanol FF and 40% (w/v) sucrose). 1kb DNA 
ladder (Promega) was used as a molecular size marker. The gel was run at 100 V until the 
first dye front (bromophenol blue) has migrated about 2/3 of the gel. The gel was then 
removed from the tank and visualised on an ultraviolet transilluminator (Gel Doc XR+ 
System, Bio-Rad).  
 
2.3.5     Quantification of DNA concentration 
The concentration of purified DNA was determined by Nanodrop 3300 spectrophotometer 
(Thermo Scientific). Absorbance wavelength was set at 260 nm and 280 nm. The A260:A280 
ratio determines the purity of DNA where a value of 1.8 is indicative of highly purified 
DNA. The DNA concentration was calculated using the Beer-Lambert law, where an A260 
reading of 1.0 optical density (OD) unit is equivalent to 50 µg/ml double-stranded DNA 
(Sambrook et al., 1989). 
 
2.4      Mammalian cell culture 
All cell culture procedures were carried out in a Class II hoods using standard aseptic 
techniques and sterile instruments. All culture reagents were supplied by Sigma. The tissue 
culture flasks, dishes and pipettes were supplied by Corning. All cultures were examined 
regularly under a phase contrast inverted microscope (Leitz Diavert, Germany) to confirm 
the healthy status of the cells and the absence of contamination. 
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2.4.1     Primary culture of cardiomyocytes 
The preparation of neonatal rat cardiomyocytes was based on a modification of the 
methods described by Bogoyevitch et al. (1995) and Chlopeikova et al. (2001). 
Cardiomyocytes were dissociated from the ventricles of neonatal Sprague-Dawley rat 
hearts (1-3 days old) by serial digestion with 0.3 mg/ml Type 2 collagenase (Worthington) 
and 0.6 mg/ml pancreatin (Sigma) in a balanced salt solution containing 120 mM NaCl, 20 
mM HEPES, 5.5 mM glucose, 5.4 mM KCl, 1 mM NaH2PO4 and 0.8 mM MgSO4 (pH 7.4). 
The first digestion supernatant (5 min at 130 cycles/min in a shaking water bath at 37 
o
C) 
was removed and discarded. The digestion step was repeated 3-5 times till tissue was 
digested completely (20 min each at 160 cycles/min shaking). Cell suspensions from every 
digestion were collected and centrifuged at 1250 rpm for 5 min. Each cell pellet was then 
resuspended in 2 ml of newborn calf serum and kept at 37 °C in a humidified incubator 
with an atmosphere of 95% air and 5% carbon dioxide. After the final digestion, the cell 
suspensions were pooled and centrifuged at 1250 rpm for 5 min before being resuspended 
in plating medium containing Dulbecco’s modified Eagle’s medium (DMEM)/M199 [4:1 
(v/v)], supplemented with 10% horse serum, 5% fetal calf serum, 100 units/ml penicillin-
streptomycin). Since non-myocardiomyocytes attach to the substrate more readily than 
cardiomyocytes, the cells were pre-plated on non-coated T-75 flask (Corning) for 2 h to 
allow differential attachment of non-myocardial cells. The non-adherent cardiomyocytes 
were then collected and centrifuged at 1250 rpm for 5 min. After counting, the cells were 
plated at a density of 2 x 103 cells/mm
2
 on culture dishes pre-coated with sterile 1% (w/v) 
gelatin (Sigma-Aldrich). The purity of cardiomyocytes culture was determined by 
immunocytochemistry with an anti-α-sarcomeric actinin mouse antibody, a well-known 
protein marker in the cytosol of cardiomyocytes (See Section 2.11.2). 
For hypertrophy induction, plating medium was removed after 24 h and cells were cultured 
in serum-free maintenance medium containing DMEM/M199 [4:1 (v/v)] and 100 units/ml 
penicillin and streptomycin. After 48 h of culture in the serum-free medium, 
cardiomyocytes were stimulated by 10 µM of ISO for 24 h. 
Alternatively, for microscopic experiments, cardiomyocytes were plated at a density of 1.4 
x 10
3
 cells/mm
2
 on slides pre-coated with laminin (BD Biosciences). Where appropriate, 
cardiomyocytes were pretreated with compounds before being stimulated for 24 h with 10 
µM isoprenaline for hypertrophy induction. Cells derived from the same primary culture 
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were used for each set of experimental comparisons (n=1). All experiments were 
performed at least 3 times with different primary cell isolates. 
 
2.4.2     HEK293 cells 
The human embryonic kidney 293 (HEK293) cells were cultured in 75 cm
2
 culture flasks 
at 37 
o
C in a humidified atmosphere of 5% CO2 and 95% air.  Cells were maintained in 
growth media containing DMEM supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 100 U/µg penicillin-streptomycin in a humidified atmosphere containing 5% 
CO2. For routine cultures, the media were replenished every 2-3 days. The cells were 
passaged when reaching approximately 80% confluency to improve cell growth.  To 
passage, growth medium was removed and the cells were gently washed in sterile pre-
warmed phosphate buffer saline (PBS) to remove traces of serum. The PBS was then 
discarded and the cells were treated with 2 ml of trypsin-EDTA solution per 75 cm
2
 culture 
flask of cells to dissociate cells in the monolayer. 8 ml of growth medium was then added 
to inactivate the trypsin-EDTA solution and cells were collected by centrifugation at 
12,000 rpm for 3 min at room temperature. The supernatant was removed and the cell 
pellet was resuspended in fresh growth media. The volume of PBS, trypsin-EDTA and 
growth media were adjusted according to the size of the culture flask. When cells were 
harvested for long term storage, the cells were resuspended in 10% dimethyl sulfoxide 
(DMSO) containing growth medium and stored at -80 
o
C. 
 
2.4.3     Transfection of plasmid DNA 
 
DNA plasmid constructs used for transfection included V5-HSP20 in pDEST vector and 
GFP-PKD in pEF-BOS vector. For transient expression, HEK293 cells were plated at a 
density of 4 x 10
5
 cells per 100 mm dish. Transfections were performed at 50–70% 
confluence with 8 µg of circular plasmid DNA using Polyfect transfection reagent (Qiagen) 
according to the manufacturer's instructions. Briefly, the cells were plated at a density of 4 
x 10
5
 cells per 100 mm dish. After 24 h transfection, the medium was replaced with fresh 
prewarmed culture medium and was further incubated for 24 h prior to experiments. This 
assay was scaled down for smaller culture dishes. For microscopic experiments, cells were 
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plated out onto poly(L-lysine)-treated slides at approximate 40% confluence. 24 h after 
transfection, cells were fixed and permeabilised before immunostaining. 
 
2.4.4     siRNA-mediated gene knockdown in cardiomyocytes 
Small interfering RNA (siRNA) knockdown was carried out to access gene function of 
PKD1 protein. Cardiomyocytes were plated at a density of 2 x 10
5
 cells/ well in 6-well 
plates. The cells were cultured in antibiotic-free normal growth media supplemented with 
FBS prior to transfection. A siRNA transfection kits containing siRNA specific for rat 
PKD1 (sc-36260), control siRNA-A (sc-37007) and siRNA transfection reagent (sc-29528) 
were purchased from Santa Cruz Biotechnology. The cells were transfected with control 
siRNA or PKD1 siRNA at a final concentration of 80 pmols according to the 
manufacturer’s protocol. The siRNA duplex solution was added directly to the transfection 
reagent and incubated for 30 min at room temperature before adding drop-wise onto the 
cells. The cells were incubated for 5-7 h at 37 
o
C in a CO2 incubator. At the end of the 
incubation, normal growth medium containing 2 times the normal serum and antibiotics 
concentration was added to the culture and incubated for an additional 24 h. The medium 
was then removed and replace with fresh 1x normal growth medium. Effect of PKD1 
siRNA on phospho-HSP20 expression was determined 48 h post-transfection. 
 
2.5      Preparation of cell lysates 
2.5.1     Whole cell lysates 
Protein extracts were prepared from cardiomyocytes and HEK293 cells. The culture media 
was removed and the cells were washed thrice in ice cold sterile PBS. The culture plates 
were drained thoroughly before adding 3T3 cell lysis buffer (50 mM NaCl, 50 mM NaF, 
25 mM HEPES, 5 mM EDTA, 30 mM sodium pyrophosphate, 10% glycerol, 1% Triton X-
100; pH 7.5) supplemented with protease cocktail inhibitor tablet (Roche). The cell lysates 
were collected using a sterile scraper and transferred into 1.5 ml Eppendorf tubes kept on 
ice. The tubes were placed on a rotating wheel for 30 min at 4 
o
C before centrifuging at 
2000 x g for 10 min at 4 
o
C.  The lysate supernatant was then snap frozen in dry ice and 
stored at -80 
o
C until required. 
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2.5.2     Subcellular fractionation of cardiomyocytes 
Cardiomyocytes were harvested and washed twice with ice-cold phosphate-buffered saline 
(PBS). Subsequently, cells were fractionated into cytosolic, membrane and nuclear 
fractions using FractionPrepTM (BioVision, Mountain View, CA) following the 
manufacturer’s protocol. Equal amounts of each cell lysate were used for Western blot 
analysis. To assess the purity of fractionation, cytoplasmic, membrane and nuclear 
fractions were confirmed by immunoblotting using anti-HSP90 as cytoplasmic marker, 
anti-GM130 as membrane marker and anti-Lamin A/C as nuclear marker, respectively. To 
assess subcellular distribution of a specific protein in each fraction, lysates from each 
fraction were subjected to SDS-PAGE and Western-immunoblotting as described in 
Section 2.6.4 and 2.6.5. 
 
2.5.3     Determination of protein concentration 
The protein concentration of purified recombinant proteins and cell lysates were 
determined according to the Bradford dye-binding method (Bradford, 1976) using dye 
reagent from Bio-Rad (Hampstead, U.K.). The quantification is based on the colour change 
of Coomassie Blue G-250 in response to various concentrations of protein. Briefly, 
Bradford reagent was prepared by diluting 1 part of concentrated Bio-Rad dye reagent with 
4 parts of sterile water. A range of bovine serum albumin (BSA) concentrations (0-5 µg/µl) 
were prepared as protein standards. The protein samples were assayed in triplicates at 
various dilutions (1:10, 1:50) in 96-well microtitre plates followed by 200 µl of Bradford 
reagent added to each well. The 96-well plate was then analysed at 595 nm using an MRX 
microplate reader (Dynex Technologies, UK). A standard graph of absorbance against 
BSA concentration was plotted using least squared regression analysis to provide a relative 
measurement of protein concentration. The concentration of protein samples was then 
adjusted to account for any dilution factor. 
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2.6      Protein analysis 
2.6.1     SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gel electrophoresis was carried out 
to separate proteins according to their molecular weight. Briefly, equal concentration of 
protein samples were denatured and reduced in 5x SDS-PAGE sample buffer (10% SDS, 
300 mM Tris-Cl; pH 6.8, 0.05% bromophenol blue, 50% glycerol, 10% β-mercaptoethanol) 
followed by boiling for 5 min. After brief centrifugation, protein samples were resolved on 
precast polyacrylamide gels (4-12% NuPAGE Novex Bis-Tris gel, Invitrogen) immersed 
in MOPS or MES SDS running buffer according to nature of the samples and different 
protein separation range. Pre-stained protein marker (Bio-Rad) was loaded to the first well 
of the gel while the protein samples were loaded to the subsequent wells. The gel was then 
run for 1 h at 200 V. 
 
2.6.2     Coomassie staining 
For direct protein visualisation, gels were removed from the precast gel cassette and 
stained with Coomassie blue (1.25 g Coomassie Brilliant Blue, 44% methanol [v/v], 6 % 
acetic acid [v/v]) and incubated for 20 min at room temperature with gentle agitation. 
Residual Coomassie background stain was then removed using destain solution (10% 
methanol [v/v], 10% acetic acid [v/v]) and incubated for 5-6 h at room temperature with 
gentle agitation to give clearly visible bands. The gel was washed in sterile water with 10% 
glycerol to prevent gel cracking following drying. The molecular weight of proteins was 
estimated by referring to the protein marker. 
 
2.6.3    Western immunoblotting 
For Western blotting, resolved proteins were electrotransferred onto nitrocellulose 
membranes (0.45 µm pore, Protran, Whatman GmbH) using X-Cell II blotting modular  
(Invitrogen) in Nu-PAGE transfer buffer containing 20% methanol for 2 h at 25V or 
overnight at 10V. Successful transfer was indicated by full transfer of the prestained 
molecular weight markers onto the nitrocellulose membrane. The membrane was then 
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blocked in 5% (w/v) non-fat dry milk (Marvel) or PhosphoBLOCKER blocking reagent 
(Cell Biolabs, Inc.) in TBST (20 mM Tris-Cl; pH 7.6, 150 mM NaCl, 0.1% Tween 20) for 
1 h at room temperature with gentle agitation. Membranes were then probed with specific 
primary antibodies (Table 2.1) diluted in 1% milk/TBST solution and incubated overnight 
at 4 
o
C. The membranes were washed thrice for 10 mins each in TBST before adding 
appropriate horseradish peroxidise (HRP) conjugated anti-immunoglobulin G (IgG) 
secondary antibody diluted 1:5000 in 1% milk/TBST solution. After secondary antibody 
incubation, membranes were washed and detected by enhance chemiluminescence (ECL) 
Western Blotting Substrate (Thermo Scientific) and autoradiography. Chemiluminescent 
images of immunodetected bands were recorded on blue-light sensitive autoradiography X-
ray films (Kodak BioMax MS, Carestream Health, Inc.) which were then developed using 
the Kodak
®
 X-Omat Model 2000 processor. Immunoblots intensities were quantitatively 
analysed using Quantity One software (Bio-Rad) and averaged from at least three 
independent experiments.  
Alternatively, blots could also be scanned using the Odyssey Infrared Imaging System (LI-
COR Biosciences, UK) for fluorescence detection of the secondary antibodies. 
Fluorescence signal intensity could then be quantified using the Odyssey application 
software (LI-COR Biosciences, UK). 
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Table 2.1. List of primary antibodies used. 
Antibody Supplier 
Catalogue 
No. 
Host Dilution Applications 
α-Actinin 
(sarcomeric) 
Sigma A7811 Mouse 1:800 ICC 
ANP (FL-153) Santa Cruz sc-20158 Rabbit 1:1000 WB 
α-tubulin Abcam ab-18251 Rabbit 1:20k WB 
GFP Abcam ab290 Rabbit 
1:1000,  
1 µl/0.4 µg 
WB 
IP 
GM130 Abcam ab-52649 Rabbit 1:2000 WB 
GST (1E5) Santa Cruz sc-53909 Mouse 1:1000 WB 
His Sigma H 1029 Mouse 1:2000 WB 
HSP20 Upstate 07-490 Rabbit 
1:2000 
1:400 
1 µl/0.4 µg 
WB 
ICC 
IP 
HSP20 Santa Cruz sc-51955 Mouse 1:400 ICC 
HSP90 Abcam ab13495 Rabbit 1:10k WB 
Lamin A/C Santa Cruz sc-56140 Mouse 1:100 WB 
PDE4D5 In-house Rabbit 1:10k WB 
Pan-PDE4D 
Scottish Antibody Production 
Unit (SAPU) 
Sheep 1:5000 WB 
Phospho-HSP20 
(Ser 16) 
Abcam ab58522 Rabbit 
1:2000 
1:400 
WB 
ICC 
Phospho-PKD 
(Ser 916) 
Cell Signaling 2051 Rabbit 1:1000 WB 
PKCµ (C-20) Santa Cruz sc-639 Rabbit 1:1000 WB 
PKD/PKCµ Cell Signaling 2052 Rabbit 1:1000 WB 
PRKD1 Abnova 
H00005587-
A01 
Mouse 1:400 ICC 
V5 Sigma V8137 Rabbit 
1:2000 
1 µl/0.4 µg 
WB 
IP 
 
Application key: WB=Western blot; ICC=immunocytochemistry; IP=Immunoprecipitation. 
For ECL and film detection, the mouse (Amersham) and rabbit (Sigma) secondary 
antibodies were used at a 1:5000 concentration. 
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2.7      Protein-protein interactions 
2.7.1     ProtoArray 
ProtoArray○R  Human Protein Microarray v4.0 (Invitrogen) is a powerful tool to identify 
novel protein-protein interactions without previous knowledge of potential interactions 
using one common protocol. ProtoArray chips containing more than 8000 recombinant N-
terminal glutathione S-transferase (GST)-tagged human proteins were used for protein 
interaction screening. The target proteins were expressed using a baculovirus expression 
system and purified under native conditions. They cover a wide range of biologically 
important proteins, including kinases, membrane proteins, cell signaling proteins and 
metabolic proteins. All proteins (including internal standard controls to verify the 
reliability and accuracy of the detection) are spotted in duplicates on a nitrocellulose-
coated glass slide in an arrangement of 4 x 12 subarrays and 20 x 20 spots in each subarray. 
To compensate inter-lot variations among arrays, each microarray has a barcode for 
acquiring ProtoArray Lot Specific information from the ProtoArray Central Portal website 
(http://tools.invitrogen.com/content.cfm?pageid=10356). 
To prepare the probe for ProtoArray analysis, Ultimate™ ORF clone IOH57317 
(Invitrogen), containing the open reading frame (ORF) of HSP20 in pENTR221 vector, 
was used to generate N-terminal His-fusion protein by Gateway cloning technology into 
pDEST-17 vector (Invitrogen). The His-tagged HSP20 protein was expressed in E.coli and 
purified by Ni-NTA Superflow resin (Qiagen). The purity and specificity of the probe were 
verified by Coomassie Blue staining and Western blot with mouse monoclonal anti-His 
antibody (Sigma) and rabbit polyclonal anti-HSP20 antibody (Upstate-Millipore). 
Briefly, the array was incubated in blocking buffer (1xPBS, 1% BSA and 0.1% Tween 20) 
for 1 h at 4 
o
C with gentle shaking to block non-specific binding. The array was then 
probed with 10 µM (200 µg/ml) of His-HSP20 protein in probing buffer (1xPBS, 5 mM 
MgCl2, 0.5 mM dithiothreitol (DTT), 0.05% Triton X-100, 5% glycerol, 1% BSA) for 1.5 
h at 4 
o
C. After washing, the array was incubated at 4 
o
C with mouse monoclonal anti-His 
antibody (Sigma) and Alexa Fluor 647 goat anti-mouse IgG (H+L) (Molecular Probes, 
Invitrogen) diluted 1:2000 in probing buffer for 45 min and 30 min, respectively. After 
washing and drying, the array was scanned by ScanArray Express Microarray Scanner 
(Packard Bioscience Biochip Technology, PerkinElmer) at a wavelength of 633 nm (Fig. 
2.1). The results were analysed using BlueFuse for Microarrays software (BlueGnome, 
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Cambridge), following acquisition of the ProtoArray Lot Specific information. The 
Confidence Flags were used to indicate the degree of confidence showing potential 
interactions. A control array was also included in parallel to determine probe-specific 
interactions and exclude any non-specific interactions. 
 
 
 
 
 
 
Figure 2.1. Schematic diagram showing experimental procedure used for HSP20 
interactors identification on ProtoArray. 
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2.7.2      In vitro pull-down assay 
In vitro pull-down assays were carried out to validate direct interactions between two or 
more proteins. One of the proteins of interest is expressed with an affinity tag allowing 
binding on a solid support while the other protein is immunolabelled for the detection of 
interaction. Briefly, equal molar concentrations of purified recombinant His (negative 
control) or His-HSP20 and PKD1 (Abcam) were mixed in 3T3 lysis buffer and incubated 
end-on-end with gentle agitation for 1 hour at 4 
o
C. Pre-equilibrated Ni-NTA Superflow 
resin (Qiagen) was then added to the protein cocktail and incubated with gentle agitation 
for another hour at 4 
o
C. The two proteins were allowed to interact and any protein 
complexes formed were captured on the beads which were then sedimented by 
centrifugation at 10,000 x g for 3 min, followed by washing thrice with 3T3 lysis buffer 
and drained. Bound proteins were eluted by boiling in SDS-PAGE sample buffer for 10 
min. Proteins were then resolved by SDS-PAGE with PKD1 protein as positive control run 
alongside, following by blot transfer and detection by Western blotting using an anti-PKD1 
antibody.  
 
2.7.3     Co-immunoprecipitation 
Co-immunoprecipitation is an ex vivo method for the confirmation of interactions. Cell 
extracts were adjusted to equal protein amount (1 µg/µl) using 3T3 lysis buffer. After 
preclearing, HSP20 or PKD1 and V5 or GFP antibodies were used to immunoprecipitate 
(IP) endogenous and over-expressed PKD1 or HSP20, respectively. The resulting 
immunocomplexes were captured using Protein A beads (Invitrogen) at 4 
o
C overnight 
with shaking. The immunocomplexes were then collected by centrifugation at 13 000 rpm 
for 3 min and washed three times with 3T3 lysis buffer. Bound proteins were then eluted in 
SDS-PAGE sample buffer and subjected to SDS-PAGE and Western immuno-blotting as 
described previously. Negative controls using isotype-matched IgG (Jackson 
ImmunoResearch Laboratories, Inc.) from the same species as the antibodies were 
included to screen for non-specific binding. 
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2.7.4     SPOT synthesis of peptides and overlay experiments 
Peptide arrays were produced by automatic SPOT synthesis as described by Kramer and 
Schneider-Mergener (1998) and Frank (2002) utilising the AutoSpot-Robot ASS 222 
(Intavis Bioanalytical Instruments) followed the Fmoc (9-fluorenylmethoxycarbonyl) 
chemistry which based on solid phase peptide synthesis methodology (Fields and Noble, 
1990). The fundamental principle of this technique is the use of the spots formed upon the 
dispensation of a solvent droplet on the array membrane surface which serves as a reaction 
vessel. These peptide arrays are able to bind purified recombinant proteins and identify 
biologically active motifs to understand particular cellular activities. A library of 
overlapping 25-mer peptides, each shifted by five amino acids was produced sequentially 
to increase the reliability of the screening (Fig. 2.2). The immobilised spots of peptide 
sequences were then directly synthesised on Whatman 50 cellulose membranes as peptide 
arrays.  
Firstly, the arrays were activated by immersion in 100% ethanol and then washed in TBST 
(150 mM NaCl, 0.1% Tween20, 20 mM Tris-HCl, pH 7.6) to remove all preservative 
materials. This was followed by blocking with 5% milk (Marvel) dissolved in TBST for 1 
h at room temperature with shaking. 10 µg/ml of recombinant fusion protein diluted in 1% 
milk dissolved in TBST was added onto the arrays and incubated at 4 
o
C overnight with 
shaking. The arrays were then subjected to three 10 min washes in TBST. The interaction 
of spotted peptides with protein of interest was detected with a specific primary antibody. 
After 1h incubation, the arrays were washed several times before adding secondary 
antibody coupled with horseradish peroxidase (HRP) diluted in 1% milk TBST solution for 
1 h at room temperature. The arrays were again washed several times with TBST before 
subjected to enhanced chemiluminescence (ECL) Western immuno-blotting kit for 
autoradiography as described previously. The dark spots detected were indicative of a 
positive interaction of the recombinant fusion protein with the peptide array.  
Scanning alanine substitution analyses was performed to determine the specific amino acid 
residue(s) which are important to the functionality or stability of a given protein (Morrison 
and Weiss, 2001). Amino acid residues were replaced with alanine (A) one at a time unless 
the indicated amino acid was alanine (A), when it would be substituted for aspartate (D). 
Control spots with known binding affinity to the protein of interest were also included for 
calibration purpose and comparative measurement of binding affinity. The arrays were 
immunolabelled and detected by autoradiography as described above 
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Figure 2.2. Schematic diagram showing SPOT synthesis of peptide. Immobilised 
peptide spots of overlapping 25-mer peptides each shifted by five amino acids across the 
entire PKD1 sequence were probed for interaction with a purified His-HSP20 probe and 
detection with anti-His antibody.  
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2.8      In vitro phosphorylation assays 
2.8.1     In vitro phosphorylation of His-HSP20 
A range of purified His-HSP20 concentration (0.5-2 µg) was incubated with 1.0 g/ml or 
without active PKD1 protein (Abcam) in PKD phosphorylation buffer (20 mM Tris-HCl; 
pH 7.5, 10 mM MgCl2, 0.5 mM CaCl2, 1 mM DTT, 0.2 mg/ml BSA) supplemented with 
100 µM adenosine-5’-triphosphate (ATP) for 1 h at 30 oC with agitation. The 
phosphorylated protein was then subjected to SDS-PAGE and immunoblotted with an anti-
phospho-HSP20 (Ser 16) antibody.  
 
2.8.2     In vitro phosphorylation of peptide array 
Phosphorylation of HSP20 peptide array was carried out to identify phosphorylation site(s) 
by PKD. Briefly, the peptide array membrane was soaked in 100% ethanol to activate it 
and washed with TBST, followed by overnight blocking in 5% phosphoblocker containing 
0.5 mM DTT and 1 mM ATP at 4 
o
C. The membrane was then reacted with PKD 
phosphorylation buffer (20 mM Tris-HCl; pH 7.5, 10 mM MgCl2, 0.5 mM CaCl2, 1 mM 
DTT, 0.2 mg/ml BSA, 1 mM ATP) supplemented with 10 µg of active PKD1 (Abcam) and 
5 µCi (0.185 MBq) of [γ-32P] ATP EasyTides (Perkin Elmer, UK) for 30 min at 37 oC with 
gentle agitation. After the phosphorylation reaction, the membrane was washed extensively 
with 1 M NaCl followed by 5% H3PO4 and finally ethanol. The membrane was air dry and 
placed in intensifying screen cassette (Kodak BioMax MS, Carestream Health, Inc.) for a 
week before developing using the Kodak
®
 X-Omat Model 2000 processor. 
 
2.9      Cell-based experiments 
2.9.1     Manual measurements of cell size 
Cardiomyocytes were plated out on gelatin (Sigma) pre-coated 6-well plates and placed in 
an incubator at 37 °C and an atmosphere of 5% CO2. After 24 h the cardiomyocytes were 
cultured in a serum-free condition for 48 h before experiments. The cardiomyocytes were 
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then challenged for 24 h with either 10 μM ISO alone or ISO following a 2 h pre-treatment 
with disruptor or control peptide. Thereafter, cell size was determined on a phase contrast 
Nikon Eclipse TE2000-S microscope (Nikon, UK) under 400× magnification. About 100 
cells from several randomly chosen fields were captured digitally by a Nikon UFX-DX II 
camera (Nikon, Japan) and analysed. Cross-sectional area was determined by the following 
formula: cross-sectional area = (radius)
2 
× π. Values are expressed as means ± S.E.M. of 
five separate culture preparations. A Student’s t-test was performed to compare the two 
groups, and the P values are indicated. 
 
2.9.2     Real-time xCELLigence measurements 
The xCELLigence technology (Roche Applied Science) which allows a quantitative 
measurement of the cell size through real-time cell-electronic sensing (RT-CES) was used 
according to the manufacturer’s instruction. As cardiomyocytes are unable to divide, they 
tend to increase in cell volume in respond to stress. And this method allowed us to observe 
the change in impedance which is automatically converted to cell index and provides 
quantitative measurement that reflects the nature of the cells, i.e. cell size.  
Cardiomyocytes were counted using a haemocytometer and adjusted to the desired 
concentration. An initial population of 40,000 cardiomyocytes/well was plated out on the 
laminin (BD Biosciences) pre-coated E-Plate 96 (Roche) in triplicates after background 
measurements were taken. Briefly after 48 h of culture in the serum-free medium, 
cardiomyocytes were treated with either 10 μM isoprenaline alone or isoprenaline 
following a 30 min or 2 h pre-treatment with peptides. Controls with vehicle (DMSO alone) 
were also performed. The cultures were continuously monitored for up to 48 h and the 
impedance as reflected by cell index (CI) values was set to record every 30 min. The 
xCELLigence data were then analysed using the RTCA software (Roche Applied Science). 
The results were expressed by normalised CI, which are derived from the ratio of CIs 
before and after the addition of compounds. 
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2.9.3     Measurement of protein content 
Cardiomyocytes were plated on six-well plates and cultured in a serum-free condition for 
48 h before experiments. After stimulation of cardiomyocytes (2 h of compound + 24 h of 
ISO or 24 h of ISO alone), each well was rinsed three times with cold PBS. The cells were 
then scraped with 1 ml of 1× standard sodium citrate (SSC) containing 0.25% (w/v) SDS 
and vortexed extensively. The total cell protein and the DNA content were determined by 
the Ohnishi & Barr modified Lowry method and the Hoechst dye method using Total 
Protein Kit (Sigma #TP0200) and DNA Quantitation Kit (Sigma #DNA-QF), respectively. 
The protein content was normalised by the DNA amount to correct for differences in the 
cell number. 
 
2.9.4     Disruptor peptide synthesis 
All peptides were synthesized by Genscript and dissolved in DMSO to a stock 
concentration of 10 mM and then used at a final working concentration of 10 µM (Table 
2.2). Based on the information gathered from peptide arrays, cell-permeable peptides 
which allow transport across the cell membrane were synthesised with a stearic acid group 
(CH3(CH2)16COOH) attached to the N-terminus.  
 
Table 2.2.  Synthesised peptides used in this study. 
Peptide name Sequences 
PDE4D5-HSP20 
disruptor peptide 
‘bs906’ 
ENHHLAVGFKLLQEENSDIFQNLTK 
scrambled peptide KELGAINHEFDLSHNFQTQKLNLVE 
 
PKD1-HSP20 disruptor 
peptide ‘HJL09’ 
GRDVAIKIIDKLRFPTKQESQLRNE 
control peptide GAAVAIKIIAKLRFPTKQESQLRNE 
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2.10     Quantitative real-time   PCR   analysis of   fetal    gene  
            expression 
Real-time PCR has been widely used to determine relative gene expression. This detection 
method is based on the changes of fluorescence accumulation during thermocycling which 
can be reflected on a sigmoidal amplification plot and give a quantitative result of the 
amplified product (Kubista et al., 2006). Variability in qPCR can be influenced by steps 
upstream which consist of template preparation and reverse transcription. 
 
2.10.1     RNA extraction 
Total RNA was extracted using TRIzol reagent (Invitrogen) which contained phenol and 
guanidine thiocyanate in a procedure based on the method of Chomczynski and Sacchi 
(1987). Cells were first rinsed with PBS and subsequently lysed in TRI reagent for 5 min at 
room temperature. RNA was separated from DNA and protein by extraction with 
chloroform. The aqueous phase was then precipitated with ½ volume of isopropanol and 
spun at 12,000 x g for 15 min at 4 
o
C. The precipitate containing the RNA was then 
washed with 75% ethanol, centrifuged at 7,500 x g for 5 min, followed by air drying for 10 
min at room temperature. RNA was then resuspended in Ambion
®
 nuclease-free water 
(Invitrogen) and subsequently purified with the RNeasy Mini Kit (Qiagen). To remove 
genomic DNA contamination, the isolated RNA was subjected to RNase-free DNase I 
(Roche) digestion for 30 min at 37 
o
C. The reaction was terminated by adding 1 µl of 25 
mM EDTA and incubated at 65 
o
C for 10 min. Total RNA was quantified using the 
Nanodrop 3300 spectrophotometer (Thermo Scientific). 
 
2.10.2     Reverse transcription of PCR 
One microgram of DNase-digested total RNA was reverse-transcribed to first strand 
complementary DNA (cDNA) using AffinityScript Multiple Temperature cDNA synthesis 
kit (Agilent, Edinburgh, UK) according to manufacturer’s instructions. The total RNA was 
first incubated with 0.5 µg of oligo(dT) primer for 5 min at 65 
o
C to remove any secondary 
structures in the RNA. Oligo(dT) primer was used in this experiment as it only binds to the 
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poly-A tail of the RNA and only transcribes RNA. Consequently, oligo(dT) shows better 
specificity than other primers such as random hexamer primer, thus producing more 
consistent RT-PCR. The reaction was then cooled to room temperature for 10 min to allow 
the primers to anneal to the RNA. A reaction mixture containing 2 µl of 10x AffinityScript 
RT buffer, 2 µl of 100 mM DTT, 0.8 µl of 100 mM dNTP mix (25 mM each dNTP), 20 
units of RNase Block Ribonuclease Inhibitor and 1 µl of reverse transcriptase (RT) was 
added to the RNA/oligo(dT) primer mixture mentioned above and incubated at 42 
o
C for 1 
h. The reaction was then terminated by heating at 70 
o
C for 15 min and subsequently 
chilled on ice. The cDNA was diluted to 10 ng/µl with nuclease-free water and stored at -
20 
o
C until use. For negative controls, 1 µl of nuclease-free water was added in place of RT. 
 
2.10.3      TaqMan real-time PCR 
Gene-specific TaqMan probes and PCR primers sets (Eurofins MWG operon) were 
designed assisted by the Primer 3 software (http://frodo.wi.mit.edu/primer3/) as shown in 
Table 2.3. If possible, the primers were designed to span an exon-intron-exon boundary to 
exclude amplification of genomic DNA. 18S rRNA was used as an internal control for 
normalising relative expression levels in the different samples. Real-time PCR was 
performed from reverse transcribed cDNA samples using the Platinum Quantitative PCR 
SuperMix-UDG with ROX (Invitrogen) following the manufacturer’s instructions. Briefly, 
100 ng of cDNA were added to a 96-well MicroAmp
®
 Fast Optical Reaction Plate (applied 
Biosystems) with 12.5 µl TaqMan probe mix, 1 µl each of the 10 µM primer pair and 0.25 
µl of 10 µM fluorogenic probe (either gene-specific inventoried assays or endogenous 
reference assays). Thermal cycling and fluorescent monitoring were performed using the 
ABI Prism 7700 Sequence Detection System (Applied Biosystems). Each PCR 
amplification was run in triplicate using the following conditions: initial denaturation at 
95 °C for 2 min, followed by a total of 40 cycles (15 sec at 95 °C for denaturation, 15 sec 
at 57 °C for annealing and 1 min at 60 °C for extension). Fluorescence data were collected 
during the extension step of each cycle. Negative controls using RNA as template were 
also included in all runs to test for the presence of genomic DNA contamination.  
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Table 2.3. Sequences of oligonucleotide primer-probe sets used in quantitative real-
time PCR assay. All assays contain sequence-specific unlabelled primers pair and a 
TaqMan probe labelled with a fluorophore FAM attached to the 5’ end and a quencher 
TAMRA on the 3’ end. Rat 18s rRNA was used as an endogenous control. 
Gene Oligonucleotide sequence Accession No. 
Atrial natriuretic 
factor (ANF) 
Forward: 5’-GGATTGGAGCCCAGAGCGGAC-3’ 
Reverse: 5’-CGCAAGGGCTTGGGATCTTTTGC-3’ 
Probe: 5’-AGGCTGCAACAGCTTCCGGT-3’ 
NM_012612 
Brain natriuretic 
peptide (BNF) 
Forward: 5’-AGCCAGTCTCCAGAACAATCCACG-3’ 
Reverse: 5’-AGGGCCTTGGTCCTTTGAGAGC-3’ 
Probe: 5’-GCTGCTGGAGCTGATAAGAGAAAAGT-3’ 
NM_031545 
β-myosin heavy 
chain (β-MHC) 
Forward: 5’-CCAACACCAACCTGTCCAA-3’ 
Reverse: 5’-CAGCTTGTTGACCTGGGACT-3’ 
Probe: 5’-CTGGATGAGGCAGAGGAGAG-3’ 
NM_017240 
Rat 18S rRNA 
Forward: 5’-CGCGGTTCTATTTTGTTGGT-3’ 
Reverse: 5’-CGGTCCAAGAATTTCACCTC-3’ 
Probe: 5’-TGAGGCCATGATTAAGAGGG-3’ 
M11188.1 
 
 
 
2.10.4    qPCR data analysis 
Relative changes in gene expression of the three target genes (listed in Table 2.3) in 
different samples were quantified using the comparative Ct method (∆∆Ct) as described by 
Livak and Schmittgen (2001). The objective of this method is to compare the PCR signal 
of a target gene in a treatment group to the untreated control after normalising to an 
endogenous reference gene. Firstly, the point at which the PCR was detected above a set 
threshold in exponential phase, termed threshold cycle (Ct), was obtained from the real-
time PCR instrumentation. Ct is determined from a log-linear curve where PCR signal is 
plotted against the cycle number. The Ct values of each sample were then imported into 
Microsoft Excel and the average Ct of triplicate samples was calculated. The amount 
detected at a certain cycle number is directly related to the initial amount of target in the 
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sample. Hence, to determine the quantity of gene-specific transcripts present in cDNA, Ct 
values for each treatment had to be normalised first to obtain ∆Ct. This was accomplished 
by subtracting the mean Ct value of endogenous reference gene 18s rRNA of each group 
from the corresponding mean Ct value of gene of interest (GOI) accordingly (∆Ct = CtGOI - 
Ct18s rRNA). The concentration of gene-specific mRNA in treated cells relative to untreated 
cells was then normalised through subtraction again to obtain ∆∆Ct values (∆∆Ct = ∆Ct of 
treated cells - ∆Ct of untreated cells). Finally, the relative expression which is often termed 
as RQ value was determined by raising 2 to the power of the negative value of ∆∆Ct (2-∆∆Ct) 
for each sample (Amount of target = 2
-∆∆Ct
). Alteration in mRNA expression of target 
genes was defined as fold difference in the expression level in cells after the treatment 
relative to that before treatment. Samples with poor technical replicate values were 
excluded from analysis. 
 
 
2.11      Microscopic analyses 
2.11.1     Differential interference contrast microscopy 
Differential interference contrast (DIC) microscopy also known as Nomarski microscopy is 
extremely useful for resolving individual transparent living cells. This method allows 
observation of unstained specimens by generation of monochromatic shadow-cast image 
laminin-coated contrast through different refractive index gradients. Cardiomyocytes were 
seeded on coverslips and placed in extracellular buffer (140 mM NaCl, 3 mM KCl, 2 mM, 
MgCl2.6H2O, 2 mM CaCl2.2H2O, 15 mM Glucose, 10 mM HEPES; pH 7.2). The cells 
were then observed under a Nikon Eclipse FN-1 microscope equipped with DIC optics. 
Images were captured on a CoolSNAP HQ2 monochrome camera (Photometrics, UK) 
using an image acquisition software (Opto-Fluor Version 7.6.3.0, Cairn Research Ltd, 
Kent). 
 
 
Chapter 2              
41 
 
2.11.2    Immunostaining and confocal microscopy 
For immunofluorescent labeling, cardiomyocytes were plated onto laminin-coated 8-well 
chamber slides (Lab-Tek, Sigma). Cells were fixed in 95% ice-cold methanol/ 5% acetone 
mixture at -20 
o
C for 10 min and permeabilised with 0.1% Triton X-100 in PBS for 10 min 
at room temperature. After several washes with Tris-buffered saline (TBS) (150 mM NaCl, 
20 mM Tris-HCl, pH 7.6), the cells were blocked with 10% donkey serum and 2% BSA 
(w/v) in TBS for 2 h followed by three washes with TBS. The primary antibodies used was 
diluted to the required concentration in blocking buffer diluted 1:1 with TBS and added to 
the cells for 2 h followed by three washes with TBS. After washing, cells were incubated 
with 1:400 diluted secondary antibodies Alexa Fluor 488 donkey anti-mouse IgG and 
Alexa Fluor 594 donkey anti-rabbit IgG (Molecular Probes) for 1 h. Following several 
extensive washes with TBS, the slides were dehydrated and mounted under coverslips with 
ProLong Gold anti-fade reagent with 4’,6-diamidino-2-phenylindole (DAPI) nuclear stain 
(Invitrogen). Staining was visualized using a Zeiss Pascal laser-scanning confocal 
microscope (LSM) 510 Meta and an Axiovert 100 microscope (Carl Zeiss, UK) equipped 
with an oil immersion objective (63x/1.4 NA plan apochromat lens). Images were captured 
and processed on Zeiss LSM Image Examiner and analysed using the NIH Image J 
software (ImageJ, http://rsb.info.nih.gov/ij/). All incubations were carried out at room 
temperature unless stated otherwise. 
 
2.11.3    Phalloidin staining of actin 
Phalloidin staining was carried out for visualisation of the actin cytoskeleton. 
Cardiomyocytes were cultured on laminin-coated 8-well chamber slides (Lab-Tek, Sigma). 
Cells were maintained in serum-free media for 48 h before treated with peptides for 2 h 
prior to hypertrophy induction by ISO for 24 h. The cells were then washed with PBS, 
fixed with 3.7% methanol-free formaldehyde in PBS for 10 min at room temperature, 
followed by permeabilisation with 0.1% Triton X-100 in PBS for 10 min and washing 
twice again with PBS. Actin fibers were stained with Alexa Fluor 488 phalloidin 
(Molecular Probes, Invitrogen) diluted 1:500 in PBS for 30 min at room temperature and 
washed thrice in PBS. DAPI was used for nuclear counterstain. Finally, the slides were 
dried and mounted for laser scanning confocal microscopy as described previously. 
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2.11.4     Duolink
TM
 proximity ligation assay 
PKD1 association with HSP20 was investigated further by using a more sophisticated in 
situ analysis of protein interactions, i.e. the Duolink
TM
 Proximity Ligation Assay (PLA) 
(Olink Bioscience, Uppsala, Sweden). Besides determining the subcellular localisation of 
the interacting complex, this method also allows the study of the dynamics of the 
interactions in intact living cells (Söderberg et al., 2008, Bellucci et al., 2011). After 
fixation, permeabilisation and blocking, slides were incubated with primary antibodies 
against PKD1 and HSP20 raised in two different species. Then PLA probes, which are 
conjugated with oligonucleotides, were introduced to recognise the primary antibodies. A 
solution that promotes hybridization between the PLA oligos was then added, where a 
hybridisation reaction only occurred if the two proteins were in close proximity (<40 nm), 
but not if they were far apart. This reaction was followed by ligation of the 
oligonucleotides and a rolling circle amplification (RCA) reaction, where a repeated 
sequence product was made. This product was then detected using fluorescently labeled 
oligonucleotides, where a PKD1-HSP20 association appeared as discrete red dots under the 
microscope (Fig. 2.3). 
To confirm where the PKD1-HSP20 associations occur in the cardiomyocytes, cells were 
counterstained with α-actinin to show sarcomeric stained. Slides were finally mounted 
under coverslips with DUOLINK mounting media, and observed using the Zeiss Pascal 
laser-scanning microscope (LSM510 Meta (Carl Zeiss, UK) as described above.  
 
2.12    Statistical analysis 
Values are presented as mean ± S.E.M. from at least three independent experiments. 
Statistical significances between groups were determined by the use of Student’s t-test. 
Values were considered significant if p < 0.05. Where representative immunoblots or 
immunocytochemistry images were shown, similar data were obtained ≥ 3 times. 
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Figure 2.3. Schematic diagram of in situ PLA. (A) Cells are incubated with target 
specific primary antibodies raised in two different species. A pair of PLA probes (PLUS 
and MINUS) with unique DNA strand attached are added and bind their respective primary 
antibody. (B) When in tight nearness, the two DNA strands can interact through circle-
forming DNA oligonucleotides which are then joined by enzymatic ligation. (C) and (D) 
Rolling-circle amplification by polymerase and fluorescent probes are hybridised to the 
synthesised DNA strand allowing the product to be visualised. (Adapted from Söderberg et 
al., 2008).     
B A 
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3.1    Introduction 
Cell signalling is the process by which extracellular stimuli are interpreted to elicit a 
specific intracellular response that acts to coordinate cell activities. The mechanisms that 
underpin signal transduction in cells are complex and involve many signalling components. 
Generally, signal transduction from the outside of a cell to its inner compartments involves 
three main steps: receptor activation, signal transmission and target cell response. 
Although the agonist action on cell surface receptors can trigger a variety of intracellular 
signalling events, the ligand-receptor interaction and their downstream responses are very 
specific.  For example, signals initiated by hormones and neurotransmitters commence via 
activation of specialised receptors such as plasma membrane localised transmembrane G-
protein-coupled receptors (GPCRs). These in turn activate intracellular messenger 
molecules and result in a relevant physiological response in cells. Any error in the cellular 
transduction cascade will thus lead to diseases. Hence, understanding of cell signalling 
networks are essential. 
 
3.1.1    cAMP signalling and compartmentalisation 
3’,5’-cyclic adenosine monophosphate (cAMP) is a ubiquitous key second messenger, 
which is involved in a wide variety of  intracellular signal transduction cascades that 
usually start with a receptor stimulation (Beavo and Brunton, 2002). cAMP is generated by 
adenylyl cyclases following stimulation of transmembrane receptors such as β2-adrenergic 
receptors (β2AR). GPCRs are seven transmembrane-spanning helices which interact with 
heterotrimeric G proteins (comprised of a GDP/GTP-binding α, β, and γ subunits) 
(Wheeler-Jones, 2005). Regulation of GPCR signalling involves rapid attenuation of 
receptor responsiveness (desensitisation) and resensitisation which alter the availability of 
receptors to be stimulated, and up- or down-regulate receptor expression. 
The β2AR generates signal specificity by interacting with a member of the heterotrimeric G 
protein family, the stimulatory G protein (Gs) (Houslay et al., 2007). This causes activation 
of Gs via GDP-GTP exchange on the Gα subunit, follow by the release of Gβγ subunit, 
thereby stimulating membrane bound adenylyl cyclase (AC) activity and leading to the 
production of a cAMP cloud (Cooper, 2003). The increase in intracellular levels of cAMP 
at the inner surface of the plasma membrane can then activate downstream effectors such 
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as protein kinase A (PKA), exchange protein activated by cAMP (Epac) and cyclic 
nucleotide gated ion channels, which in turn trigger downstream signals that lead to the 
regulation of various cellular processes including proliferation, differentiation and 
movement, apoptosis and cardiac function (Tasken and Aandahl, 2004; Houslay et al., 
2007). 
cAMP is freely diffusible within the cell and the specificity of receptor response is 
achieved by the generation of cAMP signalling microdomains as generally visualised using 
fluorescence-resonance-energy-transfer (FRET)-based approaches (Zaccolo and Pozzan, 
2002; Mongillo 2004). This high temporal and spatial resolution technique is a useful tool 
to investigate the dynamics of molecular interactions in living cells based on the ability of 
a high energy fluorophore (donor) to transfer energy to a lower energy fluorophore 
(acceptor) particularly when the two molecules are in close proximity (<10 nm). Hence, a 
change in fluorescence signal strength will reflect a conformational change upon cAMP 
binding (Terrin et al., 2006). The investigations clearly showed that the gradients of cAMP 
are depending on the source of cAMP generation by AC located at discrete intracellular 
loci. It is well accepted that the compartmentalised cAMP gradient which mediates the 
activation of intracellular effectors, most notably PKA is regulated by PDEs. This 
regulation greatly depends on the degradation of cAMP to 5’ AMP, thereby preventing 
cAMP saturation in the cell interior (Lugnier, 2006).  
Using genetically encoded sensors based upon either PKA or the cAMP binding domain of 
EPAC, cAMP gradients were shown to be dynamically formed and shaped by tethered 
PDEs which provide physical barriers to free diffusion of cAMP from restricted 
microenvironments (Mongillo et al., 2004). However, later studies using siRNA-mediated 
knockdown of cAMP-dependent PDE4 in HEK293 cells showed that cAMP microdomains 
do not require impeded diffusion or diffusional barriers. In fact, cAMP degradation and 
intracellular gradients were actually achieved by tethered PDEs forming localised cAMP 
sinks (Terrin et al., 2006). It is thought that the PDEs regulate the magnitude and duration 
of cAMP gradients by acting as sinks to locally drain cAMP and preclude inappropriate 
activation of downstream substrates resulting from fluctuations in basal cAMP levels 
(Baillie, 2009). Interestingly, silencing of PDE4D was shown to disrupt cAMP 
microdomains, but this was not the case for silencing of PDE4B, further confirming that 
PDE4D is mainly responsible for the integrity and duration of cAMP microdomains. 
Seemingly, PDE4D decreases cAMP concentration in the cytosol more than in the 
submembrane region (Terrin et al., 2006). It was also noted that sink size greatly depends 
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on the tethered PDE and localised elevation in cAMP is regulated by high PDE activity. 
Indeed, PDE4 activity is enhanced by PKA phosphorylation since a PKA inhibitor, H89 
was shown to eliminate cAMP microdomains measured using the FRET sensor, thereby 
suggesting a role of PKA-mediated phosphorylation of PDE on cAMP dynamics (Terrin et 
al., 2006). 
 
 
 
 
Figure 3.1. The cAMP signalling cascade. Under ISO stimulation in response to 
physiological stress, β-adrenergic transmembrane receptor couples to the stimulatory G 
protein (Gs), thereby activating effector protein adenylyl cyclase (AC) which are mostly 
embedded in the cell surface plasma membrane. AC generates intracellular cAMP which 
then rapidly diffuses into the cell cytosol and activates PKA that phosphorylates 
downstream substrates. The PDEs which anchors the AKAP scaffold modulates the 
intensity and duration of cAMP through hydrolysis (Adapted from Houslay, 2007). 
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3.1.2    PDE family 
Phosphodiesterases (PDEs) serve as major regulators of cAMP signal transduction as they 
dynamically control localised pools of cAMP by breaking cAMP down to 5’ AMP to 
underpin specificity of physiological responses (Houslay et al., 2007). There are different 
isoforms of PDEs that are located at distinct intracellular locations and possess different 
affinities for cAMP (Stangherlin and Zaccolo, 2012). Generally, the PDEs are classified 
into 11 gene families (PDE1-11) based on their sequence homology, substrate specificity, 
regulatory and kinetic characteristics. Three families specifically hydrolyse cAMP (PDE4, 
7, 8), three families specifically hydrolyse cGMP (PDE5, 6, 9), and the others hydrolyse 
both cAMP and cGMP (PDE1, 2, 3, 10, 11). This happens in selected functional 
compartments upon stimulus-specific receptor activation. (Lugnier, 2006; Conti and Beavo, 
2007). Within each family, PDEs can have several genes and each gene can have multiple 
gene products. This leads to many different isoforms within PDE families, PDE4 for 
example, has over 25 different isoforms. The different isoforms share identical catalytic 
units and are a result of alternative mRNA splicing coupled to the use of distinct promoters.  
PDEs exhibit tissue- and cell-specific expression where the cAMP levels are controlled by 
the specific PDE isoforms in different subcellular compartments and at different times in 
response to different stimuli. There are nine PDE families expressed in cardiovascular 
system, i.e. PDE1, 2, 3, 4, 5, 6, 7, 8, and 9 (Francis et al., 2011). In particular, members of 
the PDE3 and PDE4 families play pivotal roles in modulation and compartmentation of the 
cAMP signal in heart, contributing about 90% of the total cAMP hydrolysis (Richter et al., 
2005). Using genetically encoded FRET optical sensors in neonatal rat ventricular 
myocytes (NRVMs), β-AR stimulation was shown to generate localised increases in cAMP 
levels at the sarcomeric Z lines (Zaccolo and Pozzan, 2002). Further evidence showed that 
PDE4B is localised at the plasma membrane, whilst PDE4D is mainly distributed 
throughout the cytosol (Terrin et al., 2006).  Clearly, these two isoforms are spatially 
organised to modulate the cAMP levels in specific subcellular compartments. Of them all, 
PDE4D has been studied extensively in heart. Hence, this chapter will focus on the role of 
PDE4D family in cAMP signal compartmentation. 
 
Chapter 3              
48 
 
3.1.3     PDE4 structure and isoforms 
The PDE4 family is highly evolutionarily conserved and is encoded by four genes, namely 
PDE4A, PDE4B, PDE4C and PDE4D (Houslay and Adams, 2003). These four PDE4 
genes further encode 25 different isoforms that are characterised by a unique N-terminal 
region which confers intracellular targeting of the enzymes. This isoformity is a result of 
alternative mRNA splicing coupled to the use of different promoters which allow cells to 
express numerous PDE4 enzymes (Houslay and Adams, 2003). PDE4 isoforms consist of 
two upstream conserved regions (UCR1 and UCR2) which are joined together by two 
regions known as linker region 1 (LR1) and linker region 2 (LR2) (Fig. 3.2). UCR1 and 
UCR2 are involved in the regulation of the PDE4 catalytic unit through phosphorylation of 
PKA (MacKenzie et al., 2000, 2002). However, the functional significance of the two 
linker regions is still unknown. In addition, there is a highly conserved catalytic unit 
common to all PDE4s and a C-terminal region, which is unique to each of the four PDE4 
subfamilies. The catalytic unit contains a serine within the consensus site PQSP which 
allows phosphorylation by ERK to modulate PDE activity (MacKenzie et al., 2000). 
Recent findings have revealed a binding pocket for cAMP in the PDE4 catalytic unit, 
which contains tightly bound Zn
2+
 and loosely bound Mg
2+ 
(Houslay and Adam, 2003). It 
is thought that PDE4 activation by PKA phosphorylation is determined by the 
concentration of Mg
2+
. There is also a kinase interaction motif (KIM) docking site 
(VxxKKxxxxxxLL) located at the N-terminal to the target serine, and an ERK specific 
binding motif (FQF) at the C-terminal to the target serine.  
PDE4 isoforms can be subcategorised as dead-short, super-short, short and long as 
indicated in Fig. 3.2 due to distinct splicing mechanisms rendering different combinations 
of the UCR1 and UCR2 domains (Houslay and Adams, 2003; Houslay et al., 2007). The 
long forms which are most common kind within the PDE4 subfamily, possess a full intact 
UCR and LR regions. These isoforms can be phosphorylated by PKA at the serine residue 
within the conserved RRESF motif (MacKenzie et al., 2002). This results in an increase in 
PDE activity, thereby leading to cAMP desensitisation in cells where these isoforms are 
selectively expressed, for example, in cardiomyocytes (Mongillo et al., 2004). 
Alternatively, PDE phosphorylation by PKA can form a feedback loop whereby localised 
cAMP levels are further decreased to reduce PKA activity, thereby allowing the 
dephosphorylation of PDE to reset the system. In contrast, the super-short and short forms 
lack UCR1 and LR1 but contain a truncated and intact UCR2, respectively. The dead-short 
isoforms do not have the regulatory and linker regions and are both N- and C- terminally 
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truncated. Since it is enzymatically inactive and has survived through evolution, it is 
speculated that it may be involved in protein scaffolding (Johnston et al., 2004). 
Interestingly, the functional outcome of ERK phosphorylation of PDE4s is dependent on 
the presence or absence of the two UCRs, where in long isoforms they confer inhibition 
but in short isoforms confer activation and in super-short isoforms, weak inhibition 
(MacKenzie et al., 2000). In other words, cAMP signalling is modulated by ERK 
activation depending on the types of isoform expressed. Interestingly, PKA 
phosphorylation can be induced by ERK-mediated PDE4 longform inhibition, which in 
turn leads to an increase in cAMP levels and activation of PKA (Houslay et al., 2007). 
 
 
Figure 3.2. Structure and encoding of PDE4 isoforms. Different mRNA splicing 
resulted in the long and short of PDE4 isoforms, categorised according to their unique N-
terminal targeting region. Sites for PKA-mediated phosphorylation and ERK-mediated 
phosphorylation are depicted as red and black circle, respectively. LR1, Linker Region 1; 
LR2, Linker Region 2; CTR, C-terminal region; NTR, N-terminal region. (Adapted from 
Houslay, 2010). 
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One aspect that underpins the unique functions of individual PDE4 isoforms is the 
complexes they form with binding partners. Each isoform has a unique set of interacting 
partners and binding is usually achieved via the PDE4 isoform’s unique N-terminal. For 
example, PDE4 enzymes interact functionally with β-arrestins and orchestrate the dual 
desensitisation of β2AR signalling (Baillie et al., 2003; Houslay et al., 2007). ISO 
stimulation causes β-arrestin to direct mainly PDE4D5 (because of its binding site within 
its unique N-terminus) to β2AR upon β2AR phosphorylation by GRK2 (G-protein-coupled-
receptor kinase 2), thereby creating a localised sink for cAMP degradation in the vicinity 
of β2AR and attenuating local PKA activity (Lefkowitz et al., 2002). In this context, 
PDE4D5 serves to intercede the switching between Gs-mediated activation of AC and Gi-
mediated activation of ERK2 signalling. Notably, the attenuation of PKA phosphorylation 
of the β2AR by PDE4D5 and the switching of β-adrenoceptor from Gs to Gi resulting in its 
signalling altered to ERK is critically dependent on the recruitment of PDE4D5 to the 
β2AR-β-arrestin complex (Baillie et al., 2003). 
 
3.1.4     cAMP-signalling modulation in the heart 
The progression of cardiac disease to end-stage heart failure in particular hypertrophy, is 
often a consequence of long-term, signalling defects. In cardiac cells, the cAMP signalling 
pathway is an important regulator of myocardial function through the control of 
intracellular calcium concentration as a consequence of PKA-mediated phosphorylation of 
ryanodine receptors, phospholamban and L-type calcium channels (Stangherlin and 
Zaccolo, 2012). Spatial and temporal signalling dynamics of cAMP is achieved by various 
proteins, including PKA, PDEs and facilitated by scaffolding proteins such as A-kinase-
anchoring proteins (AKAPs) (Dodge-Kafka et al., 2007).  
The main effector of cAMP is PKA which mediates diverse cellular functions via direct 
phosphorylation of its substrates. PKA is a tetrameric complex, which consists of two 
regulatory (R) subunits with four encoded genes (RIα, RIβ, RIIα and RIIβ), and two 
catalytic (C) subunits with three encoded genes (Cα, Cβ and Cγ) (Skålhegg and Taskén, 
1997). PKA holoenzymes are classified as type I or type II depending on the type of R 
subunit present (RI or RII). These two PKA types exhibit differental sensitivity to cAMP 
activation and have different subcellular distribution. Signalling complexes that are 
scaffolded by AKAPs often contain PDE4 and PKA in close proximity. Such an 
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arrangement vastly increases the threshold of activation of PKA, only allowing 
phosphorylation of PKA substrates at times of high cAMP, for example, immediately 
following receptor activation. Alternatively, intracellular cAMP actions can also be 
modulated by a newly discovered cAMP receptor, Epac (exchange proteins directly 
activated by cAMP) in a PKA-independent manner (de Rooij et al., 1998). As many 
receptor-mediated signalling events in cardiomyocytes are mediated via cAMP generation, 
alterations of the cAMP signalling pathway resulting from dysregulation of the 
compartmentalisation of β-AR signaling can be primary determinants in the development 
of cardiac remodelling and heart failure.  
There are two main β-AR isoforms in the heart, namely β1 and β2 which are both coupled 
to the conventional Gs-AC-cAMP-PKA pathway, resulting in diffused signal throughout 
the cell. One notable distinction is that β2AR activates both the Gs/Gi cAMP pathway and 
induces localised cAMP signals to regulate cardiac contractility (Xiang et al., 2005). It is 
thought that βAR signalling undergoes a time-dependent switch upon persistent stimulation 
(Fig. 3.3). In other words, continuous activation switches the β1AR receptor signaling from 
PKA cascade to calcium/calmodulin-dependent protein kinase II pathway (CaMKII), 
resulting in cardiomyocyte apoptosis and maladaptive remodelling (Patterson et al., 2007). 
In addition, sustained activation of β2AR stimulates phosphatidylinositol 3’-kinase (PI3K)-
Akt mediated cardioprotection by inducing anti-apoptotic effect via the activation of 
inhibitory G protein (Gi) (Xiao et al., 2006). 
Several studies have also highlighted the importance of PDEs, as well as specific roles for 
individual PDE isoforms in cAMP/PKA signalling in heart. Using neonatal 
cardiomyocytes, it was demonstrated that PDE4D is the main PDE associated with β-
adrenergic regulation where it acts predominantly on β2AR signaling (Dodge et al., 2001; 
Lehnart et al., 2005). There is increasing evidence to indicate that the inhibition of these 
PDE4s activities is associated with cardiovascular diseases. For example, PDE4D3 has 
been shown to bind to a striated muscle-specific AKAP (mAKAP) to regulate the trophic 
responses of cAMP in cardiomyocytes (Dodge et al., 2001). PDE4D is also associated with 
the ryanodine receptor 2 (RyR2) which is activated by calcium influx and mediates 
calcium release from sarcoplasmic reticulum (SR) (Lehnart et al., 2005). Notably, 
deficiency in this gene is associated with heart failure and arrhythmias. However, not much 
is known about the specific PDE isoforms which regulate PKA signalling during 
cardioprotective signalling mechanisms. HSP20 was identified as a substrate protein of 
cAMP-dependent PKA whereby PKA activation increases HSP20 phosphorylation at 
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Ser16 (Beall et al., 1997, 1999). Using cells that expressed the PKA inhibitory peptide 
(PKI) and phospho-HSP20 antibodies, it was reported that PKA is the sole kinase 
responsible for the ISO-induced HSP20 phosphorylation of HSP20 on Ser16 (Komalavilas 
et al., 2008). Furthermore, recent studies have provided evidence of HSP20’s 
cardioprotective role through its phosphorylation on Ser16 by PKA (Fan et al., 2004, 2005, 
2006). Importantly, HSP20 can only confer its cardioprotective ability after PKA-mediated 
phosphorylation upon an increase in the concentration of cAMP within cells (Fan et al., 
2005). However, the mechanism(s) that modulates the spatiotemporal control of this 
modification is still unknown. Hence, it was interesting to investigate the molecular 
mechanism, in particular, to determine the identities of the individual PDEs that coordinate 
PKA activation and downstream signalling events involving HSP20 in hypertrophy. 
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Figure 3.3. Schematic diagram showing multidimensional outline of βARs signalling. 
βARs dynamically bind to G proteins and subsequently other signalling proteins in a 
spatiotemporally regulated fashion. Persistent stimulation of βAR undergoes a time-
dependent change which involves switching between two signalling pathways. (Adapted 
from Patterson et al., 2007). 
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3.2      Aims  
Given that PDE4 isoforms play major roles in the compartmentalisation of cAMP 
signalling in the heart (Houslay et al., 2007) and that HSP20 has been shown to be 
phosphorylated by cAMP-dependent PKA to confer cardioprotection (Fan et al., 2005, 
2006), it was hypothesised that PDE4 may be involved in the regulation of HSP20 
phosphorylation to attenuate hypertrophic growth of cardiomyocytes via the control of 
local cAMP signals and activation of compartmentalised PKA.  
 
The aims of this chapter are as follows: 
1. to define the molecular composition of the signalling domain containing PKA, PDE4 
and HSP20. 
2. to address whether the spatial and temporal phosphorylation of PKA and/or HSP20 
elicited by β-adrenergic receptor stimulation are influenced by PDE4 activity. 
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3.3      Results 
 
3.3.1     Characterisation of neonatal rat cardiomyocytes 
Most in vitro studies in this project were conducted in cardiomyocytes isolated from 1-3 
day old Sprague-Dawley neonatal rat hearts. In order to provide reliable evaluation of the 
cellular response from cardiomyocytes to a given intervention, the number of 
contaminating non-myocardial cells such as fibroblasts was kept at a minimum. This was 
exceptionally important in interpreting data in order to provide reproducible results. There 
are several ways to eliminate non-myocardial cells, including deprivation of serum, 
inhibition of proliferation using cytosine-β-arabinofuranoside, differential attachment 
techniques and percoll density gradient centrifugation (reviewed in Chlopeikova et al., 
2001). The differential attachment method is most popular and was used in this study to 
enrich cardiomyocyte preparations.  The purity of neonatal rat cardiomyocyte cultures was 
determined by immunocytochemistry using an anti-α-sarcomeric actinin antibody. 
Immunocytochemical inspection confirmed the purity of the culture. A randomly selected 
microscopic field showed that the vast majority of cells were cardiomyocytes exhibiting a 
distinctive pattern of cross-striations stained by α-actinin. This suggests sarcomere 
organisation (Fig 3.4). Non-cardiomyocyte contamination 48h after isolation consisted of 
approximately 5% (1 out of 20 cells) of the total cell population. 
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Figure 3.4. Primary culture of neonatal rat cardiomyocytes. Cells were obtained from 
differential plating procedure as described in ‘Materials and Methods’. The cells were then 
assayed for α-sarcomeric actinin (green) and nuclei were detected by DAPI staining (blue), 
followed by laser scanning confocal microscopic visualization. Most of the 
cardiomyocytes interlaced with each other to form a confluent monolayer and were 
positive for sarcomeric staining. (A) Bright-field image, (B) DAPI-stained nuclei, (C) 
Actinin-stained cardiomyocytes, and (D) Composite image.  Images are representatives of 
three separate experiments on different culture preparations. 
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3.3.2     Regulation of PKA-mediated HSP20 phosphorylation by PDE4 
Strategically localised PDE4 isoforms underpin the compartmentalisation of cAMP 
signalling in the heart (Houslay et al., 2007). To investigate whether PDE4 isoforms 
regulate phospho-HSP20 levels in response to β-agonist treatment, cardiomyocytes that 
had either been pre-treated or not with the PDE4 selective inhibitor, rolipram (10 µM) 
were subsequently challenged with ISO (1 µM) for selected times. Upon ISO stimulation, 
cardiomyocytes exhibited an increase in endogenous phospho-HSP20 levels and this effect 
was markedly increased by rolipram pre-treatment (Fig. 3.5). Moreover, PDE4 inhibition 
alone in the absence of ISO sufficed to induced HSP20 phosphorylation when compared to 
cells under basal conditions.  
To determine the role of PDE4 in modulating PKA-mediated phosphorylation of HSP20 at 
Ser16, cardiomyocytes were treated with ISO alone, ISO + rolipram, or pre-treated with 
the PKA inhibitor KT5720 prior to stimulation with ISO + rolipram. The immunoblots 
were then probed using the phospho-HSP20 antibody, which recognised HSP20 only when 
phosphorylated at Ser16. Results showed that the inhibition of PKA (Fig. 3.6) attenuated 
phosphorylation on HSP20 following stimulation with ISO + rolipram pre-treatment, 
confirming the importance of PDE4 and PKA in HSP20 phosphorylation in response to 
ISO treatment. 
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Figure 3.5. PDE4 involved in the modulation of HSP20 phosphorylation at Ser16 in 
cardiomyocytes. (A) Neonatal rat cardiomyocytes were treated with ISO for indicated 
time with or without pre-treatment with rolipram. Cells were also treated with 0.01% (v/v) 
DMSO as control for addition of solvent. Endogenous lysates were immunoblotted for 
phospho-HSP20 (Ser16) and total HSP20. (B) Densitometry analysis showed percentage of 
maximum HSP20 phosphorylation normalised to HSP20. Data was expressed as mean ± 
S.E.M. of three separate experiments. Significance level was set at P < 0.05 over ISO 
treatment. 
This work was carried out by Dr Xiang Li. 
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Figure 3.6. The phosphorylation of HSP20 at Ser16 is modulated by PKA. Upper 
panel: Cardiomyocytes were treated with ISO for indicated times with or without pre-
treatment with rolipram or rolipram + KT5720. Lysates were blotted for phospho-HSP20 
(Ser16) and HSP20. Lower panel: Densitometry analysis showed percentage of maximum 
HSP20 phosphorylation. Data was expressed as mean ± S.E.M. of three separate 
experiments. Significance level was set at P < 0.05 over ISO treatment. 
This work was carried out by Dr Xiang Li. 
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3.3.3      HSP20 interacts directly with PDE4 isoforms  
Intracellular cAMP induced by βAR signalling is regulated by different PDEs which are 
responsible for controlling local PKA activity (Conti and Beavo, 2007; Houslay et al., 
2007). Knowing that rolipram could affect PKA-mediated HSP20 phosphorylation, it was 
possible that PDE4 could form a signalling complex with HSP20 to exert a 
phosphorylation control mechanism. Hence, biochemical studies were carried out to 
determine if PDE4s associate with HSP20 either dynamically in response to β-adrenergic 
agonist or constitutively under basal conditions. Co-immunoprecipitation analyses using 
lysates from untreated and ISO-treated cardiomyocytes showed that HSP20 immuno-
complex contained PDE4D isoforms (Fig. 3.7A). In order to verify the identities of the 
specific PDE4D isoforms which may potentially associate with HSP20, HEK293 cells 
were co-transfected with HSP20 and five most common PDE4D isoforms (4D3, 4D4, 4D7, 
4D8 and 4D9). Similarly, lysates were subjected to co-immunoprecipitation using anti-
HSP20 antibody and then immunoblotted with anti-Pan-PDE4D antibody. Interestingly, 
bands corresponding to all the five PDE4D isoforms were detected in the 
immunoprecipitates, which may suggest the presence of common association site within 
the conserved region of the PDE4D family (Fig. 3.7B).  
In addition, in vitro pull-down assays using purified species were carried out to assess the 
interaction between HSP20 and PDE4 family. Results showed that recombinant His-
HSP20 proteins co-purified with GST-PDE4B3. GST-PDE4D3 and GST-PDE4D5 but not 
GST alone (Fig 3.8), suggesting direct in vitro interaction between these proteins. 
Immunocytochemical studies were also carried out to ascertain whether HSP20 and 
PDE4D colocalised to the same micro-compartment within cardiomyocytes. 
Unsurprisingly, confocal images of neonatal rat cardiomyocytes showed that both HSP20 
and PDE4D localised with α-actinin in a striated pattern (Fig 3.9), suggesting that these 
proteins exist in the same cellular compartment. This finding is in agreement with previous 
studies in which localisation of PDE4D was observed at the sarcomeric Z-disk (Mongillo 
et al., 2004). It is thus postulated that the close proximity of PDE4D is likely to modulate 
the phosphorylation of HSP20.  
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Figure 3.7. HSP20 forms a complex with PDE4D isoforms. (A) Immunoprecipitation of 
HSP20 from lysates extracted from cardiomyocytes following treatment with 1 μM of ISO 
was immunoblotted with anti-Pan-PDE4D antibody for the presence of PDE4D isoforms. 
(B) Five members of the PDE4D subfamily were co-expressed with HSP20 and HSP20 
immuno-complex was then probed for PDE4D isoforms. Blots are representative of three 
separate experiments. 
This work was carried out by Dr Xiang Li. 
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Figure 3.8. HSP20 interacts directly with PDE4 isoforms. In vitro pull-down assay of 
purified His-HSP20 and purified GST-PDE4 showed that His-HSP20 was co-precipitated 
in GST-pulldowns containing the PDE4 proteins. 
This work was carried out by Dr Xiang Li. 
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Figure 3.9. HSP20 colocalises with PDE4D. Confocal images of PDE4D and HSP20 
localisation in neonatal rat cardiomyocytes. The cells were treated with ISO and rolipram 
for 10 min before co-staining anti-α-actinin with anti-HSP20 or anti-Pan-PDE4D 
antibodies. The magnification of the boxed area showed that both PDE4D and HSP20 
localised into the same cellular compartment containing α-actinin. Images are 
representative of three independent cell culture preparations. 
This work was carried out by Dr Xiang Li. 
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3.3.4      Mapping interaction sites between HSP20 and PDE4D5 
PDE4D5 has been shown to be implicated in the interactions with diverse partners such as 
RACK1, β-arrestin and DISC1 (Millar et al., 2005; Bolger et al., 2006). In all of these 
cases, SPOT immobilized peptide libraries of PDE4D5 sequences were used to provide 
information on the molecular binding nature of these interacting proteins. This array-based 
method was also carried out in this study to define the HSP20 binding site within the full-
length PDE4D5 sequence. Peptide array libraries of overlapping 25-mer peptides (each 
shifted by five amino acids) that spanned the entire sequence of PDE4D5 were probed for 
interaction with purified recombinant His-HSP20 protein or BSA (control). Dark spots 
signify positive association whereas clear spots represent no interaction. Whilst no signal 
was observed on control arrays overlaid with BSA, a cluster of binding spots (spots 93-96) 
were detected which encompassed the amino acid sequence Y
461
-K
500 
within the conserved 
catalytic domain of PDE4D5 (Fig. 3.10A). Notably, this result is in agreement with the 
data obtained earlier, in that this region is highly conserved in all PDE4 isoforms and could 
represent a pan-PDE4 binding site for HSP20.   
 A more detailed analysis to determine the specific residues important in the protein 
interactions was undertaken using alanine scanning substitution arrays which focused on 
the E
468
-K
492
 region of PDE4D5.  The alanine scanning peptide libraries were constructed 
by sequentially substituting each residue to alanine or aspartate (if an alanine was the 
natural amino acid at that position). This approach identified a significant loss of binding 
ability at three regions, namely the double histidine (H
470
 and H
471
), K
477
 and the acidic 
region consisting of E
481
, E
482
 and D
485
 (Fig. 3.10A), denoting their importance in the 
interaction. Superimposing these six residues on the documented crystal structure of the 
PDE4 catalytic domain showed that all of these amino acids (except H
471
) are surface 
associated, having a potential to act as docking sites for signalling proteins such as HSP20 
(Fig. 3.10B). 
In addition, a reciprocal scanning peptide array analysis was also carried out to identify the 
binding site of PDE4D5 on full-length HSP20. Results showed high-affinity binding 
regions in the WDPF and α-crystallin domains (Fig. 3.11). In particular, the binding region 
at the N-terminal encompasses a consensus sequence RRASA which serves as cAMP-
dependent protein kinase A (PKA)– specific phosphorylation motif (Beall et al., 1997). 
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Figure 3.10. Mapping the site of HSP20 interaction on PDE4D5. (A) The disposition of 
the peptides is shown relative to a schematic representation of PDE4D5 structure. Peptide 
array analysis identified binding sites for HSP20 in the catalytic unit of PDE4D5. Binding 
spot numbers relate to peptides in the scanned array and whose residues position and 
sequences are shown. Alanine scanning analysis using the sequence covering E
468
-K
492
 
identified amino acids critical for the binding. (B) PDE4D5 residues critical for the 
interaction with HSP20 were superimposed on the crystal structure of the PDE4D5 
catalytic unit.  This work was carried out by Dr Allan Dunlop and Prof Dave Adams. 
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Figure 3.11. Mapping the site of PDE4D5 interaction on HSP20. HSP20 array was 
overlayed with full-length purified GST-PDE4D5 and detected by anti-GST antibody. The 
disposition of the peptides is shown relative to a schematic representation of HSP20 as in 
Gusev et al. (2002) with slight modifications. The dark shaded area represents the WDPF-
domain, the light shaded area represents the conserved region in the N-terminal part of 
sHSP, the black area denotes conservative α-crystallin domain. P is the sites of 
phosphorylation and the zigzag denotes the flexible C-terminal region. Binding spot 
numbers relate to peptides in the scanned array and whose residues position and sequences 
are shown below. 
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3.3.5      Peptide disruption of PDE4D5-HSP20 complex 
Based on the information gathered from peptide array analyses, cell-permeable analogues 
of the 25-mer peptide encompassing residues E
468
-K
492
 
(ENHHLAVGFKLLQEENSDIFQNLTK) was synthesised and named ‘bs906’. At the 
same time, a control peptide consisted of a scrambled version of peptide ‘bs906’ 
(KELGAINHEFDLSHNFQTQKLNLVE) that had the same net charge and weight was 
also synthesized. Both peptides carry a C-terminal stearate group that has been shown to 
allow peptide transport across the cell membrane into the cells while not affecting the 
peptide’s ability to disrupt signaling complexes (Meng et al., 2009). The ability of the 
disruptor peptide to displace PDE4D-HSP20 interaction was assessed by 
immunoprecipitation experiments and evaluation of the phosphorylation level of HSP20. 
Co-immunoprecipitation experiments using lysates from co-transfected HEK293 cells 
showed that the HSP20–PDE4D5 complex disruptor ‘bs906’ attenuated the association 
between PDE4D5 and HSP20 and the effect was significantly enhanced at higher 
concentration of disruptor peptide (Fig 3.12). However, no such disruption was evident 
upon use of the scrambled control peptide, hence confirming the target specificity. 
 
3.3.6      The effect of PDE4D5-HSP20 interaction on HSP20 phosphorylation 
Next, the effect of PDE4D5-HSP20 complex disruption on Ser16 phospho-levels was 
investigated. Co-transfected HEK293 cells treated with disruptor peptide ‘bs906’ but not 
scrambled control peptide resulted in a robust and significant increase in the 
phosphorylation of HSP20 at Ser16 (Fig 3.13). In particular, the maximum effect of the 
disruptor peptide ‘bs906’ was seen after 60 min. Conversely, scrambled control peptide 
modestly increased HSP20 phosphorylation and reached a final level of phosphorylation 
that was significantly lower than disruptor peptide ‘bs906’. These findings suggested that 
the disruption of PDE4D5-HSP20 interaction is likely to alleviate PKA inhibition by 
preventing sequestration of PDE4D5 to the HSP20 complex. Gratifyingly, these data are in 
agreement with earlier studies showing that treatment with rolipram alone was sufficient to 
promote HSP20 phosphorylation at Ser16 (Fig 3.5). In this regard, the basal concentrations 
of cAMP would thus be expected to trigger PKA-mediated HSP20 phosphorylation in the 
absence of localised PDE4 activity, pinpointing a pivotal role of sequestered PDE4 in the 
regulation of HSP20 phosphorylation by PKA. 
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Figure 3.12. Disruption of PDE4D5-HSP20 interaction. Upper panel: HEK293 cells 
were co-transfected with PDE4D5 and HSP20 and subjected to increasing concentrations 
of disrupt peptide ‘bs906’ or scrambled control peptide for 2 h. Lysates were 
immunoprecipitated with HSP20 and then probed for PDE4D5. Anti-HSP20 antibody was 
used as loading control. Lower panel: Densitometric analysis of the amount of PDE4D5 in 
HSP20 immunoprecipitates normalised to expression level. Data are means ± S.E.M. of 
three separate experiments. Statistical significances between the two treatment groups were 
determined by the use of Student’s t-test. *P < 0.05 values were considered significant. 
This work was carried out by Dr Frank Christian. 
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Figure 3.13. Disruption of PDE4D5-HSP20 interaction promotes HSP20 
phosphorylation at Ser16. Upper panel: HEK293 cells were co-transfected with PDE4D5 
and HSP20 and treated with disrupt peptide ‘bs906’ or scrambled control peptide for 
indicated times. Lysates were immunoblotted with phospho-HSP20 (Ser16) and HSP20. 
Lower panel: Densitometric analysis of HSP20 phosphorylation levels normalised to total 
HSP20. Data are means ± S.E.M. of three separate experiments. Statistical significances 
between the two treatment groups were determined by the use of Student’s t-test. *P < 0.05 
values were considered significant. 
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3.3.7      The role of PDE4D5-HSP20 complex in hypertrophy 
Recent findings have reported that prolonged treatment with ISO results in the 
phosphorylation of HSP20 in order to trigger its cardioprotective functions to attenuate the 
hypertrophic growth of cardiomyocytes (Fan et al., 2005, 2006). As shown earlier in this 
chapter, phosphorylation of HSP20 could be induced when the HSP20-PDE4 complex is 
dismantled by treating cells with disruptor peptide ‘bs906’. As such, it was particularly 
interesting to find out if this disruptor peptide ‘bs906’ could also attenuate the hypertrophic 
response in neonatal rat cardiomyocytes following sustained β-agonist stimulation. 
Chronic β-adrenergic stimulation has been implicated in the development of 
cardiomyocyte hypertrophy (Fan et al., 2004). In order to mimic hypertrophic induction in 
this study, cardiomyocytes were cultured under serum-free conditions for 48 h before 
being treated chronically with β-adrenergic agonist, ISO for 24 h. The role of the PDE4D5-
HSP20 complex in hypertrophic growth was then evaluated by three methods: 
measurement of cell size, assessment of protein synthesis and real-time qPCR analysis of 
fetal gene expression. 
 
3.3.7.1  Measurement of cell size 
The hypertrophic phenotype was evaluated using a traditional approach where the cross-
sectional areas of the cardiomyocytes were measured manually by tracing the cell 
perimeter on digitised images acquired on a microscope. In parallel with this traditional 
method, a novel approach employing xCELLigence technology was also undertaken to 
monitor cardiomyocytes in real-time. This method allowed quantitative measurement of 
cell size increases and changes in morphology through real-time cell-electronic sensing 
(RT-CES) (Atienza et al., 2006; Yu et al., 2006; Vistejnova et al., 2009). The change in 
electrode impedance is automatically converted to cell index (CI) values which reflect the 
quantitative measurement on any changes in cell morphology that alter resistance to the 
current, thereby allowing unbiased detection of specific cellular processes in real-time. 
Because cardiomyocytes are unable to divide, they tend to increase in cell size in respond 
to stress which can ultimately lead to thickening of the heart wall. Hence, in this context, a 
higher cell index value directly reflects an increase in cell cross-sectional area.  
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In this study, the change in cell size was monitored over time, with a special focus on 
changes that occurred after 24 h ISO treatment. Importantly, the reproducibility of my 
manual measurement was verified by the results obtained from RT-CES. Both techniques 
produced strikingly similar data, showing a significant 2-fold increase in cardiomyocyte 
size following 24 h ISO treatment. Interestingly, this hypertrophic phenotype could be 
rescued by pre-treatment of disruptor peptide ‘bs906’ but not the scrambled control peptide 
(Fig. 3.14). These results also provided evidences for hypertrophic responsiveness of 
cardiomyocytes isolated from neonatal rats to continuous β-adrenergic stimulation by ISO.  
Clearly, my study demonstrates that 24 hours of ISO treatment is sufficient to induce 
hypertrophy in cultured neonatal rat cardiomyocytes. Gratifyingly, this observation is 
consistent with previous reports by Morisco et al. (2001) who utilised ISO-stimulated 
hypertrophic neonatal rat cardiomyocytes to investigate the mechanism underlying 
induction of cardiac hypertrophy by different subtypes of β-adrenergic agonist receptors. 
 
3.2.7.2    Measurement of protein content 
Next, to determine the effect of PDE4D5-HSP20 complex on protein synthesis, the overall 
hypertrophic growth response of cardiomyocytes was determined by measuring 
protein/DNA ratio post-treatment. The total cell protein and the DNA content were 
quantified by the Ohnishi & Barr modified Lowry method, and the Hoechst dye method 
(see ‘Materials and Methods’), respectively. As expected, the relative protein/DNA ratio in 
ISO-treated cardiomyocytes was significantly higher than those of the DMSO-treated 
controls (Fig 3.15). Clearly, ISO stimulation increased cardiomyocyte growth partially by 
promoting protein synthesis. In agreement with the findings reported above, increases in 
protein synthesis could be rescued by the disruptor peptide ‘bs906’, but not the scrambled 
control peptide.  
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Figure 3.14. Disruption of PDE4D5-HSP20 complex inhibits cardiomyocyte 
enlargement. Cardiomyocytes were cultured for 48 h in a serum-free condition prior to 
indicated treatment. (A) Upper panel: A hundred beating cardiomyocytes from randomly 
selected microscope views were analysed and the cross-sectional area was measured 
manually. Surface areas of cardiomyocytes were calculated according to the formula stated 
in ‘Materials and Methods’. Bottom panel: Graphical depiction of the mean areas of cells. 
(B) Impedance measurements were used to calculate continuous normalised cell index 
using RT-CES. Data were presented as a percentage of change of experimental groups 
compared with untreated controls. Values are expressed as means ±  S.E.M of four 
separate experiments on different cardiomyocyte preparations. A Student’s t-test was 
performed to compare untreated control with cells exposed to indicated treatment. *P < 
0.05 values denotes statistically significant. 
A
S 
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Figure 3.15 Disruption of PDE4D5-HSP20 complex inhibits protein synthesis. The 
protein content was normalised by the DNA amount to correct for differences in the cell 
number. Data are means ± S.E.M. of three experiments on different cardiomyocytes 
preparations. A Student’s t-test was performed to compare the two groups as shown and 
statistically significance was set at P < 0.05. 
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3.2.7.3    Expression of ANF mRNA and protein expression  
One of the most striking characteristics of the hypertrophic response is the phenotypic 
modification which leads to the re-expression of fetal genes. Atrial natriuretic factor (ANF) 
is a haemodynamic peptide hormone which regulates cardiovascular homeostasis. In 
mammals, ANF is normally produced in the atria but can be found in both atrial and 
ventricular cardiomyocytes during embryonic development (de Bold, 1985). As ventricular 
ANF expression usually ceases after birth, re-expression of ANF during hypertrophy 
indicates initiation of a compensatory response (Chien et al., 1991; Rosenzweig and 
Seidman, 1991). 
Hence, in addition to changes in cellular morphology and increased protein synthesis, the 
levels of fetal gene expression was also assessed in this study. An invariant endogenous 
gene, rat 18s rRNA was also included as internal control to correct for small variations in 
sample loading. Normalisation of target gene expression was performed to sample-to-
sample and run-to-run variation (Pfaffl and Hageleit, 2001). As shown in Figure 3.16A, 
ISO treatment strongly enhanced the transcriptional activity of ANF, resulting in a 
significant 2-fold increase in ANF mRNA levels. In parallel, expression of ANF protein 
was increased by 1.5-fold, as detected by immunoblotting with anti-ANF antibody (Fig. 
3.16B). However, the expression of α-tubulin which is expressed constitutively remained 
unchanged. In addition, similar changes were observed in the cardiomyocytes pre-treated 
with control peptide. Interestingly, disruptor peptide ‘bs906’ appeared to augment the 
increase in both ANF mRNA and protein expression triggered by ISO stimulation.  
 
 
A 
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Figure 3.16. Disruption of PDE4D5-HSP20 complex enhanced transcriptional 
activation of hypertrophy response gene. Cardiomyocyte cultures were treated with 
disruptor peptide ‘bs906’ and control peptides prior to 24 h ISO stimulation. (A) Changes 
in relative ANF expression compared to wild-type. The changes in ANF mRNA transcript 
levels were determined by real-time qPCR analysis and normalised to reference gene rat 
18s rRNA which was used as an internal control for RNA loading. Expression of each 
transcript was quantified and expressed as the level of expression relative to untreated 
cultures. (B) Upper panel:  Representative immunoblot of ANF protein expression detected 
by an anti-ANF antibody. Lower panel: Quantitative analysis of immunoblots showing fold 
ratio of ANF normalised to α-tubulin. Data are mean ± S.E.M. of two or more experiments 
on different cardiomyocytes preparations. Statistical differences were determined using the 
Student’s t-test and statistical significance was set at P < 0.05. 
B 
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3.4      Discussion 
3.4.1     Background 
Despite therapeutic advances in the area of β-adrenergic signalling, hypertrophy leading to 
heart failure, remains a prime cause of death in industrialised nations. As mentioned earlier, 
HSP20 is known to confer cardioprotection during times of stress such as sustained β-
adrenergic stimulation (Fan et al., 2004, 2005, 2006). It is well-appreciated that the 
mechanism underlying its protective function is greatly contingent on its phosphorylation 
by cAMP-dependent PKA at Ser16 (Fan et al., 2004; Qian et al., 2009; Zhu et al., 2011). 
However, little is known about the exact molecular mechanisms that link the spatial and 
temporal control of cAMP signalling to the post-translational modification of HSP20. The 
driving notion behind this present study is that PDEs contribute to the generation of 
intracellular cAMP microdomains which is critical for the specificity of cAMP signaling 
(Mongillo et al., 2004; Terrin et al., 2006). Moreover, cAMP accumulation upon 
extracellular hormone stimulation is highly localised in cardiomyocytes (Zaccolo and 
Pozzan, 2002; Mongillo et al., 2004). Specifically, compartmentalised PDE4 is a major 
regulator of cAMP gradients in the heart (Richter et al., 2005). With these statements in 
mind, we wanted to determine whether HSP20-targeted PDE4 was involved in dampening 
the activation of the PKA pool that directed HSP20 phosphorylation. I hypothesised that if 
this was true, disruption of the HSP20-PDE4 complex should attenuate hypertrophic 
growth of cardiomyocytes and trigger cardioprotection.  
 
3.4.2     PDE4 modulates PKA-mediated HSP20 phosphorylation upon ISO  
             stimulation 
Part of the work in this study was carried out in transfected HEK293 cells, while most of 
the findings were verified in the more physiological setting of neonatal rat cardiomyocytes 
with endogenously expressed proteins and an established model to mimic hypertrophy 
(Morisco et al. 2001). It should be noted that in this study, all experiments with primary 
cultures were performed using highly purified cardiomyocytes, hence excluding possible 
variations attributable to other non-myocardial cells present in the heart (Fig. 3.4). The first 
part of this study showed that PKA-mediated phosphorylation of HSP20 was modulated by 
PDE4 activity in cardiomyocytes in response to ISO treatment (Fig. 3.5). The chemical 
ablation of PDE4 using the PDE4 specific inhibitor, rolipram could dramatically increase 
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ISO-induced HSP20 phosphorylation at Ser16. In addition, inhibition of PKA activity by 
KT5720 markedly attenuated HSP20 phosphorylation at Ser16 (Fig. 3.6). Clearly, PDE4s 
are highly expressed in cardiomyocytes and contribute to most PDE activities for cAMP 
degradation (Mongillo et al., 2004). Moreover, the cardioprotective mechanism triggered 
by HSP20 is associated with its phosphorylation on Ser16 by PKA (Fan et al., 2005). In 
this context, inhibition of PDE4 activity with rolipram which is required to achieve 
maximal cAMP accumulation (Thompson et al., 2002) is likely to result in an increase in 
PKA-mediated phosphorylation of HSP20. Interestingly, inhibition of PDE4 alone is 
enough to increase phosphorylation levels of HSP20 in resting cells, suggesting that 
sequestration of PDE4 may play a key role in maintaining the dephosphorylated state of 
HSP20 under basal condition. Seemingly, HSP20 exists in the inactive state by virtue of its 
association with PDE4. This enzyme is known to control cAMP dynamics by acting as 
‘sinks’ to locally drain cAMP, thus preventing inappropriate PKA phosphorylation caused 
by variations in basal cAMP levels (Baillie, 2009). Intracellular cAMP levels are the result 
of the balance between cAMP synthesis and its exclusive hydrolysis by PDE4 (Lugnier, 
2006). Presumably, PDE4 can protect HSP20 from inappropriate PKA phosphorylation 
due to fluctuations in basal cAMP levels. However, under conditions of elevated cAMP, 
the PDE4 activity associated with HSP20 is not sufficient to protect HSP20 from 
phosphorylation and cAMP concentration increased upon β-adrenergic stimulation saturate 
tethered PDE4 to allow PKA activation and consequently, the phosphorylation of HSP20. 
 
3.4.3     PDE4 isoforms associate directly with HSP20 
Further work using co-immunoprecipitation and in vitro binding assays provided evidences 
of direct interaction between PDE4 (in particular PDE4D) and HSP20 in cardiomyocytes 
(Fig. 3.7 and 3.8). Immunocytochemistry studies suggested that both HSP20 and PDE4D 
are likely to exist in the same cellular compartment since both proteins localised with α-
actinin (Fig. 3.9). Indeed, PDE4 has been shown to be localised to the sarcomeric Z-disk in 
proximity to βAR (Mongillo et al., 2004). The findings outlined above support the 
hypothesis that PDE4 co-exists in a complex with HSP20 to modulate PKA-mediated 
HSP20 phosphorylation. This notion is supported by previous results showing that PDE4D 
isoforms are associated with βAR and the regulation of cAMP accumulation (Mongillo et 
al., 2004; Xiang et al., 2005; Richter et al., 2008). Using a transfected cyclic nucleotide-
gated (CNG) channel sensitive to cAMP, PDE4 activity was increased upon β-adrenergic 
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stimulation and was shown to control the subsarcolemmal cAMP levels in cardiomyocytes 
(Rochais et al., 2004). Clearly, activated βAR couples to Gs proteins to stimulate adenylyl 
cyclases (ACs) for the production of cAMP and increases PKA activity for the 
phosphorylation of a range of substrates (Lefkowitz et al., 2002; Conti and Beavo, 2007; 
Houslay et al., 2007). PKA activity is greatly depending on cAMP diffusion (Saucerman et 
al., 2006). Collectively, these findings suggest a key role of PDE4 in shaping β-AR-
dependent cAMP signals and thereby regulating cAMP-dependent PKA activity. In this 
context, PDE4 is thus considered to be particularly important in protecting HSP20 from 
inappropriate phosphorylation during basal cAMP oscillations and to regulate cAMP-
dependent PKA phosphorylation induced by β-agonists. 
 
3.4.4     HSP20 binds to the conserved catalytic region of PDE4 
Peptide array technology was carried out as a rapid and informative means of determining 
protein-protein interaction sites (Bolger et al., 2006). Indeed, this method has been used in 
my laboratory to considerable advantage to define the binding sites on PDE4D5 for 
RACK1 (Bolger et al., 2006) and β-arrestin (Baillie et al., 2007). Here, a recombinant 
purified His-HSP20 was used to probe a library of overlapping, immobilized 25-mer 
peptides that scanned the full-length sequence of PDE4D5. An interacting peptide 
spanning V
466
-L
490
 was subsequently used as a template to generate a library of progeny 
where individual amino acids in the 25-mer parent were each substituted with alanine (or 
substitute aspartate for alanine). This array-based method uncovered the interaction site of 
PDE4D-HSP20 within the conserved catalytic region and highlighted the critical residues 
involve in the binding (Fig. 3.10A). The nature of the interaction surfaces was then 
revealed by superimposing the key residues on a known crystal structure of PDE4D 
catalytic domain (Fig. 3.10B). The critical residues are mostly surface-exposed and hence 
available for interaction. These findings are also particularly interesting in view of the 
engagement of a single docking site for HSP20 on PDE4 which located within an 
evolutionarily conserved region. In fact, this result would contradict the notion that 
interacting partners of PDE4 often bind at multiple docking sites on the enzyme, as seen in 
RACK1-PDE4D5 (Bolger et al., 2006) and DISC1-PDE4B (Millar et al., 2005). However 
in this context, the binding of HSP20 to PDE4 does not require such isoform specificity. 
On the other hand, mapping of the interaction site of PDE4D5 on HSP20 identified a 
physiologically relevant phosphorylation motif RRASA within its N-terminus (Fig. 3.11), 
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a site which is implicated in the β-adrenergic/cAMP-dependent PKA signalling pathway 
(Beall et al., 1997). This region is likely to enhance the influence of PDE4D5 on the 
activation of PKA and the phosphorylation status of PKA-targeted HSP20. Further studies 
utilising site-directed mutagenesis approach together with structural information may 
identify other surface–associated residues of putative importance to binding. 
In many cases, the biological functions of a signalling complex can be further characterised 
by cell-permeable analogues of 25-mer peptides that are identified from peptide array 
studies (Smith et al., 2007; Meng et al., 2009). Previously, my laboratory had successfully 
used such approach to disrupt the interactions between β-arrestin and its binding partners, 
PDE4D5 (Smith et al., 2007) and MAPK kinase, MEK1 (Meng et al., 2009) to study the 
functional consequences of these complexes. Results showed that the disruptor peptides 
displaced the β-arrestin complexes in cells and resulted in aberrant cellular signalling. 
Hence in this study, in order to gain insight into the functional role of the PDE4D5-HSP20 
complex, the sequence information gleaned from alanine scanning array analysis was then 
used to generate a cell-permeable disruptor peptide ‘bs906’ which specifically interfered 
with the interaction between HSP20 and PDE4D5 (Fig. 3.12). Interestingly, the disruption 
of the interaction between PDE4D5 and HSP20 triggered an increase in the 
phosphorylation of HSP20 at Ser16 under resting conditions in HEK293 cells (Fig. 3.13). 
This may indicate that the association between PDE4D5 and HSP20 is required to gate the 
protective PKA-mediated phosphorylation of HSP20. Clearly, this peptide-mediated 
approach which allowed the incorporation of exogenous peptides into living cells has 
enhanced our understanding of the molecular mechanism behind fundamental cellular 
events.  
 
3.4.5     Disruption of PDE4D5-HSP20 complex protects against hypertrophy 
Given that PDE4D5 is associated with HSP20 and modulates its phosphorylation, 
disruption of this association is likely to have potentially beneficial effects on HSP20 
phosphorylation and related function. Indeed, treatment of neonatal rat cardiomyocytes 
with this disruptor peptide ‘bs906’ resulted in hyperphosphorylated endogenous HSP20 
and the induction of cardioprotective mechanisms, an outcome not seen in cells treated 
with scrambled control peptide. Interestingly, phospho-HSP20 was shown to attenuate 
ISO-mediated hypertrophic response in cultured neonatal rat cardiomyocytes as 
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determined by a reduction in the increase in cell size and protein synthesis (Fig. 3.14, 3.15). 
It is in agreement with previous results which showed increased phospho-HSP20 levels are 
required for cardioprotective responses during sustained β-agonist treatment (Fan et al., 
2004, 2006; Nicolaou et al., 2008). Clearly, phosphorylation of HSP20 at Ser16 is essential 
to trigger the cardioprotective ability of HSP20. Hence, displacement of PDE4D5 
association with HSP20 is likely to be a novel strategy for the development of 
cardioprotective targets.  
Moreover, disruptor peptide ‘bs906’ appeared to augment the expression of fetal gene 
ANF. Despite being a marker for cardiac hypertrophy, it is noteworthy that ANF could also 
exert local anti-hypertrophic effects in the heart via inhibition of cell growth (Horio et al., 
2000). Moreover, an increased in ANF expression may serve as a compensation 
mechanism to reduce both cardiac preload and after load via natriuretic and vasodilatory 
actions (Nishikimi et al., 2006). In this regard, the increase of ANF expression is thus 
likely to be part of a compensatory protective response against hypertrophy. Whether this 
compensatory mechanism is triggered by HSP20 hyperphosphorylation resulting from 
disruption of association with PDE4D5 or if other protective mechanism is involved, 
remains to be elucidated. 
 
3.4.6     Conclusion 
In conclusion, I present the first evidence for the specific association of PDE4D5 with 
HSP20 to regulate its biological function. This study also further verifies the importance of 
HSP20 phosphorylation and its cardioprotective role in counteracting the hypertrophic 
growth of cardiomyocytes in response to hypertrophic stimuli. Clearly, disruption of the 
PDE4D5-HSP20 interaction with the cell-permeable peptide ‘bs906’ that corresponds to 
the HSP20 docking site on PDE4D5 results in the hyperphosphorylation of HSP20. 
Importantly, this post-translational modification is required for cellular protection against 
hypertrophy. Since current conventional PDE4 inhibitors are limited by their poor 
selectivity which leads to serious dose-limiting side effects, such displacement strategies as 
that used for the selective inhibition of the PDE4D5-HSP20 signalling complex this study 
are likely to be a novel route for therapeutic exploitation. Observations of the effect of the 
disruptor peptide ‘bs906’ on cardiomyocytes in vitro are likely to provide the basis for 
studies to determine its in vivo efficacy in experimental cardiac disease models. As such, 
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further work may include optimisation of disruptor peptide ‘bs906’ to generate a small, 
higher affinity and metabolically stable peptide analogue for better therapeutic viability. 
Disruptor peptide ‘bs906” could also be used in an assay to screen for small molecules that 
may also disrupt the HSP20-PDE4 complex. Where appropriate, these small molecule 
disruptors could be testing in vivo in animal models of cardiac hypertrophy to confirm that 
pharmacological manipulation of the target is therapeutically beneficial. 
 
3.4.7     Small molecules therapies for heart disease 
A growing body of evidence has demonstrated that small molecules inhibitors could be 
used to target intracellular signalling pathways inside the cardiac muscle cells to suppress 
or reverse hypertrophy. Of interest, a cGMP-specific PDE5 inhibitor, sildenafil (Viagra, 
Pfizer) have been shown to induce vasorelaxation of precontracted pig coronary artery in a 
dose-dependent manner which is accompanied by a substantial increase in the 
phosphorylation level of HSP20 (Tessier et al., 2004). Takimoto et al., (2005) later 
demonstrated that chronic inhibition of PDE5A using sildenafil hindered the progression of 
hypertrophy and enhanced cardiac function in mice exposed to sustained pressure overload 
induced by thoracic aortic banding. It was also reported that sildenafil reversed pre-
existing hypertrophy by preventing contractile dysfunction and reversing pathological 
remodeling. In addition, ruboxistaurin (LY 333531), which is a PKCβ inhibitor has been 
shown to attenuate pathological fibrosis and remodeling in rats subjected to myocardial 
infarction (MI) (Boyle et al., 2005). It was proposed that the anti-hypertrophic effect may 
involve inhibition of PKC-mediated transforming growth factor-beta (TGF-beta) 
expression via the MAP kinase cascade. Clearly, there is growing promise in the use of 
small molecules peptides as drugs. 
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4.1.     Introduction 
 
4.1.1    The study of protein-protein interaction 
Proteins need to interact with other proteins to exert their biological functions. Hence, 
comprehensive protein-protein interaction profiling is of immense value in providing 
mechanistic insight into complex regulatory networks, which underlie specific cellular 
function. Recently, human protein microarray (ProtoArray) technology has been 
established to allow rapid and robust screening of protein-protein interactions in a high-
throughput manner (Schweitzer et al., 2003). This flexible technique can be used for a 
wide range of applications including characterisation of antibody specificity, identification 
and validation of immune response biomarkers and novel molecular targets, as well as drug 
profiling (Michaud et al., 2006; Satoh et al., 2006, 2009; Sumiyoshi et al., 2010).  
The ProtoArray has many classes of highly purified, full-length, recombinant GST-tagged 
human proteins that are immobilised on a chip. These proteins are expressed in insect cells 
using the baculovirus expression system and subsequently purified under native conditions 
by employing glutathione affinity chromatography to ensure structural and functional 
stability (Satoh et al., 2006, 2009). The target proteins extend from the array surface via 
the epitope tag, which serves as a spacer to enhance binding. Interactions with the spatially 
accessible target proteins can then be detected by probing the array with a separate protein 
of interest that has been pre-purified by the user. ProtoArray chips also contain a series of 
built-in control spots that allow evaluation of inter- and intra-array variability. 
 
4.1.2    Background and project aim 
Previous studies have described various cardioprotective functions of HSP20 in a cardiac 
setting (Fan et al., 2005). To date, possible targets of HSP20 include cytoskeletal elements, 
actin and the apoptotic protein, Bax which result in the stabilisation of cytoskeleton and 
inhibition of apoptosis, respectively (Fan et al., 2004). In addition, HSP20 also alters the 
downregulation of apoptosis signal-regulating kinase 1 (ASK1), leading to an inhibition of 
isoprenaline-mediated hypertrophy (Fan et al., 2006). Nevertheless, the molecular 
mechanism that underpins HSP20-induced cardioprotection is not yet clearly defined as it 
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remains to be determined whether other signalling pathways are involved. As the 
regulation of protein function often relies on protein-protein interactions, an insight into 
the function of a particular protein and the regulatory signalling networks involved can be 
obtained if potential interaction partners are defined. 
This project sought to characterise potential interactors of HSP20 using high-density 
ProtoArray analysis. It is anticipated that the identification of novel signalling complexes 
containing HSP20 will help to gain further insight into the function of HSP20 in 
hypertrophy signalling pathways. 
 
 
4.2.    Results 
 
4.2.1    ProtoArray identified 21 HSP20 interactors 
Recombinant His-HSP20 fusion protein was purified under native conditions (see 
‘Materials & Methods’ for details). Coomassie staining of purified HSP20 sample showed 
a single 20-25 kDa band indicating a highly purified His-tagged HSP20 that was used to 
probe ProtoArray chips (Fig. 4.1). The identity of the band was further confirmed by 
immunoblotting using both anti-His (Fig. 4.2A) and anti-HSP20 antibodies (Fig. 4.2B). 
Following screening with His-HSP20 probe, the data suggested that 21 of the 8000 target 
proteins showed significant interaction with HSP20 (Table 4.1). Positive control spots such 
as Alexa Fluor 647-labelled antibody were detected, verifying the probing and detection 
protocols.  However, no signal was detected from the negative control spots including 
those of BSA, GST, calmodulin, human IgG, anti-biotin antibody and buffer-only control, 
confirming the reliability of the data obtained. 
The expression profiles of the 21 HSP20 interactors were studied using the National Center 
for Biotechnology Information (NCBI) website (http://www.ncbi.nlm.nih.gov). The 
database search suggested that most of the interactors are involved in neuronal, cardiac or 
immune functions. Following intensive searches for the biological implications of the 
putative HSP20 binders on PubMed, protein kinase D1 (PKD1) (Fig. 4.3) was found to 
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have physiological relevance as both it and HSP20 are known to have roles in hypertrophy 
signalling. Hence, PKD1 was chosen as the focus of this study. The interaction between 
HSP20 and PKD1 is novel and this is the first report of such an interaction.  
 
 
 
 
 
 
Figure 4.1. Native purification of His-tagged HSP20. The protein was purified with Ni-
NTA resin as described in materials and methods. The resin with bound protein was 
washed with buffer containing10 mM imidazole and eluted with a linear gradient from 20 
mM to 250 mM imidazole. 2x 500 µl fractions from each concentration were collected. 
Eluted fractions were then analysed on 4-12% SDS-PAGE gel and visualised by 
Coomassie staining. T=0: before induction; T=3: after 3 h of IPTG induction; E1: first 
eluate; E2: second eluate. 
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Figure 4.2. The His-tagged HSP20-specific probe utilised for ProtoArray analysis. 
The protein was separated by 4-12% SDS-PAGE gel. The blots were then labelled with 
anti-His antibody (A) and anti-HSP20 antibody (B), and detected by fluorescence 
secondary antibodies on Odyssey Infrared Imaging System. IB: Immunoblotting.
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Table 4.1. The list of HSP20 interactors identified by ProtoArray. 
 
No. Accession No. Name Putative function 
1 NM_002737 Protein kinase C, alpha (PRKCA) Regulation of cardiac contractility 
2 NM_002738 Protein kinase C, beta (PRKCB) B cell activation, regulation of neuronal functions 
3 NM_002739 Protein kinase C, gamma (PRKCG) Involves in long term potentiation/depression 
4 NM_002742 Protein kinase D1 (PRKD1) Regulation of myocardial contraction and remodeling 
5 NM_024482 Glucocorticoid modulatory element binding protein 1 (GMEB1) Transactivation of gluococorticoid receptor 
6 NM_004281 BCL2-associated athanogene 3 (BAG3) 
Inhibition of chaperone activity by promoting 
substrate release 
7 NM_145796 Pogo transposable element with ZNF domain (POGZ) Interact with transcription factor SP1 
8 BC012289 HLA-B associated transcript 2-like Control of apoptosis and regulating HSP 
9 BC012984 Par-3 partitioning defective 3 homolog B (C. elegans) (PARD3) Asymmetric cell division and polarised growth 
10 NM_178191 ATPase inhibitory factor 1 (ATPIF1) Inhibition of mitochondrial ATPase to ATP hydroysis 
11 NM_022101 Chromosome X open reading frame 56 (CXorf56) Unknown 
12 BC042333 F-box protein 21 
Substrate-recognition component of E3 ubiquitin 
ligase complex 
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Table 4.1. (Continued) 
 
No. Accession No. Name Putative function 
13 NM_022165 Lin-7 homolog B (C. elegans) (LIN7B) Unknown 
14 BC001709 NAD kinase 
Catalyses the transfer of a phosphate group from 
ATP to NAD to generate NADP 
15 BC034028 SHANK-associated RH domain interactor Immune development and control of inflammation 
16 NM_003161 Ribosomal protein S6 kinase, 70kDa, polypeptide 1 (RPS6KB1) Protein synthesis and cell proliferation 
17 NM_020375 Chromosome 12 open reading frame 5 (C12orf5) 
Block glycolysis, protection from DNA damage-
induced apoptosis 
18 NM_002688 Septin 5 (SEPT5) Regulation of cytoskeletal organisation, cytokinesis 
19 NM_014321 Origin recognition complex, subunit 6 like (yeast) (ORC6L) DNA replication and segregation with cytokinesis 
20 NM_002788 Proteasome subunit, alpha type, 3 (PSMA3) Processing of class I MHC peptides 
21 NM_002609 Platelet-derived growth factor receptor, beta polypeptide (PDGFRB) As mitogens for cells of mesenchymal origin 
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                 A 
 
 
                B 
 
Figure 4.3. Identification of PKD1 on ProtoArray. (A) The array containing duplicate 
spots of more than 8000 proteins is composed of 4 x 12 sub-arrays. Each sub-array 
contains 20 x 20 spots composed of target proteins, control and empty spots. (B) Image 
showing sub-arrays (red boxes) of a control array (left) and an array probed with purified 
His-tagged HSP20 protein (right). A robust signal showing regular spot morphology 
positioned at row 19 and columns 9-10 represented PKD1. Other signals were from 
reference spots or proteins for which signals were not duplicated. 
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4.2.2     Validation of the interaction between HSP20 and PKD1 
To validate the results of ProtoArray analysis, biochemical studies were carried out. The 
interaction between HSP20 and PKD1 was first confirmed using in vitro pull-down 
experiment where purified His-HSP20 but not purified His-tag alone acted to pull-down 
PKD1 (Fig. 4.4A). Co-immunoprecipitation analyses were then carried out to investigate if 
the interaction could also be observed ex vivo using endogenous and overexpressed 
proteins. First, an anti-PKD1 antibody was used to pull down endogenous PKD1 from 
lysates prepared from cardiomyocytes, while a GFP-specific antibody immunoprecipitated 
exogenously expressed GFP-PKD1 from lysates made from transfected HEK293 cells. The 
immunocomplexes were then tested for the presence of HSP20 protein using anti-HSP20 
and anti-V5 antibodies, respectively.  Fig. 4.4B-C shows that PKD1 and HSP20 co-
immunoprecipitate in both cell lines. The interaction was detected between the endogenous 
and transfected proteins. Bands were also detected in reciprocal experiments where HSP20 
immunoprecipitates were tested for the presence of PKD1 protein. This robust evidence 
suggests that a pre-formed and stable interaction exists between these interacting partners. 
In contrast, control experiments using mock IPs (IgG alone) recovered neither HSP20 nor 
PKD1, supporting the specificity of the interaction. Although co-immunoprecipitation is 
not evidence of direct interaction as it is possible that other proteins may be associated 
with the PKD1-HSP20 immunocomplex, the in vitro pull-down experiments suggest that 
there is direct contact.  
ProtoArray is a useful technique for screening proteins of interest for interacting partners, 
however it does not provide information on whether interactions are functionally relevant. 
Often, the location of a protein within a cell is relevant to its function. To this end, I 
undertook cell imaging analyses to evaluate whether the locations of PKD1 and HSP20 
showed any similarity. Confocal microscopy imaging showed that PKD1 and HSP20 
localise in close proximity in both cardiomyocytes and co-transfected HEK293 cells (Fig. 
4.5). These observations may suggest that interaction between PKD1 and HSP20 is likely 
to occur and play a functional role in cells. 
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Figure 4.4. Immunoblots showing in vitro and in vivo association of HSP20 and PKD1. 
(A) In vitro pull-down: Purified His-tagged HSP20 acts as bait to pull-down PKD1. 
Purified PKD1 (Abcam) was used as positive control. (B) Endogenous HSP20 and PKD1 
were immunoprecipitated from neonatal cardiomyocytes lysates. (C) Lysates of HEK293 
cells co-expressing V5-HSP20 and GFP-PKD1 were immunoprecipitated using anti-V5 or 
anti-GFP antibodies. The first lanes of lysate represent input control while second lanes of 
IgG as negative control. Blots are representative of three separate experiments. 
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Figure 4.5.  PKD1 colocalises with HSP20. Subcellular distribution of PKD1 and HSP20 
assessed by immunostaining and confocal microscopic analyses using cardiomyocytes and 
co-transfected HEK293 cells. Cardiomyocytes were double immunolabelled with anti-
PKD1 (mouse) and anti-HSP20 (rabbit) antibodies, whereas HEK293 cells were 
immunostained with anti-V5 (rabbit) antibody. The cells were then labelled with Alexa 
Fluor 488-conjugated anti-mouse IgG (green) and Alexa Fluor 594-conjugated anti-rabbit 
IgG (red). The merged images show the extent of overlap between PKD1 and HSP20 
localisation signals. Images are representative of three separate experiments on different 
cell culture preparations. 
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4.2.3.     Mapping binding region of HSP20 on PKD1 
Peptide array is a rapid and flexible technique that has been used recently to map protein-
protein interactions (Bolger et al., 2006). Peptide array libraries of overlapping 25-mer 
peptides (each shifted by five amino acids) that encompassed the entire sequence of PKD1 
were synthesized using SPOT synthesis. The array was probed with purified recombinant 
His-tagged HSP20 protein and then detected with anti-His antibody. Positively interacting 
peptides generated dark spots whereas non-interacting peptides were left blank. Whilst no 
signal was observed on control array overlaid with anti-His antibody alone, five binding 
spots were detected when the arrays were probed with His-HSP20. These spots were 
located in the pleckstrin-homology (PH) and catalytic domain of PKD1 (Fig. 4.6A).  
In order to gain further insight into the interaction, the optimal interacting sequence with 
strongest binding affinity (as shown by darkest spot) was selected for subsequent scanning 
alanine substitution analyses. Alanine is a non-polar, hydrophobic amino acid. It is a good 
substitution because it carries a relatively small methyl side chain (CH3) and is less likely 
to disrupt the protein structure (Cunningham and Wells, 1989). Alanine scans of the 
peptide encompassing amino acids G
606
-E
630 
(GRDVAIKIIDKLRFPTKQESQLRNE) in 
PKD1 clearly identified several amino acids that were essential for the direct interaction 
between HSP20 and PKD1. Seven residues in particular (R
607
, D
608
, V
609
, I
611
, I
613
, D
615
, 
E
624
) appeared critical for the binding of HSP20 to PKD1 (Fig. 4.6B). 
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Figure 4.6. Identification of HSP20-PKD1 interaction sites. (A) The disposition of the 
peptides is shown relative to known regulatory regions in a schematic representation of 
PKD1 structure, which includes its N-terminal region, cysteine-rich domains, pleckstrin-
homology (PH), catalytic domain and C-terminal region. Peptide array analysis defines 
binding sites for HSP20 in the pleckstrin-homology (PH) and catalytic domain of PKD1. 
Binding spot numbers relate to peptides in the scanned array and whose residues position 
and sequence are given in the table below. (B) Scanning alanine substitution analysis using 
the sequence showing the greatest interaction (G
606
-E
630
) identified key amino acids 
involved in HSP20 binding to the PKD1 catalytic unit (red box). Native peptide (Ctr) plus 
progeny with the indicated residue substituted for alanine or aspartate. Red arrow indicates 
ablation or severe attenuation of binding. Arrays are representative of at least three 
separate experiments. 
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4.2.4.     Protein structure prediction of PKD1 catalytic domain 
As the crystal structure of PKD1 structure remains unsolved, protein structure prediction 
was carried out to predict the three-dimensional (3D) structure of the PKD1 catalytic 
domain. The structural prediction was done using the Protein Homology/analogY 
Recognition Engine Version 2.0 (Phyre2) web server 
(http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) which implements the 
principles of comparative homology modeling. The modeling was undertaken by referring 
the protein of interest to the previously solved structure of another homologous protein 
(Kelley and Sternberg, 2009). Typically, the procedure for homology modeling involves 
four steps which consist of template selection, sequence alignment, model building, and 
finally analysis and evaluation. As protein structures are more likely to be evolutionally 
conserved than related amino acid sequences, it was expected that the two homologous 
kinases would share high similarity in structures.  
 
Based on studies of local sequence alignment, a serine/threonine protein, human p21-
activated kinase 6 (PAK6) (Protein Data Bank ID: 2c30) was chosen as the best template 
hit for modeling the structure of PKD1 catalytic domain using Phyre2 web server. 
Selection was based on comparison of primary sequence and alignment accuracy. 
Although the template shares 33% sequence identities with target sequence, confidence 
values were given along with the predictions as 100%, indicating high probability of 
homology between the two sequences. Where necessary, sequence alignment was also 
carried out to examine individual aligned residues and provide information on the patterns 
of sequence conservation, as well as secondary structure elements (Fig. 4.7). The predicted 
secondary structure type for each residue is the type with the highest propensity or 
probability. 
Alternatively, structures were presented using a molecular visualisation program named 
Visual Molecular Dynamics (VMD) (Humphrey et al., 1996). Superimposing the seven 
residues (R
607
, D
608
, V
609
, I
611
, I
613
, D
615
, E
624
) on a predicted 3D structure of PKD1 
catalytic domain showed that all of these amino acids are on solvent accessible surface of 
the macromolecule, thereby forming a well-defined surface-exposed patch that could serve 
as a HSP20 docking site (Fig. 4.8).  
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Figure 4.7. Amino acid alignment of PKD1 catalytic domain with 2c30 protein as template on Phyre2 web server. Sequence alignment and 
secondary structure similarity between PKD1 catalytic domain and the template used for structure prediction are shown. The amino acid sequences are 
represented in standard single-letter code. The polypeptide secondary structure of this domain was predicted in 3 states: α-helix, β-strand and coil. Green 
helices represent α-helices, whereas blue arrows indicate β-strands and straight lines indicate coil. 
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Figure 4.8. Predicted structure of PKD1 catalytic domain and location of residues 
implicated in HSP20 binding. PKD1 residues critical for the interaction with HSP20 were 
superimposed on a predicted 3D structure of PKD1 catalytic unit prepared from 2c30 
structure as a template, presented in (A) front view and (B) back view, related by 180 
degree rotation.  
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4.3.   Discussion 
The identification of interacting partners is one way to find clues about the functional role 
of a given protein. There are several methods to investigate protein-protein interactions 
including biochemical biophysical and computational methods. In this study, a new 
proteomic technology named ProtoArray was carried out as a discovery platform (Schnack 
et al., 2008; Satoh et al., 2009; Sumiyoshi et al., 2010). ProtoArray is a powerful tool to 
allow rapid, large-scale screening of protein-protein interactions in parallel under the same 
experimental conditions. The target proteins spotted on the glass slides were expressed in 
baculovirus expression system to promote the preservation of native conformations and 
post-translational modifications which often lacks in bacterially expressed proteins 
(Tennagels et al., 1999; Schweitzer et al., 2003). This approach has been utilised not only 
in basic biomedical research, but also in drug discovery research such as identification of 
protein kinase substrates and protein targets of small molecules (Chan et al., 2004; 
Michaud et al., 2003, 2006). For instance, ProtoArray substrate screen identified protein 
phosphatase 1, regulatory subunit 14A (PPP1R14A)/(CPI-17) as a novel substrate of a 
serine-threonine kinase, cyclin-dependent kinase (Cdk) 5 (Schnack et al., 2008), thus 
contributed to a better understanding of neuronal development and synaptic signalling. 
This array-based method was also used to characterise a comprehensive profiling of 14-3-
3-interacting proteins, including those unpredicted by the Biomolecular Interaction 
Network Database (BIND) and PubMed database search (Satoh et al., 2006). 
Here in this study, a comprehensive profile of human HSP20-interacting proteins was 
studied using high-density ProtoArray probed with recombinant purified HSP20 protein. 
This method was chosen over the conventional yeast two-hybrid assay because the latter 
requires labour-intensive steps and usually results in lower accuracy scores as it is prone to 
false positive and false negative interactions. Yeast two-hybrid discrepancies are 
commonly due to variations in bait and prey proteins levels, self-activating bait proteins, 
spontaneous activation of reporter transcription and alterations in yeast physiology 
(Knudsen et al., 2002; Vidalain et al., 2004). Moreover, the data sets obtained from yeast 
two-hybrid assay are often biased towards particular cellular localisation of interacting 
proteins, for example, the associations of tested proteins normally take place in the nucleus 
and not in their native cellular compartment (Fields and Song, 1989; Uetz et al., 2000). 
Hence, it is less likely to reflect the true physiological setting. 
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In addition, as the identity of proteins spotted on the array is known, any antibody cross-
reactivity with these proteins can be further investigated to obtain information on the 
common sequence motifs that lead to cross-reactivity (Michaud et al., 2003). The 
fluorescent detection method used in ProtoArray analysis is also more sensitive than the 
commonly used chemiluminescent-based detection. 
Utilising ProtoArray screening, a list of 21 proteins was identified as putative binding 
partners of HSP20. Among all the interactors, PKD1 was chosen for further studies 
because of its physiological relevance in hypertrophy. PKD1, also known as PKCµ, is an 
intracellular serine/threonine protein kinase which is involved in many biological functions 
(Lint et al., 2002). Being a major PKD isoform in the heart, it is involved in the regulation 
of myocardial contraction, hypertrophy and pathological cardiac remodeling (Harrison et 
al., 2006). Moreover, previous studies have shown that PKD1 is implicated in the 
phosphorylation of several myocardial proteins, such as cardiac troponin I and cardiac 
myosin binding protein C (cMyBP-C) (Haworth et al., 2004). Moreover, there is also 
evidence reported that PKD1 phosphorylates class II HDAC which functions as a negative 
regulator of cardiac remodeling through their repressive influence on myocyte enhancer 
factor 2 (MEF2) (Zhang et al., 2002). These findings suggest that PKD1 is a promising 
therapeutic target for a number of diseases within a cardiac setting. Nevertheless, the 
detailed intracellular mechanism(s) underlying cardiac hypertrophy remains to be 
uncovered. 
Despite being a powerful tool for systematic identification of protein-protein interactions, 
ProtoArray has limitations that relate to the binding nature of the proteins. In fact, this 
method only detects direct protein-protein interaction that occurs in stable protein 
complexes. The protocol relies on rigorous washing steps, which may not allow weak or 
transient interactions to be easily detected. Indirect interactions which involve intervening 
molecules are also less likely to be detected. As such, it is worth noting that some other 
biologically important interactors could be left undetected. Nevertheless, protein 
microarray technology has been reported to be reliable and reproducible (Huang et al., 
2004; Michaud et al., 2006; Satoh et al., 2006, 2009; Sumiyoshi et al., 2010). 
The molecular interaction between HSP20 and PKD1 were investigated by biochemical 
and immunocytochemical studies. In vitro pull-down assay and co-immunoprecipitation 
experiments provided further evidence of a direct physical interaction and in vivo 
association of these two proteins. Additionally, scanning confocal imaging showed some 
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degree of overlapping punctuate staining of PKD1 and HSP20 which is primarily in the 
cytoplasm, suggesting that they are likely to localise to the same cellular compartment. 
Thus, it is speculated that the PKD1-HSP20 interaction is likely to be biologically relevant. 
Interestingly, this study was the first to show that PKD1 is a binding partner of HSP20. As 
both proteins are involved in hypertrophy signalling pathways, these observations may 
suggest a potential role of PKD1-HSP20 complex in regulating the hypertrophic response. 
Peptide array analyses were carried out to map the interaction sites of HSP20 on PKD1. 
This method provides valuable information to inform predictions of binding events of 
proteins with peptide ligands (Bolger et al., 2006). Results showed that HSP20 binds 
mainly in the PH and catalytic domain of PKD1, having stronger binding affinity with the 
latter.  
Previous studies have performed yeast two-hybrid screens of human cardiac libraries to 
identify myocardial substrates of PKD1 by using the PKD catalytic domain as bait 
(Haworth et al., 2004). This work has highlighted several myofilament proteins such as 
cardiac troponin (cTnI), cardiac myosin-binding protein C (cMyBP-C) and telethonin as 
forming complexes with PKD. My findings represent another demonstration that the PKD 
catalytic domain is likely to be responsible for the regulation of cardiac function via its 
association with HSP20. 
Sequence alignment using the Basic Local Alignment Search Tool (BLAST) at the NCBI 
website (http://www.ncbi.nlm.nih.gov/blast) was undertaken to compare the 25-mer 
sequence spanning G
606
-E
630 
(which yielded the strongest binding signal) to the whole 
human protein component database for sequence similarity and profiling. It is apparent that 
this sequence has a high degree of specificity for the PKD family (Table. 4.2). Interestingly, 
homology studies performed to investigate evolutionary relationships revealed that this 25-
mer sequence is highly conserved in eukaryotic PKD, providing evidence for sequence and 
structural conservation (Table. 4.3). Hence, it is postulated that this region may have 
functional importance.  
Subsequent alanine scanning analysis of the conserved sequence (G
606
-E
630
) highlighted 
seven amino acid residues which are potentially involved in PKD1-HSP20 interaction, 
namely the basic (R
607
), non-polar (V
609
, I
611
, I
613
) and acidic region consisting of D
608
, 
D
615
 and E
624
 which formed a motif of R
607
DVxIxIxDxxxxxxxxE
624
 (where x is not a key 
amino acid). This 25-mer peptide sequence could then serve as a basis for the design of 
cell-permeable disruptor peptide to inhibit PKD1-HSP20 interaction. 
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In summary, using a novel array-based approach, PKD1 was identified as a new interactor 
of HSP20. The present study provides validation of the interaction between PKD1 and 
HSP20, as proved by in vitro pull-down assay, co-immunoprecipitation and 
immunocytochemical studies. Furthermore, probing the PKD1 peptide array with His-
HSP20 not only identified the binding sites, but also highlighted seven surface-exposed 
amino acid residues critical for the interaction. In combination with structural 
superposition analysis of the predicted 3D model of the PKD1 catalytic domain, the 
putative location of interaction sites was suggested. Interestingly, sequence alignment 
analyses showed high sequence homology between species suggesting a ubiquitous 
complex between PKD1 and HSP20.  
Taken together, the data presented in this chapter suggests that HSP20 binds directly to 
PKD1 within the conserved catalytic region to form a highly specific complex. The 
integration of ProtoArray data with protein biochemical and immunocytochemical studies 
may lead to the discovery of a novel hypertrophy signalling complex with functional 
significance. Further studies were carried out to investigate the role(s) of PKD1-HSP20 
complex in hypertrophic response. This will be discussed in Chapter 5. 
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Table 4.2. Sequence alignment of G
606
-E
630
 of PKD1. 
 
Analysis was done using the Basic 
Local Alignment Search Tool (BLAST) at the NCBI website 
(http://www.ncbi.nlm.nih.gov/blast). 
 
 
 
 
Table 4.3. Amino acid homology showing comparison of G
606
-E
630
 between species. 
Homology analysis was done using the Basic Local Alignment Search Tool (BLAST) at 
the NCBI website (http://www.ncbi.nlm.nih.gov/blast). 
Species  Sequence  NCBI Reference  
Homo sapiens  GRDVAIKIIDKLRFPTKQESQLRNE  NP_002733  
Mus musculus  GRDVAIKIIDKLRFPTKQESQLRNE  NP_032884  
Rattus norvegicus  GRDVAIKIIDKLRFPTKQESQLRNE  NP_001019434 
Xenopus laevis  GRDVAIKIIDKLRFPTKQESQLRNE  NP_001087707  
Bos taurus  GRDVAIKIIDKLRFPTKQESQLRNE  NP_001192467  
Gallus gallus  GRDVAIKIIDKLRFPTKQESQLRNE  NP_001026372  
Drosophila melanogaster  QREVAIKVIDKLRFPTKQEAQLKNE  NP_650710  
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The role of the PKD1-HSP20 complex in 
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5.1      Introduction 
Protein phosphorylation is a fundamental mechanism that has the ability to regulate a 
myriad of cellular processes. This post-translational modification is catalysed by various 
protein kinases in response to different stimuli (Edelman et al., 1987; Yarden and Ullrich, 
1988). By adding phosphate groups from a nucleoside triphosphate to substrate proteins, 
kinases act as regulators of receptor-mediated signal transduction that are central to cellular 
growth, metabolism, apoptosis and gene transcription (Hunter and Karin, 1992). Human 
protein kinase families can be divided into seven main groups. They consist of cyclic 
nucleotide regulated protein kinases, calcium-calmodulin-dependent protein kinases 
(CaMK), casein kinase 1 group (CK1), CMGC group (including cyclin-dependent kinases 
(CDKs), mitogen-activated protein kinases (MAPK), glycogen synthase kinases (GSK) 
and CDK-like kinases), yeast sterile-phenotype kinases (STE), tyrosine kinases (TK) and 
tyrosine-kinase like group (TKL). This chapter will focus on protein kinase D1 (PKD1) 
and review current understanding of its structure and function, as well as its role in cardiac 
hypertrophy. 
 
5.1.1     Background and structure of PKD 
PKD was first discovered in 1994 (Johannes et al., 1994; Valverde et al., 1994) and 
characterises a family of stress-activated ubiquitous serine/threonine intracellular kinases 
which phosphorylates the OH group of serine or threonine amino acids. There are three 
isoforms known in mammals, namely, PKD1 (formerly protein kinase Cµ (PKCµ), PKD2 
and PKD3 (also named PKCν), sharing similar structure and exhibiting high degree of 
homology. Although similar, these three isoforms execute independent biological functions 
due to different expression patterns in distinct tissues and different subcellular distribution 
(Rozengurt et al., 2005). Of the three isoforms, PKD1 has been most extensively studied 
and is also referred to as PRKD1 to differentiate it from polycystic kidney disease (PKD). 
PKD1 is evolutionarily well-conserved, spanning 912 amino acids long and having a 
molecular mass of 115 kDa. It contains an N-terminal regulatory domain (containing two 
zinc finger-like cysteine-rich domains (CRD) that bind both diacylglycerol (DAG) and 
DAG analog phorbol esters with high affinity), an internal pleckstrin homology (PH) 
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domain which maintains its inactive state by inhibiting catalytic domain, and a C-terminal 
serine/threonine kinase catalytic domain (Fig. 5.1). PKD1 was previously classified as a 
member of the PKC family due to its resemblance to the DAG-binding domains of PKC.  
However, it was later shown that PKD1 has distinct structural and enzymatic properties, 
and does not phosphorylate a variety of substrates targeted by PKC (Van Lint et al., 1995). 
In fact, based on the sequence homology of catalytic domain and substrate specificity, 
PKD1 is now thought to be distinct from PKC isoforms, being classified into the 
calcium/calmodulin-dependent kinase (CaMK) group in the human kinome (Manning et al., 
2002). Nevertheless, recent evidence has shown that PKD1 is activated in living cells 
through a PKC-dependent pathway, suggesting that PKD1 can function either downstream 
of or in parallel with PKC (Zugaza et al., 1996). Indeed, in many cases, PKD1 activation is 
known to be attenuated by PKC inhibition (Harrison et al., 2006; Haworth et al., 2007).  
 
 
 
 
 
Figure 5.1. Functional domains and conserved phosphorylation sites of PKD1. PKD1 
is composed of two N-terminal cystein-rich regulatory domains which mediate binding to 
diacylglycerol (DAG), an internal pleckstrin homology domain with auto-inhibitory 
functions and a C-terminal catalytic domain. Distribution of phosphorylation sites and the 
kinases that phosphorylate these sites are indicated. CRD1/CRD2 indicates cysteine-rich 
domain; PH, pleckstrin homology domain. 
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5.1.2     PKD1 phosphorylation  
PKD1 is a kinase that can be phosphorylated on a number of different sites and its 
activation requires distinct regulatory mechanisms. Mass spectrometry, phosphopeptide 
mapping and mutational analyses showed that DAG stimulation is not sufficient to activate 
PKD1. In fact, PKD1 activation requires the phosphorylation of Ser744 and Ser748 in 
mouse (human Ser738 and Ser742) within the activation loop of the catalytic domain, 
along with alleviation on the inhibitory effect of the PH domain via a PKC-dependent 
signalling pathway (Iglesias et al., 1998; Vertommen et al., 2000; Waldron et al., 2001; 
2003; Rykx et al., 2003). Notably, PKD1 can also be targeted by tyrosine kinases and 
activated via a PKC-independent pathway. For instance, in response to oxidative stress, the 
phosphorylation of PKD1 at Tyr463 in the PH domain is activated through a Src/Abl 
pathway that excludes the involvement of PKC (Storz et al., 2003). This leads to a 
derepression of PKD1 activity and initiation of NFκB transcription activity (Storz and 
Toker, 2003). In addition to the two activation loop sites, PKD1 also contains two 
autophosphorylation sites at Ser203 and Ser916 in the regulatory domain and carboxy-
terminal, respectively, which is not trans-phosphorylated by other upstream kinases 
(Matthews et al., 1999; Vertommen et al., 2000). 
 
5.1.3     PKD1 substrates in heart 
Several recent advances in PKD research have provided insights into its functions. Being a 
major PKD isoform in the heart, PKD1 has been a focus of interest for cardiovascular 
research. Previous studies have reported that PKD1 is involved in cardiac pathogenesis, as 
seen in the regulation of myocardial contractile function. It is also linked with hypertrophy 
and pathological cardiac remodelling in response to neurohormonal stimuli (Avkiran et al., 
2008; Fielitz et al., 2008). To date, PKD1 has been implicated in the phosphorylation of 
several sarcomeric proteins, such as cardiac troponin I, cMyBP-C and telethonin (Haworth 
et al., 2004) to regulate myocardial contractility. Additionally, PKD1 also regulates class II 
histone deacetylases (HDACs) proteins which are known as pro-hypertrophy transcription 
regulators (Vega et al., 2004). The pro-hypertrophy action of class II HDACs is exerted by 
repressing transcriptional activity as opposed to the function of histone acetyltransferases 
which initiate acetylation of nucleosomal histones to promote transcription (Kuo and Allis, 
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1998). Interestingly, these putative PKD1 substrates commonly contain a well defined 
phosphorylation motif in their sequence (LXRXXS/T), where an aliphatic amino acid 
(Ile/Leu/Val) and a basic amino acid (Arg) are located at the -5 and -3 positions relative to 
the serine target site, respectively (Nishikawa et al., 1997; Doppler et al., 2005).  
 
5.1.4     Subcellular distribution of PKD1 
In the basal state, the majority of PKD1 localises to the cytosol, while a subpopulation is 
found in various organelles, such as the nucleus, plasma membrane, mitochondria and 
trans Golgi network (Van Lint et al., 2002). Interestingly, PKD1 has previously been 
shown to translocate to the nucleus in response to G protein-coupled receptors (GPCR) 
stimulation. Notably, PKD1 is bound by DAG at its cystein-rich domain and followed by 
phosphorylation on serine residues in the activation loop by PKC and the release of PH-
mediated PKD1 inhibition, thereby promoting PKD1 activation and redistribution (Rey et 
al., 2001). These observations strongly suggest a pertinent role for PKD1 as a signalling 
mediator that has two major sites of action. First, PKD1 resides mainly in the cytosol 
during basal conditions and then it moves into the nucleus upon receptor activation via an 
as yet not well-defined mechanism. As such, the subcellular localisation of PKD is likely 
to be associated with its activation status resulting in different biological responses. Further 
work is required to elucidate the precise mechanisms which control PKD1 localisation and 
translocation.  
 
5.1.5     The roles of PKD1 in hypertrophy 
Previous studies have shown that siRNA-mediated knockdown of endogenous PKD1 
expression attenuates hypertrophy (Harrison et al., 2006), whereas over-expression of 
active PKD1 promotes hypertrophy in cultured neonatal rat cardiomyocytes (Iwata et al., 
2005). In addition, the role of PKD in cardiac pathogenesis was also confirmed in vivo 
using ventricular tissue from rodent models of hypertrophy. Hence, it is thought that PKD1 
signalling is closely associated with hypertrophic agonists through both PKC-dependent 
and PKC-independent mechanisms, resulting in a robust hypertrophic phenotype. Such a 
notion suggests a key role for PKD1 as a regulator of cardiac signalling. Indeed, there is 
Chapter 5               
 
107 
 
accumulating evidence to show that PKD1 and its upstream activator PKC, in particular 
PKC, are implicated in the control of pathological remodelling of the heart (Haworth et 
al., 2000). These kinases have been shown to phosphorylate HDAC proteins, in particular 
HDAC5, creating docking sites for 14-3-3 proteins that facilitate nuclear efflux of HDAC5 
in a chromosome region maintenance 1 (CRM1)-dependent manner (McKinsey et al., 2001; 
Vega et al., 2004). MEF2 activity is stimulated by dissociation from HDAC5, thereby 
promoting transcriptional derepression (Zhang et al., 2002). Consequently, the activation 
of MEF2 transcription factors evoke a reprogramming of cardiac gene expression that 
promotes a fetal gene response, resulting in hypertrophic growth (Chang et al., 2005). 
Indeed, mutant mice lacking HDAC5 have been shown to develop extremely enlarged 
hearts in response to hypertrophic agonists (Zhang et al., 2002). Specifically, when MEF2 
is bound to the promoters of cardiac muscle differentiation genes, it elicits a shift in 
expression of the two myosin heavy chain (MHC) isoforms. As a result, the α-myosin 
heavy chain (α-MHC) is switched to β-myosin heavy chain (β-MHC), resulting in 
reorganisation of putative contractile units and this in turn leads to cardiac remodelling and 
hypertrophic phenotype (Chien et al., 1991).  
Another kinase that impinges on PKD1’s actions is PKA. PKA activity can impose a block 
on α1-adrenergic stimulation and suppress PKD1 phosphorylation (Haworth et al., 2007). 
In this context, PKA may act as a counter-regulator to modulate PKD1 activation. This 
notion has been supported by ground breaking work, showing that acute β-adrenergic 
stimulation and activation of PKA inhibits phosphorylation of not only PKD1, but also 
HDAC5, highlighting its critical role in the induction of hypertrophy-associated genes 
(Sucharov et al., 2011). PKD1 activity has also been shown to undergo stimulation by G 
protein-coupled receptors (GPCR), which couple to the Gqα subunit of heterotrimeric G 
proteins in response to PKC activation, suggesting a causal relationship between PKC and 
PKD1 in the regulation of myocardial responses (Haworth et al., 2000). Interestingly, it 
has recently been reported that cardiac A-Kinase Anchoring Protein (AKAP)-Lbc 
functions as a scaffolding protein for PKA and PKC to mediate activation of PKD1 
(Carnegie et al., 2004; 2008). Upon neurohormonal stimuli such as endothelin-1 (ET-1) or 
phenylephrine (PE), upregulation of AKAP-Lbc facilitates PKD/HDAC5/MEF2 signalling 
and enhances the transduction of hypertrophic response. Conversely, reduced AKAP-Lbc 
expression prevents the translocation of HDAC5, thereby hindering the progression of 
hypertrophy. Since PKA and PKC are components of AKAP-Lbc anchoring complex, this 
may suggest the involvement of both cyclic AMP (cAMP) and phospholipid signalling 
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pathways in the regulation of PKD1 activation. Indeed, recent findings have revealed the 
roles of compartmentalised phosphodiesterases (PDEs) in cAMP-dependent PKA-
mediated PKD1 activation. It was reported that the combined inhibition of PDE3 and 
PDE4 is required to achieve substantial attenuation of ET1-induced PKD1 activation 
through increased PKA activity (Haworth et al., 2011). Based on these findings, it is 
tempting to postulate that AKAP-Lbc serves as a connector, providing a locus for signaling 
crosstalk between the kinases in a stimulus-dependent manner within the hypertrophy 
signaling cascades (Fig. 5.2). In addition, it is increasingly apparent that PKD1 is a key 
player in the regulation of cardiac hypertrophy, most likely through its effect on the 
transcriptional regulation of fetal gene programming via the phosphorylation of HDAC5.  
In summary, the function of PKD1 depends upon (1) its phosphorylation state, either 
directly activated by neurohormonal stimuli or by an upstream regulator and (2) its 
localisation within the cell. These findings open new routes for the investigation into the 
role of PKD1 as a potential target for novel therapeutic intervention in the treatment of 
cardiac hypertrophy. Nevertheless, the detailed intracellular mechanism(s) underlying fetal 
gene reprogramming remains to be determined. Novel insights may be gleaned from 
further exploration of the signalling network involving AKAP-Lbc and its scaffold partners. 
Further work is also required to clarify the mechanistic details underpinning the crosstalk 
between different signal transduction pathways which contribute to the induction of the 
hypertrophic response, with a particular emphasis on understanding the upstream 
regulators and downstream functional consequences of PKD activation. 
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Figure 5.2. Schematic diagram depicting the hypertrophic signalling cascades. α-
adrenergic, phorbol ester and ET receptors stimulate the nuclear export of HDAC5 via 
activation of PKC and the downstream effector PKD1. PKD1 can also be activated by ET 
receptor via a PKC independent pathway. Phospho-HDAC5 binds 14-3-3 proteins, 
resulting in nuclear export of HDAC5 and upregulation of MEF2, thereby triggering the 
induction of hypertrophic fetal gene program. PDE3 and PDE4 regulate β-adrenergic 
receptor stimulation and activation of PKA, hence preventing phosphorylation of PKD1 
and HDAC5. 
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5.1.6     Aims of Chapter 5 
The experimental evidence presented in Chapter 4 describes the molecular interaction 
between PKD1 and HSP20. Using peptide array technology, the molecular docking sites of 
HSP20 on PKD1 were mapped and critical residues for the interaction determined. The 
apparent importance of HSP20 in cardioprotective mechanisms and PKD1 in cardiac 
remodelling, coupled with the interaction between these proteins, led to the hypothesis that 
PKD1-HSP20 complex may affect the induction of hypertrophy. Here, the role(s) of the 
PKD1-HSP20 complex in hypertrophic signalling are studied in vitro. Neonatal rat 
cardiomyocytes were chosen as the model system of choice. 
 
Hence, the aims of this chapter were:  
1.  to use the molecular information from peptide array analysis to develop cell-permeable 
peptides for the disruption of the PKD1-HSP20 complex. 
 2. to examine the functional implications of PKD1-HSP20 complex in hypertrophic 
cardiomyocytes. 
3.   to identify putative phosphorylation sites on HSP20 that are modified by PKD1. 
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5.2     Results 
5.2.1   Disruption of PKD1-HSP20 interaction 
Previous work from my laboratory has shown that stearoylated, cell-permeable analogues 
of 25-mer peptides identified in peptide array analyses, could be used to disrupt signalling 
complexes within cells to affect cellular functions such as protein phosphorylation (Smith 
et al., 2007; Meng et al., 2009). In this study, the docking site of HSP20 on PKD1 
encompassing residues G
606
-E
630
 (GRDVAIKIIDKLRFPTKQESQLRNE) was used to 
manufacture a disruptor peptide named ‘HJL09’. A control peptide with three of the seven 
key residues replaced by alanine (GAAVAIKIIAKLRFPTKQESQLRNE) was also 
synthesised. More specifically, both peptides were synthesised with a C-terminal stearate 
group to facilitate cell-permeability, thereby allowing peptides transport across the cell 
membrane.  Due to a stronger affinity towards PKD1, the disruptor peptide is likely to 
compete with the binding of HSP20 on the docking site. The effectiveness of the peptides 
to disrupt the HSP20-PKD complex was then evaluated by co-immunoprecipitation 
experiments. Gratifyingly, these experiments showed that the disruptor peptide could 
successfully hinder the association of the two endogenous proteins in cardiac myocytes. 
However, this was not true for the control peptide (Fig. 5.3). In addition, a reciprocal co-
immunoprecipitation study using an HSP20-antibody also showed similar results whereby 
the peptide but not the peptide control could attenuate PKD1-HSP20 association. These 
findings verified the peptide array data and showed that the peptides were cell permeable. 
Thus, these peptides could now be utilised in functional experiments. 
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Figure 5.3. Disruption of PKD1-HSP20 interaction. Cardiomyocytes were treated with 
10 µM of control peptide or 10 µM of PKD-disruptor peptide ‘HJL09’ for 2 h. The same 
amount of lysates was then co-immunoprecipitated with anti-PKD1 (upper panel) or anti-
HSP20 (lower panel) antibody. Cellular lysates were then blotted for HSP20 or PKD1, 
respectively. Pre-cleared lysates was used as positive control and immunoprecipitate 
without antibody added (only IgG) was used as negative control. All results are typical of 
three independent experiments. 
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5.2.2 Peptide disruption of PKD1-HSP20 complex protects against 
            hypertrophy in cardiomyocytes 
As previous studies have demonstrated the cardioprotective roles of HSP20 during 
hypertrophy, it was interesting to study the role of the PKD1-HSP20 complex in this 
context. In order to address the possible functions of this complex on the hypertrophic 
response in cultured neonatal rat cardiomyocytes, the consequences of disruption of this 
signalling node was examined by use of the disruptor peptide. Experimentation was done 
using an in vitro cell model of cardiomyocyte hypertrophy that was set up as described in 
‘Materials & Methods’ and Chapter 3. In this chapter, five separate methods were 
performed to evaluate the role of the PKD1-HSP20 complex in the hypertrophic response 
in cardiomyocytes. 
 
5.2.2.1  Measurement of cell size 
As cardiac hypertrophy is characterised by enlargement in cell size, the influence of the 
PKD1-HSP20 interaction on the surface area of cardiomyocytes was examined. Firstly, 
real-time xCELLigence RT-CES analysis was undertaken to monitor cell size change in 
response to ISO stimulation in cultured neonatal rat cardiomyocytes. Real-time analysis 
provides constant monitoring and permits continuous observations of different conditions. 
The impedance recorded on the surface of the electrode-embedded 96-well plates was 
automatically converted to cell index (CI) to provide quantitative assessment. As 
cardiomyocytes are terminally differentiated and have limited proliferative capacity, a 
higher CI would represent an increase in impedance that could only be a result of a 
corresponding increase of cell cross-sectional area. Here, ISO stimulation resulted in an 
increase in the cell index, with incremental increases evident between 10-35 h. These 
increases started to level out at 38 h after treatment (Fig. 5.4). For a clearer interpretation, 
cell index values were normalized after 24 h of the indicated treatments. In contrast to the 
control cells, which were treated with DMSO (vehicle) alone, the normalised cell index 
was increased nearly 1.5x fold in ISO- and control peptide + ISO-treated cells, suggesting 
a relative increase in cell size. Excitingly, pre-treatment with PKD-disruptor peptide 
‘HJL09’ reversed this effect, preventing the enlargement in cell size despite hypertrophic 
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stimulus. These initial experiments were the first indication that disruption of PKD1’s 
association with HSP20 was a beneficial mechanism during hypertrophy. 
 
5.2.2.2    Effect on cell morphology and actin cytoskeleton dynamics 
The next step was to examine the impact of ISO stimulation and disruption of the PKD1-
HSP20 interaction on cardiomyocyte morphology. There was an easily detectable increase 
in ISO-stimulated cardiomyocyte area as seen under the differential interference contrast 
(DIC) microscope (Fig. 5.5). Remarkably, 24 h of ISO treatment triggered dramatic 
morphological changes in the cells. Treated cells differed from control untreated cells as 
they seemed stretched and enlarged to double their normal size. Similar morphological 
changes were also observed in cells treated with control peptide + 24 h ISO. However, 
cells treated with PKD-disruptor peptide ‘HJL09’ had no discernible ISO induced effects 
on morphology. I propose that such a blunted hypertrophic response is due to the 
disruption of PKD1-HSP20 interaction. 
Reorganisation of actin filaments is another important characteristic of hypertrophy (Frey 
and Olson, 2003). To determine the effect on the actin cytoskeleton, cultured cells were 
subjected to indicated treatments and Alexa Fluor 488-conjugated phalloidin staining. 
Confocal microscopic images showed that actin cytoskeletal rearrangement was 
substantially stimulated by hypertrophy induction and was reduced in cells pre-treated with 
PKD-disruptor peptide ‘HJL09’ (Fig. 5.6). Seemingly, untreated cardiomyocytes exhibited 
poorly organised actin, which was characterised by a punctate pattern. ISO-stimulated cells, 
in contrast, displayed robust stress fibres, showing extensive parallel actin alignment. This 
was also true for cells pre-treated with control peptide prior to ISO addition. Interestingly, 
cells pre-treated with disruptor peptide ‘HJL09’ were partially resistant to the actin 
reorganising effects of ISO, displaying a somewhat disorganised myofibril network. In 
addition to its role in the prevention of cell enlargement, the PKD1-HSP20 association is 
also likely to have the capacity to regulate the integrity of cellular actin filaments. This 
notion is supported by previous work showing that in cultured neonatal cardiomyocytes, 
some weak cytoskeletal staining was visible under basal conditions, whereas ISO treatment 
resulted in HSP20 redistribution to the cytoskeleton (Fan et al., 2004). Notably, these 
results may suggest that the disruption of PKD1-HSP20 complex is required to confer 
cardioprotection in cultured neonatal rat cardiomyocytes from prolonged β-adrenergic 
stimulation. 
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Figure 5.4. The effect of PKD1-HSP20 interaction on cell size. Upper panel: 
Quantitative measurement of neonatal rat cardiomyocyte cell size by real-time cell-
electronic sensing (RT-CES). Continuous impedance measurement displayed as 
normalised cell index were recorded using RT-CES instrument. Bottom panel: Average 
cell indexes were taken and normalised after 24 h of indicated treatments.  Neonatal 
cardiomyocytes were pre-incubated with PKD-disruptor peptide ‘HJL09’ or control 
peptide in the presence of 24 h ISO stimulation. Data are means ± S.E.M. of 3 experiments 
on different cardiomyocytes preparations. Statistical significances between groups were 
determined by the use of Student’s t-test. Values were considered significant if p < 0.05.  
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Figure 5.5. The effect of PKD1-HSP20 interaction on cell morphology. 
Cardiomyocytes were cultured on coverslips and subjected to different treatments as 
indicated. Differential interference contrast (DIC) imaging was employed to examine 
morphological change in cardiomyocytes. (A) Wild-type, (B) 24 h ISO treatment, (C) 
Control-peptide + 24 h ISO treatment, (D) PKD-disruptor peptide ‘HJL09’ + 24 h ISO 
treatment. Images shown are representative of three separate experiments on different 
cardiomyocytes preparations. Scale bars = 10 µm. 
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Figure 5.6. The effect of PKD1-HSP20 interaction on actin organisation. Cells were 
fixed and actin was visualised by immunostaining with actin-phalloidin. (A) Wild-type, (B) 
24 h ISO treatment, (C) Control-peptide + 24 h ISO treatment, (D) PKD-disruptor peptide 
‘HJL09’ + 24 h ISO treatment. Wild-type cardiomyocyte exhibited poorly organised actin 
which was visualised by a punctate pattern as detected by phalloidin staining. Stimulation 
of cardiomyocytes with 24h ISO alone or with control peptide significantly induced 
reorganisation of actin, showing long symmetrically spaced filaments. In contrast, 
disruption of PKD1-HSP20 interaction resulted in reduced actin assembly and organisation. 
Images shown are representative of three separate experiments. Scale bars = 10 µm. 
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5.2.2.3    Measurement of protein content 
Cytoplasmic protein synthesis was measured and expressed relative to DNA content as 
described in ‘Materials & Methods’ (Fig. 5.7). Following hypertrophic stimulation, there 
was a considerable increase (nearly 2-fold) in the total protein content of ISO- and control 
peptide + ISO- treated cells compared to untreated wild-type cells. In contrast, the PKD 
disruptor peptide ‘HJL09’ treated cells had a ‘normal’ level of protein synthesis. 
 
 
 
Figure 5.7. The effect of PKD1-HSP20 interaction on protein synthesis. The total cell 
protein and DNA content were determined by the Lowry and the Hoechst dye method. The 
protein content was then normalised to the DNA amount to correct for differences in the 
cell number. Data are means ± S.E.M. of nine experiments on different cardiomyocyte 
preparations. A Student’s t-test was performed to compare the two groups as shown and P 
values are indicated. 
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5.2.2.4    Quantification of fetal gene expression 
As mentioned earlier, cardiac hypertrophy is associated with reactivation of the fetal gene 
program, which may initially serve as a compensatory mechanism to reduce both cardiac 
preload and load by natriuretic, diuretic and vasodilatory actions, but eventually resulting 
in the loss of cardiac function. In this study, real-time qPCR analyses were carried out to 
determine whether the PKD1-HSP20 interaction influenced the transcriptional activity of 
genes (ANF, BNF and β-MHC) known to be re-expressed as part of the hypertrophic 
response. The expression level was then normalised to a reference gene rat 18s rRNA to 
correct for differences in RNA loading. This allowed evaluation of alterations in 
hypertrophic gene expression that may have occured upon disruption of PKD1-HSP20 
interaction. This information would suggest the participation of this signalling complex in 
regulation of hypertrophic gene expression. 
ISO-induced hypertrophic signaling events have been shown to culminate in gene 
expression changes in the nucleus (Izumo et al., 1988; Chien et al., 1991; Rosenzweig and 
Seidman, 1991). Indeed, the data in this chapter shows that cells pre-treated with either 
ISO or the combination of control peptide and ISO, had dramatically elevated expression 
of fetal genes, particularly BNF, as compared to wild-type (Fig. 5.8). However, treatment 
of cells with disruptor peptide ‘HJL09’ markedly reduced the expression of fetal gene 
mRNA transcripts despite application of hypertrophy stimulating conditions. In fact, the 
disruption has initiated an anti-hypertrophic effect, resulting in the suppression of fetal 
gene reactivation that drives cardiomyocyte hypertrophic growth. This effect may be the 
result of peptide blocking the nuclear translocation of PKD1 where the PKD-disruptor 
peptide ‘HJL09’ displaces HSP20 from its binding site on PKD1. It is postulated that such 
displacement hinders PKD1 from entering the nucleus, which in turn disfavours the 
phosphorylation of HDAC5. The above results not only confirm that 24 h ISO stimulation 
can activate hypertrophic gene expression, but also indicates a close relationship between 
PKD1-HSP20 interaction and fetal gene re-expression. The interaction between these two 
proteins is likely to contribute to agonist-mediated cardiomyocyte hypertrophy.  
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Figure 5.8. The effect of PKD1-HSP20 interaction on fetal gene expression. Total 
RNAs were isolated and the expression of ANF, BNF and β-MHC were examined by real-
time qPCR. Rat 18s rRNA was used to serve as an internal control. All data are presented 
as mean ± S.E.M. of seven experiments on different cardiomyocytes preparations. A 
Student t-test was performed to compare PKD-disruptor peptide ‘HJL09’+ISO and ISO-
treated cells. * P < 0.05 value was based on comparison with cells treated with 24 h ISO.  
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5.2.3      Mapping binding region of PKD1on HSP20 
Molecular information on the binding site of PKD1 on full-length HSP20 was obtained by 
scanning peptide array analysis. Results revealed overlapping high-affinity binding regions 
which mainly locate in the WDPF and α-crystallin domains (Fig. 5.9A). In addition, 
alanine scanning peptide arrays of residues 6-30 and 96-120 identified a number of key 
amino acids that are potentially involved in the HSP20-PKD1 interaction (Fig. 5.9B). 
Specifically, in an alanine substituted peptide array encompassing amino acids P
6
-D
30
 of 
HSP20, a loss of binding upon substitution of Arg
11,12
 with alanine and Ala
13,15 
with 
aspartic acid was observed. Interestingly, these amino acids form the domain surrounding 
serine 16 (RRApSAP), a site which is phosphorylated by both cAMP-dependent protein 
kinase A (PKA) and cGMP-dependent protein kinase G (PKG)
 
(Beall et al., 1997).  
Taken together all overlay studies so far, it is apparent that PKD1 and PDE4D5 shared 
common binding sites within the WDPF domain (Met
1
-Glu
35) and α-crystallin domain 
(His
96
-Gly
140
) of HSP20. Interestingly, there were also exclusive PDE4D5 binding to 
Ala
51
-Leu
55
 (Fig. 3.11) and exclusive PKD1 binding to Val
76
-Val
80
 (Fig. 5.9) of HSP20. 
These distinct but proximal sites may suggest that PDE4D5 and PKD1 interact with 
HSP20 in a mutually exclusive manner which could be potentially regulatory. 
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Figure 5.9. Identification of PKD1-HSP20 interaction sites. (A) HSP20 is shown 
schematically as in Gusev et al. (2002) with slight modifications. The dark shaded area 
represents the WDPF-domain, the light shaded area represents the conserved region in the 
N-terminal part of sHSP, the black area denotes conservative α-crystallin domain. P is the 
sites of phosphorylation and the zigzag denotes the flexible C-terminal region. Binding 
spot numbers relate to peptides in the scanned array whose residue position and sequence 
are given in the table below. (B) Scanning alanine substitution analysis using spots 1 and 
20. Native peptide (Ctr) plus progeny with the indicated residue substituted for alanine or 
aspartate. Red arrow indicates ablation or severely reduced interaction. Arrays are 
representative of at least three separate experiments. 
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5.2.4      Identification of PKD1 phosphorylation site on HSP20 
Protein phosphorylation is a ubiquitous post-translational modification (PTM), which is 
important for signal transduction and regulation of biological function. Hence, 
identification of kinase-specific phosphorylation sites is critical for molecular delineation 
of a diverse array of cellular processes. Initially, prediction of HSP20 phosphorylation sites 
by PKD1 was performed using an online computational software named GPS (Group-
based Prediction System, ver 2.0) (http://gps.biocuckoo.org/online.php). The prediction is 
based on similarity found in query sequences with respect to the known phosphorylation 
sites in at least one kinase group in the same hierarchy.  
The search consistently showed one possible phosphorylation site at Ser16 of HSP20 with 
the highest score as PKD-phosphorylated amino acid residue. Figure 5.10 depicts the 
online user interface of GPS, showing that the domain surrounding the predicted PKD-
phosphorylated HSP20 site at serine 16 contains a sequence (RRAS
16
AP). Interestingly, 
this site is similar to the phospho-motif of the AGC kinase subfamily (PKA, PKG and 
PKC) (Beall et al., 1997). More interestingly, it has also been shown that serine 16 is the 
phosphorylation site for sustained β-adrenergic signaling which leads to expression and 
phosphorylation of cardiac HSP20 (Chu et al., 2004). Hence, it is highly likely that this 
PKD1-HSP20 phosphorylation motif is physiologically significant. Nevertheless, the 
prediction is speculative and requires experimental verification. 
An in vitro phosphorylation assay was then carried out on HSP20 peptide arrays using [γ-
32
P-ATP] to validate the predicted phosphorylation site. As predicted, analysis of the 
HSP20 amino acid sequence reveals an optimal putative PKD phosphorylation site at 
Ser16. Importantly, Ser16 is part of the docking site that allows complex formation 
between PKD1 and HSP20. More interestingly, this site falls within the minimal PKD 
recognition motif of RxxS, where an arginine is normally located at the -3 position (Fig. 
5.11 Upper panel).  As reported previously, well-known substrates of PKD such as HSP27, 
HDAC5 and cTnI commonly conform perfectly to this phosphorylation motif as identified 
through combinatorial peptide libraries (Haworth et al., 2004; Vega et al., 2004; Dӧppler 
et al., 2005; Huynh and McKinsey, 2006) (Fig. 5.11 Lower panel)  
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Figure 5.10. Predicted phosphorylation site of HSP20 by PKD1. GPS software (Group-
based Prediction System, ver 2.0) was used for predicting kinase-specific phosphorylation 
sites. One potential phosphorylation site on HSP20 by PKD was identified at Ser16. 
 
 
Figure 5.11. PKD1 phosphorylates HSP20 at Ser16.  Upper panel: In vitro 
phosphorylation assay using [γ-32P-ATP] on alanine scanning peptide array of residues 1-
25 of HSP20 revealed that HSP20 is phosphorylated at Ser16 by PKD1.  Lower panel: 
Shown for comparisons are the minimal PKD1 consensus phosphorylation sequence and 
the PKD1 phosphorylation sites in HSP27, HDAC5 and cTnI. The amino acid residues in 
red with asterisks denote serine phosphorylation sites. 
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In order to verify that it is specifically HSP20 being phosphorylated by PKD1 at Ser16, a 
cold in vitro kinase assay was carried out using recombinant purified His-HSP20 protein 
and PKD1 active protein. The immunoblots were then probed with phospho-HSP20 
antibody which recognises HSP20 only when phosphorylated at Ser16 (Fig 5.12).  
Phosphobands were detected when active PKD1 was added. No appreciable 
immunoreactivity was evident when the assay mix was devoid of PKD1. These results 
clearly demonstrated that: (1) HSP20 can be directly phosphorylated by PKD1 in vitro, and 
that (2) the specificity of the phosphorylation site at Ser16 was validated by using 
phospho-Ser16 anti-sera. Taken together, it is thus concluded that HSP20 is a novel PKD1 
substrate. 
 
 
 
 
 
Figure 5.12. Ser16 is the site phosphorylated on HSP20 by PKD1. Purified His-HSP20 
was incubated in a cold in vitro kinase assay with PKD active protein and resolved by 
SDS-PAGE. HSP20 phosphorylation was determined by immunoblotting with anti-
phospho-HSP20 (Ser16). Lysates were also immunoblotted with anti-HSP20 as loading 
control. The immunoblots shown are representative of two independent experiments. 
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5.2.5      The effect of PKD1 activation on HSP20 phosphorylation 
As active PKD triggered recognition by a ser16 phospho-specific antibody, it is proposed 
that PKD1 activation may lead to the subsequent phosphorylation of HSP20. The effect of 
PKD1 activation on the phosphorylation level of HSP20 was examined in co-transfected 
HEK293 cells using commercially available activator bryostatin (10 nM) (Matthews et al., 
1997) and inhibitor Gӧ6976 (20 nM) (Gschwendt et al., 1996). PKD1 activation was then 
assessed using an anti-phospho-PKD1 (Ser916) antibody that detects only the active form 
of the kinase (Matthews et al., 1999). Using PKD1 and HSP20 co-transfected HEK293 
cells, the results show that PKD1 activation was elevated following stimulation with 
activator bryostatin, but decreased considerably after treatment with Gӧ6976. Interestingly, 
the phosphorylation of HSP20 increased along with activation of PKD1 and conversely 
inhibition of PKD1 decreased HSP20 phosphorylation (Fig. 5.13).  
 
 
 
 
Figure 5.13. The effect of PKD1 activity on HSP20 phosphorylation. PKD1 and HSP20 
co-transfected HEK293 cells were treated with bryostatin (PKD activator) alone or with 
Gӧ6976 (a potent PKD inhibitor) for the indicated times. PKD1 activation, HSP20 
phosphorylation and total HSP20 were monitored via immunoblotting with anti-phospho-
PKD1 (Ser916), anti-phospho-HSP20 (Ser16) and anti-HSP20 antibodies, respectively. 
Anti-RACK1 antibody was used as loading control. Representative immunoblots from 
three independent experiments are shown. 
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In addition, a loss-of-function approach was employed to further probe the functional role 
of PKD1 on HSP20 phosphorylation in intact cell systems. To confirm gene silencing, the 
level of PKD1 expression was assessed by immunoblotting. Figure 5.14 depicts the level 
of siRNA-mediated PKD1 knockdown in neonatal rat cardiomyocytes. Clearly, the 
transfection of cardiomyocytes with PKD1 siRNA markedly suppresses endogenous PKD1 
expression, whereas non-specific control siRNA had no effect. Notably, there was a 
profound reduction in the phosphorylation level of HSP20 as detected by immunoblotting 
total cell lysates with anti-phospho-HSP20 (Ser16). However, this knockdown had no 
evident effect on total HSP20 expression. α-tubulin, which is expressed constitutively was 
also unchanged. Decreasing PKD1 expression by siRNA knockdown significantly 
inhibited HSP20 phosphorylation. To our knowledge, this is the first direct demonstration 
that PKD1 is involved in the regulation of HSP20 phosphorylation. Because HSP20 plays a 
major role in cardioprotection against hypertrophy, it is thus speculated that HSP20 
phosphorylation by PKD1 may play a pertinent role in this cellular response. 
 
 
Figure 5.14. siRNA-mediated knockdown of PKD1 blunt phosphorylation of HSP20. 
Cells were transfected with rat PKD1 siRNA or control siRNA for 48 h to investigate the 
role of PKD1 in intact cell system. PKD1 expression levels were evaluated by 
immunoblotting with an anti-PKD1 antibody to confirm the level of knockdown. 
Phosphorylation of HSP20 and total HSP20 were monitored by immunoblotting with anti-
phospho-HSP20 (Ser16) and anti-HSP20 antibodies, respectively. Anti-α-tubulin antibody 
was used as loading control. Representative immunoblots from three independent 
experiments are shown. 
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5.2.6      The effect of PKD1-HSP20 interaction on HSP20 phosphorylation 
The regulation of protein function through protein phosphorylation is critical for the 
modulation of cellular activities. Hence, I investigated further the notion that disruption of 
PKD1-HSP20 interaction would be associated with changes in levels of HSP20 
phosphorylation. Indeed, as shown in Figure 5.15, HSP20 phosphorylation was greatly 
reduced upon disruption of the PKD1-HSP20 interaction, however, no evident effect was 
observed on total PKD activity (as measured by phospho-PKD (Ser916)). This indicates 
that PKD1 and HSP20 association is required for HSP20 phosphorylation. 
 
 
 
 
Figure 5.15. The effect of PKD-disruptor peptide ‘HJL09’ on HSP20 phosphorylation. 
Cardiomyocytes were subjected to compound treatment as indicated. Protein lysates were 
subjected to immunoblotting with antibodies that recognise phospho-PKD (Ser916) and 
phospho-HSP20 (Ser16). Anti-HSP20 antibody was used as loading control. 
Representative immunoblots from three independent experiments are shown. 
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In addition, earlier studies have shown that sustained β-adrenergic stimulation results in 
phosphorylation of cardiac HSP20 on Ser16 and that this can trigger cardioprotective 
functions and attenuate hypertrophic growth of cardiomyocytes (Fan et al., 2005, 2006). In 
light of the involvement of HSP20 phosphorylation in mediating cardiac responses in 
cultured cardiomyocytes, it was an exciting prospect to study the effect of PKD1 and 
HSP20 association on HSP20 phosphorylation in ISO-mediated hypertrophic 
cardiomyocytes. Here, cells were pre-treated with control or PKD-disruptor peptide 
‘HJL09’ prior to 24 h ISO stimulation. In agreement with earlier results in this chapter, the 
disruption of PKD1-HSP20 complex initiated decreases in the phosphorylation level of 
HSP20 (Fig. 5.16). This finding is in contrast with earlier data that researched the role of 
PKA-regulated HSP20 phosphorylation that facilitated the cardioprotective mechanism. In 
this regard, the functional consequence of PKD1 phosphorylation on serine 16 appears to 
be different from that of PKA phosphorylation at the same site. One could speculate that 
HSP20 phosphorylation may have dual anti- and pro-hypertrophic functions in the 
cardiovascular system in a kinase-dependent manner. It is also possible that different pools 
of HSP20 control different functions depending on which kinase (PKA or PKD1) they are 
associated with. 
 
Figure 5.16. The effect of PKD-disruptor peptide ‘HJL09’ on HSP20 phosphorylation 
in ISO-induced hypertrophic cardiomyocytes. HSP20 phosphorylation was determined 
by immunoblotting with anti-phospho-HSP20 (Ser16). Lysates were also immunoblotted 
with anti-HSP20 as loading control. The blots shown are representative of three 
independent experiments. 
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5.2.7     Use of a novel PLA to assess PKD1 association with HSP20 
Previous studies have shown that PKD1 translocates into the nucleus upon agonist-
dependent hypertrophic response (Vega et al., 2004). However, the mechanism of this 
nuclear influx has not been investigated. To address this issue and at the same time to 
further elucidate the mechanism underlying the role of PKD1-HSP20 interaction in 
hypertrophic response, a possible change in subcellular distribution was monitored in 
cardiomyocytes treated with the panel of compound described. Here, a novel in situ 
proximity ligation assay (PLA) was utilised to characterise patterns of protein interaction 
within cells (Söderberg et al., 2008, Bellucci et al., 2011). This method studied the 
occurrence of alterations in the distribution of PKD1-HSP20 complexes by providing 
highly specific and better resolution for the observation of the association between PKD1 
and HSP20. Specifically, a discrete fluorescent signal (red spot) would only appear when 
PKD1 and HSP20 form a complex. The proteins need to be less than 40 nm apart before 
association is detected. In order to detect all PLA signals, images were taken throughout 
the entire thickness of the cells using Z stacking. 
Under non-stimulated condition, diffuse cytoplasmic staining of PKD1-HSP20 complexes 
was observed and there was less PLA signal in the nuclei, suggesting that the PKD1-
HSP20 complex is cytosolic under basal conditions and generally excluded from the nuclei. 
(Fig. 5.17). In contrast, PKD1-HSP20 complexes were enriched and mostly confined to the 
nuclei of ISO-treated cardiomyocytes, with a small subpopulation remaining in the 
cytoplasm. A similar distribution pattern was also observed in cells treated with control 
peptide + ISO. However, treatment of the cells with PKD-disruptor peptide ‘HJL09’ 
triggered a profound change in the intracellular localisation of PKD1-HSP20. Seemingly, 
the interaction of the two proteins was perturbed, less PKD1-HSP20 complex was visible 
and complexes that were observed, were scattered in all directions throughout the cells. 
Parallel samples incubated only with the secondary antibody were also included to confirm 
that the observed fluorescence pattern could not be attributed to artifacts (data not shown). 
My results herein not only further verify that PKD1 exists in a complex with HSP20, but 
also suggest a spatial relationship between these two proteins. Clearly, the nuclear 
accumulation of the PKD1-HSP20 complex occurred in cells treated with ISO, whereas 
disruption of the interaction seemed to hinder nuclear entry of PKD1. These observations 
strongly suggest a role for HSP20 in mediating translocation of PKD1. Excitingly, the data 
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reported here provide first evidence for the role of HSP20 in mediating 
nuclear/cytoplasmic trafficking of PKD1 in response to prolonged β-adrenergic stimulation.  
 
5.2.8      Cell fractionation shows PKD1 and HSP20 localisation 
Next, cell fractionation studies were performed to extend the above findings and evaluate 
the degree of PKD1-HSP20 complex distribution. Cells were fractionated after drug 
treatment as described in ‘Materials and Methods’. Cellular proteins were fractionated into 
cytosolic, membrane and nuclear fractions before being subjected to immunoblotting to 
detect the protein levels of the PKD1 and HSP20 (Fig. 5.18 Upper panel). The purity of 
each fraction was validated by using specific markers such as cytosol (HSP90), membrane 
(GM130) and nuclear (Lamin A/C). The amount of protein recovered in each fraction was 
then quantified by densitometry and expressed as the percentage of the total protein 
content (Fig. 5.18 Lower panel). As expected, the cell fractionation results were consistent 
with the PLA data, showing that both proteins were predominantly in the cytosolic fraction 
under basal conditions and after treatment with PKD-disruptor peptide ‘HJL09’. However, 
in response to ISO alone and control peptide + ISO treatment, the nuclear pools of the 
proteins were more abundant than in unstimulated cells. These results underpin the notion 
that HSP20 has a potential role in mediating PKD1 nuclear translocation. Indeed, PKD1 
nuclear translocation during hypertrophic stimulus has been characterised previously by 
others (Rey et al., 2001; Vega et al., 2004). Interestingly, this is the first indication that the 
said dynamic movement of PKD1 is mediated by another protein (in this case HSP20).  
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Figure 5.17. The effect of PKD-disruptor peptide ‘HJL09’ on subcellular distribution 
of PKD1-HSP20 complex. PKD1-HSP20 associations were recognised with PLA as 
described in ‘Materials and Methods’. PLA signal (red) is only shown in cases where 
PKD1 forms a complex with HSP20. Cardiomyocytes were counterstained with α-actinin 
to show sarcomeric staining. DAPI staining was used to mark nuclei. Results showed that 
the distribution of PKD1-HSP20 complex between cytoplasmic and nuclear compartments 
could potentially be affected by disrupting the interaction of these two proteins. Images 
shown are representative of three separate experiments on different cardiomyocytes 
preparations. Scale bars = 10 µm.  
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Figure 5.18. Cell fractionation experiments showing PKD1 and HSP20 localisations. 
Upper panel: A representative Western blot showing protein levels of PKD1 and HSP20 in 
each fraction with respect to different treatments. Specific markers such as cytosolic 
(HSP90), membrane (GM130) and nuclear (Lamin A/C) were included to establish fraction 
purity. Lower panel: Quantification of immunoband intensities was determined by 
densitometry and was presented as mean percentage of the total protein content ± S.E.M. 
of three experiments on different cardiomyocytes preparations. 
Chapter 5               
 
134 
 
5.2.9    HSP20 phosphorylation : PKA vs PKD1 
The abovementioned contradictory findings that PKA- and PKD1-mediated HSP20 
phosphorylation at the same site (serine 16) have opposite effects on the hypertrophic 
response prompted me to carry out further biochemical studies. Because HSP20 can be 
phosphorylated by PKA, the next step was to determine whether it also affects PKD1-
mediated phosphorylation. As expected, treatment with the PKA-selective inhibitor, 
KT5720 greatly reduced HSP20 phosphorylation in hypertrophic cardiomyocytes. 
Interestingly, the combined effect of PKA inhibition and disruption of PKD1-HSP20 
complex was additive suggesting that both kinases can phosphorylate the global pool of 
HSP20 at the same time (Fig. 5.19). Based on these findings, it is tempted to suggest that 
there are different pools of HSP20 regulated by different kinases at specific times and 
places within cells. In other words, the functional roles of HSP20 are likely to be 
associated with its phospho-ser16 status resulting from different kinase activation within 
sub-pools of HSP20. Seemingly, HSP20 may also exert pro-hypertrophic effects depending 
on the cellular context. These results could have important implications for interpreting the 
findings of other potential role(s) of HSP20 in heart. 
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Figure 5.19. PKA and PKD1 modulate HSP20 phosphorylation under prolonged β-
adrenergic stimulation. The combination of both PKA inhibitor and PKD1-HSP20 
disruptor peptide greatly decreased HSP20 phosphorylation. Upper panel: Immunoblots 
showing HSP20 phosphorylation level with respect to different treatments. Total HSP20 
protein was used as loading control. Lower panel: Quantification of immunoband 
intensities was determined by densitometry and was presented as fold ratio of 
phosphorylation level normalised to HSP20 ± S.E.M. of three experiments on different 
cardiomyocytes preparations. 
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5.3     Discussion 
Peptide array technology has provided detailed information on the putative docking site for 
HSP20 on PKD1 and also highlighted several key residues within the conserved catalytic 
unit of PKD1 (Fig. 4.6). Although insight into the properties and mechanism of the 
intermolecular interactions of PKD1-HSP20 complex is hampered by the lack of structural 
information, advanced prediction methods on amino acid sequences have helped to reveal 
some major structural features of the key residues (Fig. 4.8). In trying to understand the 
functional role of the PKD1-HSP20 complex in hypertrophic cardiomyocytes, the 
sequence encompassing G
606
-E
630
 (GRDVAIKIIDKLRFPTKQESQLRNE) was utilised to 
develop a cell-permeable disruptor peptide. The stearate group which allows cell insertion 
is added to the N-terminal end of the peptide, so as not to cause any possible steric 
interference. Through displacement experiments in neonatal rat cardiomyocytes (Fig. 5.3), 
the functional relationship between HSP20 and PKD1, and the role for HSP20 in 
coordinating hypertrophic responses was studied.  
 
5.3.1    PKD1- HSP20 interaction in hypertrophic response 
Hypertrophy is characterised by the increase in cardiomyocyte size (in length and/or width), 
protein synthesis and cytoskeletal remodeling, which represent part of the compensatory 
mechanism that develops in response to hypertrophic stimuli (reviewed in Frey and Olson, 
2003). Consistent with earlier studies (Morisco et al. 2001), 24 h sustained ISO-stimulation 
induced hypertrophy in neonatal rat cardiomyocytes. Subsequently, cardiomyocytes 
displayed an increase in cell size (Fig. 5.4) and actin filament assembly (Fig. 5.5) upon 
onset of the hypertrophic response. Interestingly, pharmacological disruption of the PKD1-
HSP20 interaction altered ISO-induced morphological changes and actin organisation, 
indicating that PKD1 and HSP20 association is required for cellular enlargement and actin 
realignment in hypertrophic cardiomyocytes. As HSP20 has been shown to bind actin and 
regulate heart function through stabilisation of the cytoskeleton (Brophy et al., 1999; Fan 
et al., 2004), PKD1-HSP20 association is likely to be functionally significance to this 
process. 
Apart from the changes in cellular morphology and actin reorganisation, a significant 
increase in total cellular protein was also observed (Fig. 5.7). It is thought that this is 
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required for cellular increased growth, a typical cellular feature of pathological 
hypertrophy (Frey and Olson, 2003). In accordance, real-time qPCR results showed that 
ISO- and control peptide + ISO- treatment markedly increased the mRNA levels of the 
fetal genes: ANF, BNF and β-MHC (Fig. 5.8), which are pathological hallmarks of 
hypertrophy (Chien et al., 1991; Rosenzweig and Seidman, 1991). The reactivation of 
these fetal genes may indicate a redeployment of the transcriptional program that governs 
fetal gene expression to regulate hypertrophic growth. Interestingly, the PKD-disruptor 
peptide ‘HJL09’ suppressed the transcriptional activation of the three hypertrophy response 
genes, returning levels to that of untreated cells. These data are consistent with the 
hypothesis that PKD1 association with HSP20 is involved in the regulation of the 
hypertrophic response. Indeed, my data strongly suggests that cardioprotection is conferred 
upon disruption of the PKD1-HSP20 interaction. Seemingly, this disruption favours 
cardioprotective mechanisms by repressing expression of fetal cardiac genes. From a 
biological standpoint, it is likely to be an important mechanism to hinder the progression of 
hypertrophic phenotype. Hence, it is purported that the PKD1-HSP20 interaction plays 
important roles in cardiac development and in hypertrophic growth in response to β-
adrenergic stimulation. Nevertheless, these findings lead to two important questions: (1) 
how does the disruption of PKD1-HSP20 interaction confer cardioprotection? (2) what is 
the role(s) of HSP20 in this signalling pathway? 
 
5.3.2    PKD1 regulates HSP20 phosphorylation 
Multiple approaches were applied to assess the molecular role of PKD1 in regulating the 
biological function of HSP20. Firstly, mapping of the phosphorylation site on HSP20 using 
peptide array identified a physiologically relevant phosphorylation site at Ser16 (Fig. 5.10), 
a site which is implicated in the sustained β-adrenergic/PKA signalling (Beall et al., 1997; 
Chu et al., 2004). As previous studies have shown that PKD1 phosphorylates the same 
sites on TnI as PKA (Haworth et al., 2004; Cuello et al., 2007), it is therefore no surprise 
that PKD1 is also capable of phosphorylating other PKA targets such as HSP20 as seen in 
this study.  
In vitro validation by direct kinase assay and immunoblotting using phospho-HSP20  
antibodies (Ser16) showed that PKD1 activation corresponded to increases in the 
phosphorylation of HSP20, further confirming HSP20 as a newly identified PKD1 
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substrate (Fig. 5.11, 5.12). In addition, pharmacological inhibition of PKD1 activation 
significantly diminished phosphorylation of HSP20 (Fig. 5.13). It should be noted that 
selective pharmacological inhibitors of PKD were unavailable at the time when these 
experiments were conducted. The indolocarbazole compound Gӧ6976 used in this study is 
a PKC inhibitor that at nanomolar concentrations inhibits isozymes PKCα, PKCβ, PKCγ 
and PKCµ/PKD (Moore et al., 1999). Although Gӧ6976 was previously used to inhibit 
PKD activity in vitro (Vega et al., 2004), it may not be a perfect model to infer cellular 
functions of PKD1 especially since PKD1 can be activated through either a PKC-
dependent or PKC-independent pathway (Zugaza et al., 1996). Unless PKD1 is activated 
through a PKC-dependent pathway, PKC inhibition could neither inhibit PKC-independent 
PKD activation effectively nor lead to an outcome similar to that achieved by direct PKD 
inhibition. Hence in this context, a parallel loss-of-function approach was undertaken to 
evaluate a possible direct effect of PKD1 activation on HSP20 phosphorylation. 
Gratifyingly, genetic ablation using siRNA-mediated knockdown of PKD1 reinforced 
earlier results that showed a diminished HSP20 phosphorylation (Fig. 5.14). These results 
confirmed a direct relationship between PKD1 activation and phosphorylation of HSP20 at 
Ser16. Collectively, my study demonstrates for the first time that PKD1 is a novel kinase 
for HSP20 that modulates its phosphorylation at Ser16. As HSP20 phosphorylation is 
involved in cardioprotection against hypertrophy [as described in Chapter 3 and by other 
investigators (Fan et al., 2004, 2005, 2006; Qian et al., 2009)], I speculated that PKD1-
mediated HSP20 phosphorylation may also play a key role in this response. Further work 
may be required to assess the functional implications of PKD1 knockdown on hypertrophic 
responses. Also, PKD1 kinase-dead mutants should be used to examine whether kinase 
activity is essential for HSP20 phosphorylation in hypertrophic cardiomyocytes. 
As previous findings have shown that sustained β-adrenergic stimulation results in 
phosphorylation of cardiac HSP20 on Ser16 by PKA and that this action attenuates 
hypertrophic growth of cardiomyocytes and triggers cardioprotective functions (Fan et al., 
2004, 2005), it was interesting to study the effect of a PKD-disruptor peptide on HSP20 
phosphorylation. However, early observations on the potential role(s) of the PKD1-HSP20 
complex revealed unexpected findings. It turned out that disruption of the PKD1-HSP20 
interaction decreased the phosphorylation level of HSP20 in hypertrophic cardiomyocytes 
without affecting PKD1 activity (Fig. 5.16). In other words, the cardioprotection conferred 
by the PKD-disruptor peptide ‘HJL09’ occurred when a lower level of HSP20 
phosphorylation was evident. Clearly, this is in stark contrast with PKA-regulated HSP20 
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phosphorylation. So, what are the functional implications of HSP20 phosphorylation in this 
context? It is tempting to speculate that HSP20 may have both anti- and pro-hypertrophic 
functions in the cardiovascular system. Seemingly, HSP20 facilitates hypertrophic 
response in a kinase-dependent manner. The notion is supported by studies demonstrating 
that opposite function of cyclin-dependent kinases (CDKs), CDK1 and CDK2 which 
phosphorylate the same site on forkhead box O (FoxO) transcription factor, FoxO1 at 
Ser249. Similar to HSP20, FoxO1 shuttles between the cytoplasm and nucleus, whereby its 
subcellular localisation and biological function (its transcriptional activity) is regulated by 
intracellular kinases. Specifically, the phosphorylation of FoxO1 by CDK1 promotes 
nuclear accumulation of FoxO1 and triggers apoptosis in neurons (Yuan et al., 2008), 
whereas CDK2 phosphorylates FoxO1 results in cytoplasmic localisation and inhibition of 
FoxO1 (Huang et al., 2006). However, the mechanism underlying the opposite function of 
both CDK1 and CDK2 on Fox01 phosphorylation remains incompletely defined. Clearly, 
different kinases can elicit opposite effects despite phosphorylating the same residue. 
 
5.3.3    HSP20 is the ‘molecular escort’ of PKD1 
These apparently contradictory findings prompted me to carry out immunocytochemical 
studies to investigate the effect of PKD-disruptor peptide ‘HJL09’ on intracellular 
distribution of PKD1 and HSP20 proteins. The novel technology involved in situ PLA 
analyses holds great potential for shedding light on the function of PKD1 and HSP20 by 
positioning them within a functional signalling complex. This highly specific and sensitive 
method allowed direct observation of endogenous protein complexes without any need for 
genetic modification of target cells, such as cells with overexpressed fusion-tagged target 
proteins (Söderberg et al., 2008, Bellucci et al., 2011). It is based on the use of two 
primary antibodies raised in different species and a pair of fluorophore-labelled 
oligonucleotide PLA probes (priming and non-priming secondary antibodies). Dot-like 
positive signal is generated only when the two PLA probes bind in close proximity to each 
other. It is thought that the PLA signal is proportional to protein associations. Conversely, 
immunofluorescence (IF)-based methods which have lower sensitivity with scarce proteins 
and is likely to exhibit poor target selectivity, cannot be used to study protein-protein 
interactions (Pradidarcheep et al., 2008).  Moreover, in situ PLA results which exhibit 
higher signal to noise ratio, are shown as discrete fluorescent spots and not by measuring 
the total fluorescence intensity. It is thus less likely to encounter fluorescence 
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photobleaching which may complicate the observation of fluorescent signal compared with 
IF-based methods. Indeed, a number of studies have indicated that in situ PLA generated 
more accurate predictions of in vivo effects in primary cells than the regular IF detection 
methods, in particular for drug-induced perturbations of protein-protein interactions. For 
example, in situ PLA was used to examine the effects of small molecule kinase inhibitors 
on platelet-derived growth factor receptor (PDGFR) β signalling in primary human 
fibroblasts (Leuchowius et al., 2010). This method has also been used to study the 
redistribution of dopamine transporter (DAT)/α-synuclein complexes in the Parkinson’s 
disease brain of transgenic mice (Bellucci et al., 2011). Interestingly, my PLA results 
showed that the PKD1-HSP20 complex underwent dynamic intercellular redistribution 
from the cytoplasm under basal conditions, to the nucleus in response to 24 h ISO 
stimulation. Notably, similar observations were also obtained in biochemical fractionation 
experiments, confirming the reproducibility of in situ PLA. 
Pathological cardiac remodeling involves reactivation of the fetal gene program, which 
encodes proteins to regulate cardiac functions such as contractility (Frey and Olson, 2003). 
Previous studies have demonstrated that PKD1 phosphorylates HDAC5 leading to its 
export from the nucleus to the cytoplasm, resulting in a pro-hypertrophic phenotype 
through MEF2 transcriptional activity (Zhang et al., 2002; Chang et al., 2005; Vega et al., 
2004). However, none of these reports have provided an adequate explanation concerning 
the mechanism behind the nuclear import of PKD1 and subsequent regulation of HDAC5 
pro-hypertrophic properties. As such, one possible explanation for the dynamic cellular 
localisation of PKD1-HSP20 complex seen in present study is that HSP20 serves as a 
‘molecular escort’ for facilitating nuclear translocation of PKD1. Given that PKD1 is 
required to be translocated into the nucleus to trigger fetal gene expression (Harrison et al., 
2006), it is thus likely that the induction of hypertrophy is also a consequence of the 
PKD1-HSP20 interaction.  Moreover, it is plausible that disruption of the complex halts 
translocation and this action may be protective against the hypertrophic response. 
Additionally, because PKD1 regulates the pathological remodelling of the heart via its 
ability to modulate phosphorylation and nucleocytoplasmic shuttling of HDAC5 (Zhang et 
al., 2002), it is thus speculated that the suppression of fetal gene expression resulting from 
the disruption of PKD1 nuclear translocation involves dephosphorylation of HDAC5. 
Further experimentation is needed to prove this idea. Clearly, these findings support a role 
for PKD1-HSP20 interaction in the modulation of the repressive influence of HDAC5 on 
hypertrophic cardiomyocyte via its ability on nuclear influx.  
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Gratifyingly, results from PLA shed new light on the incomplete mechanism underlying 
the nuclear translocation of PKD1 following hypertrophic onset. As deduced from the 
results gathered in the second part of this project, a testable model is proposed to explain 
this series of molecular events (Fig. 5.20). Seemingly, the association of PKD1 and HSP20 
and the consequent effects on fetal gene program are primarily a β-adrenergic-mediated 
hypertrophic response. HSP20-mediated PKD1 nuclear translocation may account for the 
induction of fetal gene expression. In contrast, disruption of PKD1-HSP20 complex leads 
to downregulation of fetal gene program, thereby hindering the development of 
hypertrophy and cardiac failure. Although it is reasonable to suggest that the disruptor 
peptide inhibits fetal gene expression by inhibition of PKD1 nuclear translocation, it 
should be noted that other HSPs or proteins may also play compensatory roles in the 
effects exerted by HSP20. Future studies may require clarifying the specificity of this 
response to HSP20 using inducible or conditional knockout models. 
 
 
Figure 5.20. Proposed models for the role of HSP20 in PKD1 nuclear translocation. 
Upon prolonged β-adrenergic stimulation, HSP20 binds to PKD1 and mediates PKD1 
transport into the nucleus. This action leads to the activation of fetal gene program which 
promotes cardiac hypertrophy. Conversely, disruption of the PKD1-HSP20 complex 
results in the downregulation of fetal gene expression, thereby hindering the progression of 
cardiomyopathy. The PKD1-HSP20 complex may serve as a promising therapeutic target 
as they indirectly facilitate the hypertrophic growth response. 
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This study has mainly focused on the PKD1-HSP20 interaction, and has examined the 
regulation of HSP20 phosphorylation by PKD1, where phosphorylation actually induces a 
pro-hypertrophy response. Again, it should be noted that HSP20 can also be 
phosphorylated by PKA and conversely, increase PKA-mediated phosphorylation of 
HSP20 has been shown earlier to initiate anti-hypertrophy response (see Chapter 3). The 
differences in hypertrophic responsiveness between PKA- and PKD1-mediated HSP20 
phosphorylation may also suggest that although they share a similar phosphorylation site at 
Ser16, they serve different functions. As such, we cannot rule out the possibility that PKA 
regulates redundantly or in concert with PKD1 to control HSP20 phosphorylation. Indeed, 
phosphorylation assays showed that PKA inhibitor, KT5720 resulted in nearly 80% 
reduction in the level of HSP20 phosphorylation and this could be further diminished upon 
disruption of PKD1-HSP20 interaction. It is thus hypothesised that there are different pools 
of HSP20 which are regulated by different kinases in response to specific stress stimuli. 
The mechanism behind this discrepancy is still unclear, but it is likely to involve crosstalk 
between kinases and downstream targets in the hypertrophy signalling pathway. This will 
be discussed in more detail in Chapter 6. 
 
5.3.4    Conclusions 
In conclusion, the integration of ProtoArray data with biochemical and 
immunocytochemical studies have led to a new hypothesis for cardioprotective mechanism, 
which has provided a deeper insight into hypertrophy signalling. These cumulative 
observations, for the first time, reveal a novel role of PKD1 and HSP20 in ISO-mediated 
hypertrophy in neonatal rat cardiomyocytes. I strongly feel that this represents an 
important mechanism, which underpins sustained β-adrenergic effects on pathological 
cardiac growth and cardiac remodeling. In fact, my findings herein have established that 
the PKD1-HSP20 complex acts as a nuclear effector of hypertrophy signalling pathways, 
which is causally involved in the induction of fetal gene program. Importantly, my present 
findings have identified the PKD1-HSP20 complex as a new component in the hypertrophy 
signalling pathway. However, the important question remains: what is the mechanism(s) 
underlying the role of HSP20 in PKD1-mediated hypertrophy signalling? Overall, it is 
thought that at least four mechanisms are involved: (1) activation of PKD1 in response to a 
stress signal or upstream regulator; (2) HSP20 interaction with PKD1 to form a complex; 
(3) HSP20 mediation of PKD1 nuclear translocation, most likely through a post-
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translational modification such as phosphorylation; and (4) attenuation of PKD1-triggered 
fetal gene program through the disruption of PKD1-HSP20 complex. This latter point is 
particularly pertinent when considering the blockade of hypertrophic signalling in response 
to sustained β-adrenergic stimulation, thereby hindering the progress of hypertrophy and 
cardiac failure. Clearly, the stimulatory actions of the PKD1-HSP20 interaction on 
cardiomyocyte hypertrophic progression, further confirms that HSP20 is an intracardiac 
modulator of cardiomyocyte function. In other words, HSP20 serves as a pro-hypertrophic 
regulator by mediating nuclear transport of PKD1. Because cardiac hypertrophy often 
involves the nuclear export of PKD1-phosphorylated class II HDAC5 into the cytoplasm 
which derepresses hypertrophic genes (McKinsey et al., 2001; Zhang et al., 2002; Vega et 
al., 2004), it is thus postulated that PKD-disruptor peptide ‘HJL09’ derived from this study 
may ameliorate the hypertrophic effects by barring PKD1 from entering the nucleus to 
regulate repressive activities of HDAC5, thereby inhibiting MEF2-dependent fetal gene 
transcriptional activation. In this regard, PKD1 and HSP20 may emerge as promising 
therapeutic targets to hinder the hypertrophic phenotype.  
Further studies to define the functional role of PKD1 and HSP20 in experimental animal 
models would provide exciting new information on the role of the PKD-HSP20 complex 
on pathological cardiac hypertrophy. Moreover, there would be value in studies to 
investigate whether HSP20, in addition to serving as ‘transport mediator’ for PKD1, is also 
involved in the regulation of various PKD1 substrates in the hypertrophy signalling 
pathway. 
 
5.4     Further work 
Using information derived from the peptide array analyses described above, further work 
was also carried out to examine whether PDE4D5-HSP20 and PKD1-HSP20 interactions 
interfere with each other in the presence of all three interacting proteins. To do this, I 
simultaneously probed HSP20 peptide array with equimolar amounts of full-length purified 
PKD1 and PDE4D5 proteins. Simultaneous detection of equimolar PKD1 and PDE4D5 
binding was carried out on the Odyssey system using rabbit-anti-PKD1 and sheep anti-
PDE4D antibodies, each linked to distinct secondary antibodies labelled with different 
wavelength probes (anti-rabbit IRDye800 (green channel) and Alexa Fluor 680-conjugated 
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anti-rabbit IgG (red channel)). This independently identified PKD1 (green) and PDE4D5 
(red) associated with specific peptide spots in single channel analyses. The signals were 
then merged to identify peptide spots with solely PKD1-HSP20 complexes (green), solely 
PDE4D5-HSP20 (red) and those with mixed populations of PKD1-HSP20 and PDE4D5-
HSP20 (yellow) (Fig. 5.21). Overlay studies showed that PKD1 and PDE4D5 mainly 
interact at multiple overlapping sites within the WDPF domain (Met
1
-Glu
35) and α-
crystallin domain (His
96
-Gly
140
) of HSP20 which may suggest competitive binding in these 
regions.  In fact, PKD1 was able to bind to amino acids covering a broader part within the 
N-terminal of the α-crystallin domain extending from Glu41-Ser75, unlike a more localised 
PDE4D5 binding site spanning only Ala
51
-Ser
75
. Notably, this also pinpointed exclusive 
PKD1 binding (green) to the region Glu
41
-Asp
50
 of HSP20. Alternatively, superimposing 
the binding sites on a predicted 3D structure of HSP20 revealed common surface-
accessible region of both PKD1 and PDE4D5 and well-defined surface-exposed patch of 
PKD1 exclusive binding site (Fig. 5.22). 
Interestingly, the binding site of PKD1 on HSP20 showed by 2-protein simultaneous 
detection method here was inconsistent with that showed earlier in Figure 5.9 using 1-
protein overlaying approach. Seemingly, PKD1 was able to bind to the α-crystallin domain 
of HSP20 more extensively in the presence of PDE4D5. This may due to steric interaction 
caused by PDE4D5 which is likely to induce changes in conformation and binding 
properties of PKD1. Despite competing for docking site on HSP20, PDE4D5 may also 
facilitate mutual interaction of PKD1 with HSP20. However, the underlying mechanism is 
still unclear. Nevertheless, these findings may highlight, to some extent, an additional 
degree of functional complexity associated with a crucial role of PDE4D5 on PKD1-
HSP20 interaction. It is speculated that such consequence of PDE4D5 binding is likely to 
exert a functional effect on the regulation of PKD1 on HSP20.  
Further studies using yeast two-hybrid assay with HSP20 expressed as ‘bait’, PKD1 as 
‘prey’ and PDE4D5 as a ‘competitor’ and co-immunoprecipitation may help to verify 
whether PDE4D5 can enhance the binding of PKD1 to HSP20. Moreover, siRNA-
mediated knockdown of cAMP-specific PDE4D5 is required to examine explicitly whether 
the alterations in the level of PDE4D5 expression could act to modulate PKD1-mediated 
phosphorylation of HSP20. 
On the other hand, the restriction of PKD1 nuclear entry is clearly a potential route to 
attenuate the pathologic hypertrophic response. Previous studies have shown that 
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biologically active peptides can be efficaciously delivered into organs of intact animals via 
the blood vessels (Chen et al., 2001). It is thought to be more effective compared to gene 
delivery, as adaptations to any modifications induced by signal transduction modulator are 
less likely to occur. However, there are several factors regarding peptide-based therapy that 
need to be taken into consideration. These include the synthesis and solubility of peptide, 
target specificity, maintenance of peptide activity and stability, as well as degradation of 
unwanted peptide products (Mason, 2010). As such, it will be necessary to take further 
steps to translate the PKD-disruptor peptide ‘HJL09’ into small molecules for easy 
manipulation in drug development. This could be done by identifying the smallest active 
fragment required for its biological activity. Optimisation of peptide array is a fundamental 
approach to identify the minimum high affinity binding sequence of the interaction motif 
(Hummel et al., 2006). Using progressive stepwise truncations from either N- or C- 
terminal or both termini, my preliminary data suggest that peptide sequences as short as six 
amino acid residues (R
607
DVAIK
612
) may be effective for such disruption. Short peptides 
are more “drug like” and can be therapeutically viable (Fig. 5.22A). While alanine 
scanning highlights the contribution made by the functional group of each side chain, 
positional scanning of sequential substitution with other naturally occurring amino acids 
offers a route to the enhancement of peptide activity (Fig. 5.22B). Nevertheless, it should 
be noted that small length peptides does not take into account the steric chemistry of 
proteins and therefore could represent false positives. Peptide array also has the drawback 
that it will miss binding events involving a number of amino acids that are far separated in 
the linear sequence but coalesce to form a complex binding site within the 3-D protein 
structure. As such, biological techniques such as co-immunoprecipitation and site-directed 
mutagenesis are needed in parallel. Nevertheless, the development of a selective disruptor 
of PKD1-HSP20 for use in proof-of-concept studies using animal models of cardiac 
hypertrophic is likely to advance our current understanding on hypertrophy signalling. 
Further experimentation should also be undertaken into the molecular mechanism of PKD1 
nuclear influx, for instance, whether the binding of PKD1 and HSP20 affects the 
phosphorylation of HDAC5. Additional work is required to establish the underlying 
molecular requirements, for example, whether PKD1-HSP20 complex crosstalks with 
other signalling systems to regulate hypertrophic response upon β-adrenergic stimulation. 
It would also be interesting to see if the subcellular distribution of phospho-HSP20 is 
different from the non-phospho form via immunocytochemical studies. In addition, using 
in situ PLA analysis to investigate whether the binding nature of the complex is affected by 
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phospho-HSP20 may also provide valuable information on the possible function of HSP20 
phosphorylation on PKD1 translocation. I would also have liked more time to prove that 
there are different pools of HSP20 that are modified by different kinases as this would help 
to explain the obvious contradiction that both kinases (PKA and PKD1) phosphorylate 
HSP20 at the same site but have opposing actions. These experiments would have been 
carried out utilising in situ PLA which allows subcellular localisation and quantification of 
the relative amounts of endogenous PKA-HSP20 and PKD1-HSP20 complexes in cells 
based on the use of three primary antibodies (anti-PKA, anti-PKD1 and anti-HSP20), all 
raised in different species. For example, a rabbit antibody directed against HSP20 would 
be used together with a mouse PKD1 antibody and a goat PKA antibody, follow by 
secondary PLA probes directed against mouse, rabbit and goat IgG. The products would 
then be detected using two different fluorescently labelled oligonucleotides, where PKA-
HSP20 and PKD1-HSP20 associations will appear as discrete spots of two different 
colours (eg. green and red), thereby showing the subcellular localisation of these 
heteromeric complexes. To investigate if in situ PLA will be suitable for monitoring such 
interactions, perturbations of interactions between these proteins would also be studied in 
cells treated with inhibitors and/or disruptor peptides. 
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Figure 5.21. Simultaneous detection of PKD1 and PDE4D5 interactions on HSP20. 
Odyssey analysis of HSP20 peptide array incubated with equimolar (3.8 nM) PKD1 and 
PDE4D5, followed by blotting with anti-PKD1 (rabbit) and anti-PDE4D5 (sheep). PKD1 
(green) and PDE4D5 (red) binding were detected simultaneously with dual binding 
(yellow) shown in the combined channels (overlay) using fluorescence secondary 
antibodies. Null binding is black. Data are typical of those obtained using three separately 
synthesised arrays. 
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Figure 5.22. Predicted structure of HSP20 and location of binding sites with PKD1 
and PDE4D5. Interaction sites with HSP20 were superimposed on a predicted 3D 
structure of HSP20, presented in front view (upper) and back view (lower), related by 180 
degree rotation. Yellow region represents common binding sites of PKD1-HSP20 and 
PDE4D5-HSP20 whereas green patch depicts PKD1 exclusive binding region on HSP20. 
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Figure 5.23. Optimisation of peptide length and substitutional analysis. (A) Truncation 
studies omitting one or more amino acids from the amino, carboxyl or both termini. (B) 
Positional scanning shows all possible combinations of the most active amino acids at each 
position, hence identifying potential more favourable residues for enhanced peptide 
activity. 
A 
B 
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6.1    Background 
HSP20 and its phosphorylation have been implicated in many protective processes in heart. 
In particular, the role of PKA in directing HSP20 phosphorylation to trigger 
cardioprotective mechanisms has attracted much interest from research groups. My PhD 
project herein aimed to further elucidate the molecular mechanism behind HSP20 induced 
cardioprotection, in particular against hypertrophy. This project was divided into two parts: 
(1) to investigate the role of PDE4-HSP20 complex in hypertrophy; (2) to identify novel 
signalling complexes containing HSP20 in the hypertrophic signalling pathway.  
 
6.2    The association of PDE4D and HSP20 
Initial studies involved setting up an in vitro cell-based model for hypertrophy using 
sustained β-adrenergic agonist, ISO-stimulated neonatal rat cardiomyocytes. Hypertrophic 
growth was evaluated by manual microscopic measurement of cell size, quantitative 
measurements of cell size using RT-CES, protein synthesis and real-time qPCR analysis of 
fetal gene expression. The first section of my work showed that (1) members of the cAMP-
specific PDE4 family can form signalling complexes with HSP20 and (2) the PKA-
mediated phosphorylation of HSP20 can be controlled by PDE4. The selective disruption 
of PDE4D5-HSP20 complex using a competing peptide ‘bs906’ based on PDE4D5 
sequence could specifically dissociate these proteins, resulting in a local increase in cAMP 
levels in the vicinity of HSP20 that resulted in hyperphosphorylation of  HSP20 at Ser16. 
In contrast, intact PDE4D5-HSP20 complexes lower the cAMP concentration in the 
vicinity of HSP20, thereby preventing activation of localised PKA and consequently 
reducing HSP20 phosphorylation. Interestingly, disruption of the HSP20-PDE4 complex 
attenuated the hypertrophic response in cultured cardiomyocytes, as shown by a reduction 
of the increase in cell size and protein content. Seemingly, peptide ‘bs906’ augmented the 
increase in ANF expression. In summary, the protective mechanism conferred by HSP20 in 
this context depends on it phosphorylation at Ser16 by cAMP-dependent PDE4D5-
regulated PKA phosphorylation. Because HSP20 is versatile and has multiple protective 
roles, it is important to further explore the target network of HSP20, which may be 
involved in cardioprotective mechanism.   
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6.3    The association of PKD1 and HSP20 
The second part of my work identified PKD1 as a novel binding partner for HSP20 using 
proteomic analysis as described in Chapter 4. The interaction was then validated by 
biochemical means, immunocytochemistry and array-based analysis, which provided the 
first evidence of the direct association between HSP20 and PKD1. My work also revealed 
that HSP20 not only interact with PKD1 but is also substrate for PKD1 in vitro. Ser 16 
(also the PKA site) was identified as the PKD1-mediated phosphorylation site in HSP20. 
Furthermore, displacement studies using PKD-disruptor peptide ‘HJL09’ derived from 
PKD1 peptide array data provided a novel functional insight into the role of HSP20 in 
hypertrophy. My experiments showed that disruption of the PKD1-HSP20 complex 
protected against hypertrophy (as shown by a reduction in the increase in cell size and 
protein content, as well as actin reorganisation and fetal gene expression). 
In addition, PLA analysis suggested a pivotal role of HSP20 in directing nuclear 
translocation of PKD1, in which disruption of the PKD1-HSP20 interaction consequently 
suppressed activation of fetal genes. My results also demonstrated that cardioprotection 
can be induced by disruption of the PKD1-HSP20 complex which results in a decrease in 
HSP20 phosphorylation at Ser16. This is in contrast to the findings from the first part of 
my work (see Chapter 3) and previous studies (Fan et al., 2004, 2005, 2006) which showed 
that increased (PKA-mediated) phosphorylation of HSP20 at serine 16 is required to 
trigger cardioprotective mechanisms. Seemingly, PKD1 phosphorylates HSP20 at the same 
phosphorylation site, yet induces an opposite effect to PKA-mediated HSP20 
phosphorylation. These opposing functions of PKA and PKD1 on HSP20 may be a feature 
of multi-stationarity which involves mechanism of cellular decision-making. Whether the 
binding of these proteins is mutually exclusive or competitive is still unknown. 
Nevertheless, the disruption of PDE4D5-HSP20 and PKD1-HSP20 complexes with 
consequent upregulation and downregulation of fetal gene expression, respectively, 
strongly suggest that these two signalling complexes are differentially regulated in 
hypertrophic cardiomyocytes. Seemingly, PKA-mediated HSP20 phosphorylation could 
complement the function of PKD1-mediated HSP20 phosphorylation in cardioprotective 
mechanism. In this regard, cross-phosphorylation of PKA and PKD1 on HSP20 appears 
possible and interplay between these two kinases is likely, hence pinpointing the 
complexity of control mechanism in maladaptive signalling in the heart.  
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6.4    Antagonistic actions of PKA and PKD1on HSP20 
The paradoxical findings here suggested that PKA could function in concert with PKD1 to 
elicit signalling changes in response to hypertrophic stimuli. Notably, in cardiomyocytes, 
the molecular fingerprint of PKD-mediated phosphorylation differs from that of PKA, with 
only the latter targeting sites such as Ser282 in cardiac myosin-binding protein C, Ser16 in 
phospholamban, and Ser68 in phospholamban (Cuello et al., 2007). Thus, the functional 
outcome of PKD activation would be expected to be different from those of PKA 
activation. In line with my findings, there is evidence to suggest the existence of PKA-
independent mechanisms of calcium-dependent protein kinases which act in an opposing 
manner (Backs et al., 2011). The report from Backs et al. (2011), identified class II histone 
deacetylases HDAC4 as common targets of both PKA and calcium/calmodulin-dependent 
protein kinase II (CaMKII), where both docking sites lie in close proximity. It was reported 
that PKA induced proteolysis of HDAC4 and repressed MEF2 activity, thereby 
antagonising the pro-hypertrophic actions of CaMKII signalling. Clearly, HDAC4 in this 
regard, functions as an integrator of the two opposing signaling cues that regulate fetal 
gene expression. Likewise, my findings show that PKA and PKD1 signals converge on 
HSP20 phosphorylation to modulate its activity. This may imply a role of HSP20 as a 
‘regulatory hotspot’ in the control of cardiac hypertrophy. Clearly, the balance between 
PKA and PKD1 activation prescribes the consequence of hypertrophic response. However, 
how HSP20 discriminates between PKA and PKD1 in different settings remains unclear. 
There are several questions to address: (1) what factors determine which kinase 
phosphorylates HSP20? (2) are PKA- and PKD1-mediated HSP20 phosphorylations  
independently regulated or are these phosphorylation events controlled in an 
interdependent fashion?  (3) does it involve a negative feedback system that regulates the 
equilibrium between these kinases and if balance shifts upon specific receptor stimulation? 
(4) do HSP20 exist in different “pools” that are differentially regulated by separate kinase 
types? 
PKA is a well-known downstream effector of cardiac β-AR signalling where an increase 
PKA activity promotes phosphorylation of various substrates such as myofibrillar proteins 
and phospholamban which are involved in the excitation-contraction coupling (Dzimiri, 
1999; Johnson et al., 2001). However, β-AR does not activate PKD1 in vitro or in vivo 
(Harrison et al., 2006). Although β-AR signaling fails to activate PKD1, it should be noted 
that PKA, a major downstream effector of β-ARs, has been reported to regulate PKD1 
signaling. Of particular interest, are contradictory reports concerning the effect of PKA on 
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the function of PKD1. The controversy has arisen around the duration of stress stimuli and 
mechanisms involved. For example, recent studies have demonstrated that acute β-
adrenergic stimulation and activation of PKA inhibits PKD1 phosphorylation and 
downstream HDAC5 activation, thereby repressing transcriptional activity (Haworth et al., 
2007; Sucharov et al., 2011). In contrast, an opposing effect of PKA on PKD1 was 
reported by Carnegie et al. (2004). This research group revealed the existence of a multi-
protein complex containing PKD1, PKCη, PKA and the PKA anchoring protein, AKAP-
Lbc in adult rat heart. In this study, PKA-mediated phosphorylation of AKAP-Lbc in 
response to hypertrophic stimuli was shown to result in the release of PKC activated PKD1 
from the complex, and this action initiated the nuclear export of HDAC5 and the 
consequent reexpression of hypertrophic genes. So, β-AR signalling seemed to alter PKD1 
signaling by controlling its subcellular distribution rather than through direct effects on its 
catalytic activity. How do these various pathways communicate with one another to 
execute their biological functions? It is evident that AKAP-Lbc serves as a connector to 
mediate crosstalk between different pathways by providing a platform for the assembly of 
signalling complexes (Carnegie et al., 2004, 2008). Clearly, signal responsiveness is 
underpinned by AKAP-Lbc through the presence of both upstream activators and 
downstream effectors. Nevertheless, additional studies are required to elucidate the 
interconnectivity between this signalling complex and other intracellular signaling 
pathways to gain a greater understanding of the coordinated regulation of AKAP-Lbc in 
cardiac hypertrophy.  
Growing evidence pinpoints crosstalk among adrenoceptor (AR) subtypes, in particular β-
AR and α-AR that regulate contractility, as a fundamental mechanism in regulating 
cardiovascular function via second messengers and protein kinases as intermediate 
mediators (Dzimiri, 2002). In addition to cooperativity, it should also be noted that 
inhibitory interaction between distinct signalling pathways can occur at the post-receptor 
level to counter potentially detrimental effects resulting from malfunctional signal 
transduction. For instance, it was found that signals from α-AR can directly inhibit β-AR-
mediated cAMP accumulation in neonatal rat cardiomyocytes, thereby regulating 
downstream signalling components of the β-AR pathway (Barrett et al., 1993). The 
upregulation of α-AR was associated with downregulation of β-AR and increased Gi 
protein levels (Dzimiri, 1999). It was proposed that the convergence of these two receptor 
pathways was a consequence of their cross regulation via Gs or Gi coupling and that any 
malfunction or change in transduction of these signalling routes may contribute to the 
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manifestations of cardiac disease (Barrett et al., 1993; Lemier et al., 1998).  Moreover, 
negative feedback system may involve in the regulation of the equilibrium between two 
signalling mechanisms such as the reciprocal regulation of vascular tone by endothelin-1 
(ET-1) and nitric oxide (NO) (Rossi et al., 2001). A downregulated NO was shown to be 
associated with enhanced synthesis of ET-1 and vice versa, suggesting a key role of ET-1 
and NO interplay in the regulation of vasodilation and vasoconstriction. 
Alternatively, crosstalk-type cardiovascular signalling can also be excuted by two types of 
cellular responses, i.e. short- and long-term receptor activations. It is thought that 
continuous receptor stimulation will trigger a time-dependent switch to alter receptor 
signalling pathway. For instance, short-term actions normally involve the activation of 
Ca
2+ 
to stimulate contractile components and increase cardiac performance. However, 
long-term effects are implicated in the regulation of gene transcriptional activity, which is 
often seen as an adaptive mechanism of hypertrophy (Calil et al., 2007). In fact, long term 
hypertrophic stimulation could lead to maladaptive of PDE activity and loss of cAMP 
compartmentation, causing unrestricted diffusion of cAMP and chronic activation of PKA, 
thereby leading to desensitization of βAR/cAMP/PKA pathway (Frey and Olson, 2003). In 
this regard, it is likely that PKD1-mediated phosphorylation assumes greater functional 
significance in settings where the cAMP-dependent PKA pathway is downregulated. This 
notion is in agreement with the data of Xiang et al., (2005) who concluded that sustained 
stimulation of β1-AR switches the receptor signaling from a PKA activation pathway to 
calcium/calmodulin-dependent pathway. Indeed, neurohormonal stimulation of PKD1 
activity has been shown to be enhanced under conditions where PKA activity is 
downregulated, which is a hallmark of heart failure (Lohse et al., 2003; Haworth et al., 
2007). Whether these regulations involve a feedback loop or equilibrium of steady state in 
which the balance shifts upon specific receptor stimulation is an unanswered question. 
 
6.5    Conclusions 
The findings presented in my thesis suggest that HSP20 plays a dual but antagonistic role 
in the regulation of the hypertrophic response and this depends on (1) the type of kinase-
mediating the phosphorylation, (2) the localisation of PKA, PKD1 and HSP20 within the 
cell and (3) the time or duration of the stress stimuli. Excitingly, my findings have led to 
the novel idea that hypertrophy signalling does not result from the sequential activation of 
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a linear signalling pathway of proteins, but may rather involves crosstalk between complex 
interactions of multiple signalling networks. The hypertrophic response generated by PKA 
and PKD1 mediated signals in this study are likely to involve the synchronisation and 
integration of multiple hypertrophic pathways in the heart. Collectively, these studies 
highlighted the multifactorial nature of hypertrophic signaling pathways in cardiomyocytes, 
indicating that different regulatory pathways are required to work in concert to underpin 
functional responsiveness. Clearly, crosstalk between anti-hypertrophic and pro-
hypertrophic signalling routes is an important conduit of the regulation of cardiac size, 
protein turnover and gene expression patterns. It is anticipated that such crosstalk will 
provide vital insight into the role of HSP20 in heart and may provide a basis for the 
development of drug targets for cardiac hypertrophy. 
  
6.6    Future directions 
The cumulative evidence provided in this study offers possible new routes for the 
therapeutic manipulation of cardiac hypertrophy. More is required to validate the 
experimental results described in this thesis and to clarify the mechanistic details 
underpinning the crosstalk between different signal transduction pathways which 
contribute to the induction of the hypertrophic response. Special emphasis should be 
placed on gaining more understanding of the upstream regulators and downstream 
functional consequences of PKD1 activation, including identification of other possible 
mechanisms involving HSP20’s mode of action. Novel insights may also be gleaned from 
further exploration of the signalling network involving of AKAP-Lbc and its scaffold 
partners. Future work may include the use of inducible overexpression and cardiac-specific 
knockout or transgenic animal models of cardiac hypertrophy to further characterise the 
specific molecular pathways that mediate the anti-hypertrophic effects. It is anticipated that 
these findings will provide deeper insight into molecular and cellular mechanisms at the 
tissue and organ levels. 
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6.7    Limitations of this work 
My work has identified new aspects of the roles of HSP20 in cardiac hypertrophy with 
further insight into how this protein may function when regulated by different upstream 
kinases. In the present study, the power of analysing protein-protein interactions was 
exemplified through array-based methods. It has allowed the identification and definition 
of binding sites between PDE4D5-HSP20 and PKD1-HSP20, thereby provide molecular 
information to generate two structurally distinct disruptor peptides, i.e. ‘bs906’ and 
‘HJL09’ (based on PDE4D5 and PKD1 sequences, respectively) that selectively disrupt 
their interactions with HSP20. Nevertheless, the precise mechanism of action appears to be 
far more complicated than previously thought. Small molecules targeted to disrupt 
individual protein-protein interaction could provide a highly specific therapeutic means for 
the treatment of cardiac hypertrophy. It is anticipated that such approach is less likely to 
have potential side effects as seen in drugs nowadays. However, it should be taken into 
consideration that disruptor peptides that are proven to be effective in vitro may not be 
equally effective in vivo due to issues associated with toxicity towards the organism albeit 
efficient peptide delivery and tissue targeting. It is possible that the results presented here 
using an in vitro system may not be a true reflection of the phenotype seen in intact 
organisms. As is the case for most primary isolations, primary cells are more prone to 
batch-to-batch variability in quality which may provide substantial challenges for the 
reproducibility of some experimental results. For example, the inconsistent degree of 
hypertrophy induction (ISO-treated cells) as showed here in Fig 3.16 and Fig. 5.8.  
Another limitation to the work presented here is the lack of data bridging the gap between 
the molecular mechanisms of cAMP-specific PDE4D5, cAMP-dependent PKA and PKD1, 
particularly the functional outcomes of these interacting proteins in regulating the roles of 
HSP20 in cardioprotection. A great deal of research into this study still needs to be carried 
out. For instance, in this study, the effects of PKD1, its potent inhibitors and PKD-
disruptor peptide on the levels of phospho-Ser16 of HSP20 were shown (Fig. 5.14-Fig. 
5.16) but not the direct functional consequences on hypertrophy phenotype, including any 
changes in HSP20-mediated nuclear import of PKD1 which may contribute to the 
induction of fetal gene program. In addition to the short-term future work discussed in 
Chapters 3, 4 and 5, it would also be interesting to further investigate if (1) PKA- and 
PKD1- mediated HSP20 phosphorylation and (2) phosphorylations or activation of PKA 
and PKD1 can be modulated by disrupting PKD1-HSP20 and PDE4D5-HSP20 
interactions selectively or a combinatorial effect of both.   
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